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ABSTRACT OF DISSERTATION

THE ROLE OF PXR AND IKKβ SIGNALING
IN CARDIOMETABOLIC DISEASE
Cardiovascular disease (CVD) is the leading cause of death worldwide
and is partially attributed to perturbations in lipid metabolism. Xenobiotics, such
as pharmaceutical drugs and environmental chemicals, have been associated
with increased risk of CVD in multiple large-scale human population studies, but
the underlying mechanisms remain poorly defined. We and others have
identified several xenobiotics as potent agonists for the pregnane X receptor
(PXR), a nuclear receptor that can be activated by numerous drugs as well as
environmental and dietary chemicals. However, the role of PXR in mediating
the pathophysiological effects of xenobiotic exposure in humans and animals
remains elusive.
The work herein identified several widely used pharmaceutical agents and
endocrine disrupting chemicals as PXR-selective agonists such as drugs
involved in HIV therapy and phthalates/phthalate substitutes, respectively. We
investigated the role of amprenavir, an HIV protease inhibitor, and tributyl
citrate, a phthalate substitute, on PXR-dependent alterations in lipoprotein
metabolism. Acute exposure with either xenobiotic in mice elicited increases in
the proatherogenic LDL-cholesterol levels in a PXR-dependent manner. PXR
activation significantly induced expression of genes involved in intestinal lipid
metabolism. Further, we went on to identify the intestinal cholesterol
transporter, Niemann-Pick C1-Like 1 (NPC1L1), as a direct PXR-target gene.
PXR activation also stimulated cholesterol uptake in both murine and human
intestinal cells. Moreover, we provide evidence that the microsomal triglyceride
transfer protein (MTP) may be a direct PXR-target gene. Taken together, these
findings provide critical mechanistic insight into the role of xenobiotic-mediated
PXR activation on lipid homeostasis and demonstrate a potential role of PXR in
mediating adverse effects of xenobiotics on CVD risk in humans.
In addition to PXR signaling, we investigated the role of IκB kinase β
(IKKβ), a central coordinator of inflammation, in adipocyte progenitor cells.
Targeting IKKβ in adipose progenitor cells resulted in decreased high fat diet
(HFD)-elicited adipogenesis, while protecting mice from inflammation and

associated insulin resistance. Consistently, we discovered that IKKβ inhibition
by antisense oligonucleotides ablated HFD-induced adiposity, while protecting
mice against associated metabolic disorders. In conclusion, targeting IKKβ with
antisense therapy may present as a novel therapeutic approach to combat
obesity and metabolic dysfunctions.
KEYWORDS: HIV drugs, Phthalates, Pregnane X Receptor, IκB Kinase β,
Adipogenesis, Insulin Resistance
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Chapter 1: Introduction
1.1

Cholesterol Metabolism – an Overview

Atherosclerotic cardiovascular disease (CVD; otherwise known as
coronary artery disease, or CAD) is a leading cause of mortality and morbidity
worldwide [1]. Atherosclerosis is a chronic inflammatory disease characterized
by the accumulation of lipids and inflammatory molecules in the subendothelium
of the artery, which can restrict blood flow and ultimately lead to myocardial
infarction and stroke. Although atherosclerosis occurs in the general
population, some people are at greater risk for developing CAD and these risk
factors can be classified into either modifiable or non-modifiable. Nonmodifiable risk factors for developing CAD are age, gender, and genetic
heritability [2]. Moreover, modifiable CAD risk factors include smoking, obesity,
nutrition, hypertension, sedentary lifestyle, stress, and hyperlipidemia [2].
Elevated plasma lipid levels, particularly low density lipoprotein (LDL)cholesterol, have been strongly associated with atherosclerosis development [3,
4]. Lipid-lowering therapy has produced up to a 30% reduction in a major
coronary event, validating the cholesterol hypothesis [3-5]. Mechanisms
governing cholesterol homeostasis are still being evaluated and there is an
urgent need to identify new targets for cholesterol-lowering therapy to alleviate
the morbidity and mortality associated with CAD.
Cholesterol is a key structural component of cellular membranes to
maintain integrity, permeability, and fluidity, but also serves as precursors for
bile acid and steroid hormone production. The conversion of cholesterol into
bile acids is absolutely essential for solubilization of dietary fats into micelles.
Although cholesterol can by synthesized by the body, it requires a substantial
energy requirement; thus, intestinal cholesterol absorption has evolved to take
up cholesterol from the gut lumen [6]. Cholesterol derived from de novo
synthesis and absorption is carried in the circulation in the form of lipoproteins
(lipid-protein complexes) which are delivered to cells for utilization (Fig. 1.1).
Efficient cholesterol transport relies heavily on the expression of specific
1

proteins and perturbation of these proteins may disturb whole-body cholesterol
homeostasis resulting in diseases. The principle plasma lipoproteins are
chylomicrons, very low-density-lipoproteins (VLDL), LDL, and high-density
lipoproteins (HDL). It is well established that the proatherogenic lipoproteins are
chylomicrons, VLDL, and LDL, and the antiatherogenic lipoproteins are HDL. I
will briefly discuss the basic pathway of lipoprotein formation, secretion, and
uptake, as well as perturbations in these processes (see Fig. 1.1 for an
overview).
Chylomicrons are secreted by enterocytes into the lacteals of the intestine
and they ultimately reach the circulation via the thoracic duct. Chylomicrons are
comprised primarily of triglycerides and cholesterol esters. Short chain fatty
acids (less than 8-10 carbons) passively diffuse into the enterocyte and enter
the portal blood directly without being packaged into chylomicrons. Long-chain
fatty acids are internalized by enterocytes via passive diffusion and proteinfacilitated fatty acid transfer. One protein that has been reported to facilitate
fatty acid uptake is the fatty acid translocase (FAT/CD36). It is worth noting that
many groups have investigated the role of CD36 in atherosclerosis and the
studies are currently controversial. Once in the enterocyte, long chain fatty
acids are incorporated into triglycerides via the acyl CoA:diacylglycerol
acyltransferase (DGAT) enzymes. These triglycerides are complexed with
apolipoprotein B 48, a process involving the microsomal triglyceride transfer
protein (MTP; a more thorough review below) to ultimately form chylomicrons.
ApoB is a hydrophobic protein that is present in plasma as apoB-48 or apoB100. In humans, apoB48 and apoB100 are primarily associated with
chylomicrons and VLDL, respectively [7]. MTP expression is absolutely
essential for generation of apoB-containing lipoproteins. For example, intestinal
MTP-deficiency impairs the ability to secrete chylomicrons and, as a result,
there is a robust accumulation of neutral lipids in the enterocytes [8].
Free cholesterol is also absorbed from mixed micelles by the enterocytes
from the gut lumen. This process is mediated by Niemann-Pick C1-Like 1
(NPC1L1; a more thorough review below). Free cholesterol is then re-esterified
2

by the Acyl-CoA:cholesterol acyltransferase-2 (ACAT2) enzyme in the
endoplasmic reticulum (ER). The cholesterol ester is packaged along with
triglycerides to form the core of chylomicrons. Cholesterol ester packaging into
chylomicrons is also regulated by MTP [9]. It is worth noting that remaining
unesterified cholesterol may be effluxed back out of the enterocyte by the
apically localized heterodimeric sterol transporters ATP-binding cassette (ABC)
transporters G5 and G8 (ABCG5/8) (Fig. 1.1). In addition, some unesterified
cholesterol may be transported out of the enterocyte into HDL via ABCA1, which
is located at the basolateral membrane of enterocytes. In mice, approximately
30% of the steady-state plasma HDL-cholesterol levels are derived from
intestinal ABCA1 [10].
Once the chylomicrons enter the circulation, they are lipolyzed by
lipoprotein lipase, which is located on the vascular endothelium of tissues such
as skeletal muscle and adipose tissue [11]. LPL hydrolyzes the triglycerides of
chylomicrons and, as a result, produces cholesterol-rich chylomicron remnants
[11]. The chylomicron remnants are then taken up by the liver via LDL receptorlike protein (LRP) (Fig. 1.1).
Hepatic cholesterol can be derived de novo or can be taken up by
hepatocytes from circulating lipoproteins such as LDL, HDL, and chylomicron
remnants via LDL-receptor (LDLR), HDL receptor scavenger receptor class B
type 1 (SR-B1), and LRP, all of which are localized at the basolateral membrane
of hepatocytes [6]. Free cholesterol may be converted to bile acids by multienzymatic reactions that convert hydrophobic cholesterol into more watersoluble amphipathic compounds [12]. Analogous to intestinal cholesterol
metabolism, free cholesterol may be esterified to fatty acids via ACAT2 and be
packaged into VLDL particles with triglycerides in a MTP-dependent
mechanism. Free cholesterol may be transported to ABCA1 on the sinusoidal
membrane for HDL biogenesis or to ABCG5/ABCG8 on the canalicular
membrane for direct secretion into the bile. Moreover, in humans and
nonhuman primates, NPC1L1 can counterbalance the function of
ABCG5/ABCG8 by reabsorbing biliary cholesterol into hepatocytes [6].
3

Whether synthesized de novo or taken up from the circulation, intracellular
cholesterol is very tightly controlled by a variety of mechanisms. A major
mechanism for sensing intracellular sterol levels involves the sterol-response
element binding proteins (SREBPs). SREBPs comprise a subclass of the helixloop-helix leucine zipper transcription factors [13]. In mammals, there are two
SREBP genes that encode SREBP1 and SREBP2, which give rise to 3 proteins
[14, 15]. SREBP1a and SREBP1c are encoded from alternative promoters that
are expressed at varying levels in different tissues and cultured cells. These
transcripts are thought to primarily play a role in fatty acid metabolism [14, 15].
SREBP2, however, is a major regulator of cholesterol metabolism [14, 15].
SREBPs are synthesized as ER transmembrane proteins and their
activation depends on a polytopic ER membrane protein known as the SREBP
cleavage-activating protein (Scap). Scap acts as both an escort protein for
SREBP ER-Golgi transport and as a sterol sensor. The sterol-sensing property
of Scap is mediated by the polytopic membrane domain, which possesses a
motif that is shared with other proteins that are postulated to interact with sterols
[16]. Mutations within this sterol sensing domain (SSD) of Scap prevent sterol
repression of SREBP cleavage and lead to an excess cholesterol production
[16-18]. When ER cholesterol falls less than 5% of total lipids, the cholesterolfree Scap/SREBP complex translocate to the Golgi for processing by the Site-1
and Site-2 proteases [16]. Transcriptionally active SREBP then enters the
nucleus to regulate genes involved in lipid metabolism. The SREBP2 isoform,
for example, transcriptionally regulates LDLR, HMG CoA reductase, NPC1L1,
and other genes required for cholesterol synthesis and uptake to maintain
cellular cholesterol homeostasis [19].
Given the consequences of excess plasma cholesterol on CAD, there
have been extensive efforts to understand the molecular mechanisms regulating
cholesterol homeostasis. The pregnane X receptor (PXR) is a xenobiotic
receptor that has been implicated in modulating cholesterol homeostasis and
atherosclerosis. The primary focus of this dissertation was to identify specific
mechanisms by which ligand activated PXR-mediates hypercholesterolemia. In
4

Chapter 3, I provide conclusive evidence that PXR transcriptionally regulates
NPC1L1 and promotes cholesterol uptake in mouse and human intestinal cells.
Further, in Chapter 5, I demonstrate that PXR may transcriptionally regulate MTP
and promote chylomicron/VLDL secretion. Taken together, this work herein
implicates PXR as a transcriptional regulator linking xenobiotic and cholesterol
metabolism.
1.1.1
Niemann-Pick C1-Like 1 (NPC1L1)
NPC1L1 was first identified by Altmann and colleagues utilizing a
bioinformatics approach that identified genes based on the following criteria:
presence of a SSD, extracellular signal peptide, and enriched expression in
absorptive enterocytes [20, 21]. Mice deficient in NPC1L1 had a significant
reduction in sterol absorption (approximately 70%), which is similar to the
reduction produced in mice treated with the potent intestinal cholesterol
absorption inhibitor Ezetimibe [20]. Moreover, NPC1L1-deficient mice were
resistant to Ezetimibe treatment, indicating the inhibition of cholesterol absorption
by Ezetimibe was mediated through NPC1L1 [20]. Shortly thereafter, it was
discovered that the target of Ezetimibe is, indeed, NPC1L1 [22]. Ezetimibe
lowers circulating plasma cholesterol levels in humans by 15-20%, and when coadministered with statins can synergistically decrease plasma cholesterol levels
[23-25].
NPC1L1 is a polytopic transmembrane protein comprised of 1332 amino
acids. It is a homolog of Niemann-Pick C1 (NPC1), a protein when mutated
results in a genetic disorder characterized by lysosomal accumulation of
cholesterol and other lipids. NPC1L1 has a conserved N-terminal NPC1 domain,
a signal peptide, 13 transmembrane domains, and extensive glycosylation sites.
It has been demonstrated that the conserved NPC1 domain contains a sterolbinding pocket, thus it is likely that this region also binds sterols. Five of the 13
transmembrane domains constitute the SSD. The SSD is conserved in many
transmembrane proteins involved in cholesterol metabolism, including NPC1,
HMG-CoA reductase, SCAP, and 7-dehydrocholesterol reductase (7DHCR) [26].
The functional significance of the SSD in NPC1L1 remains to be determined.
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In humans and nonhuman primates, NPC1L1 is predominantly expressed
on the apical surface of absorptive enterocytes [20, 27, 28] and on the
canalicular surface of hepatocytes [29]. In rodents, however, NPC1L1 is
primarily expressed in the intestine, with little to no expression in the liver [20,
21]. However, the underlying mechanism for this species-specific expression is
still unclear.
Mechanisms governing NPC1L1 transcriptional regulation have not been
well established. Several nuclear receptors have been previously reported to
regulate intestinal cholesterol absorption, including LXR, PPARα, and RXR;
however, these effects may not be due to direct transcriptional regulation of
NPC1L1. SREBP-2, however, is a major transcriptional regulator of NPC1L1 [30,
31] and overexpression of a constitutive nuclear form of SREBP2 enhanced
NPC1L1 promoter activity quite dramatically (approximately 8 fold; R.N. Helsley
unpublished). Moreover, other groups have identified hepatocyte nuclear factor
4α (HNF4α) and HNF1α as important regulators of SREBP-2 dependent
regulation of NPC1L1 [31, 32]. More work is required to identify novel regulators
of NPC1L1. In Chapter 3 I identified PXR as a novel transcriptional regulator of
NPC1L1, which links xenobiotic and cholesterol metabolism in mice and humans.
1.1.2
Microsomal Triglyceride Transfer Protein (MTP)
MTP was first identified as a protein that associated with triglyceride and
cholesterol ester transfer activity in liver microsomes [33, 34]. It was later
identified that individuals with abetalipoproteinemia lack apoB-lipoproteins in
their plasma and have mutations in the MTTP gene, which result in the loss of
lipid transfer activity in the liver and intestine [35]. Abetalipoproteinemia is an
autosomal recessive disease that is characterized by fat malabsorption,
defective lipid transport, accumulation of fat-laden enterocytes, decreased
plasma triglyceride and cholesterol levels, and fat-soluble vitamin deficiencies
[7, 36]. MTP contains both an apoB binding domain and a lipid transfer domain.
While the two domains are thought to act independent of one another, both are
required for efficient secretion of apoB-containing lipoproteins [37-39].
Consistently, independent groups identified a physical interaction between apoB
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and MTP [40, 41]. MTP has been demonstrated to be pivotal for apoBcontaining lipoprotein assembly in two ways: (1) by acting as a chaperone
mediating translocation of newly synthesized apoB across the ER membrane
and (2) by facilitating the lipidation of apoB during its translocation into the ER
[42].
Expression of MTP is enriched in the intestine and liver; however, MTP
expression has been detected in other tissues but to a much lesser extent.
MTP expression decreases from the proximal to distal end of the intestine, with
negligible expression in the colon [43]. Moreover, MTP expression also varies
vertically within the crypt-villus axis, with the highest expression along the villi
[7]. Isolated crypts are devoid of MTP mRNA and protein [7, 44]. In Caco2
cells, MTP induction expression increases throughout differentiation into
polarized enterocyte-like cells [44]. Hepatocytes also express high levels of
MTP [7]. The consequence of altering MTP expression in these tissues will be
discussed briefly.
Homozygous deficiency in mice results in embryonic lethality.
Heterozygote deletion of MTP results in decreased LDL plasma cholesterol
levels in mice fed chow, and decreased chylomicron/VLDL and LDL cholesterol
levels under high-fat diet (HFD)-feeding conditions [45]. Homozygous deletion
of MTP in the visceral endoderm of yolk sacs produces a marked accumulation
of cytosolic fat droplets, indicative of impaired secretion of lipids [45]. To
circumvent embryonic lethality in global MTP deficiency, Raabe and colleagues
generated liver-specific MTP knockout mice and studied the effects on
lipoprotein metabolism [46]. Suppression of hepatic MTP reduces VLDL
triglycerides, as well as VLDL/LDL and HDL cholesterol levels [46]. In addition,
apoB-100 is decreased in plasma by more than 95 % [46]. The liver-specific
knockout mice possess profound hepatic steatosis, which is associated with
elevated cytosolic lipid droplets in the hepatocytes [46]. Reduced MTP
expression via antisense oligonucleotides (ASO) decreases hepatic VLDL
triglycerides and cholesterol secretion in mice [47]. In contrast, hepatic
overexpression of MTP results in elevated secretion of VLDL triglycerides [48].
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Xie and colleagues set out to investigate the overall contribution of intestinal
MTP expression on lipoprotein metabolism. Intestinal-specific knockout mice
exhibit increases in the number of lipid droplets in absorptive enterocytes and
the mice display steatorrhea, growth arrest, and decreases in cholesterol
absorption [49]. The decreases in cholesterol absorption most likely result from
reduced expression of NPC1L1 in intestinal-specific MTP KO mice.
Chylomicron secretion is impaired by 80% and plasma lipids, as well as hepatic
triglyceride and cholesterol content, are reduced in mice with intestinal MTPdeficiency [49]. Intestine-specific KO mice have an increase in both hepatic
lipogenesis and VLDL secretion, which is attributed to the liver compensating for
the lack of intestinally-derived lipid [49]. Collectively, alterations in MTP
expression clearly alter apoB-lipoprotein secretion. In Chapter 5, we provide
evidence that PXR may transcriptionally regulate MTP expression, but whether
PXR mediates apoB secretion remains to be determined.
1.2

Highly Active Antiretroviral Therapy (HAART) – an Overview

The human immunodeficiency virus (HIV) is the cause of the acquired
immune deficiency syndrome (AIDS) and is currently considered a pandemic,
with approximately 37 million people globally living with HIV (UNAIDS 2014).
Since the first class of antivirals were developed and used as a monotherapy in
the early 1990’s, the standard of care has evolved to include a combination of
antiretroviral drugs (ARVs) targeting different stages of the HIV life cycle [50].
The combination of ARVs is defined as highly active antiretroviral therapy
(HAART) and has significantly reduced the morbidity and mortality associated
with HIV infection and AIDS [50]. HAART is a customized combination of
different classes of ARVs, including: fusion inhibitors, CCR5 antagonists,
reverse transcriptase inhibitors (comprised of nucleoside [NRTIs] and
nonnucleoside [NNRTIs]), integrase inhibitors, and protease inhibitors (PIs).
Approximately 37% of all people living with HIV are currently on ARV drug
therapy (UNAIDS 2014). Consequently, AIDS-related deaths have fallen by
35% since 2005, which is partially attributed to the development of HAART
(UNAIDS 2014). As longevity increases in HIV-infected individuals, chronic
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illnesses, such as accelerated atherosclerosis and cardiovascular disease, are
emerging as leading health issues in this population [51].
1.2.1
Epidemiological Studies Linking HAART to CVD
Despite reductions in the morbidity and mortality associated with HIV
infection, HAART has been associated with dyslipidemia and increased risk of
CVD [52-62]. Findings from the Data Collection on Adverse Events of Anti-HIV
Drugs study suggested that the incidence of CVD increased with longer
exposure to HAART [63]. Another large-scale study including more than 23,000
HIV patients also concluded that ARV drugs such as PIs are associated with an
increased risk of CVD, which is partly explained by dyslipidemia [55]. A Swiss
HIV Cohort Study found that PIs can cause dyslipidemia in patients [58] and
several other studies have reached the same conclusion [64, 65]. For example,
Lang et al. conducted a case-control study nested within a large HIV patient
database and found that the risk of myocardial infarction was increased by
cumulative exposure to almost all of the studied ARV drugs [66]. Many currently
recommended first-line ARV drugs including several PIs and NNRTIs have been
shown to cause hyperlipidemia [67]. Despite the strong evidence linking
HAART with dyslipidemia and CVD, the underlying mechanisms responsible for
the adverse effects of ARV drugs remain elusive.
1.2.2

Mechanisms of HAART-Elicited Hyperlipidemia
and CVD
Mounting evidence has linked HAART to alterations in plasma lipid levels
in humans. Many of these studies are conducted in HIV-positive individuals;
however, other studies confirmed a direct association between HAART
exposure and hyperlipidemia in normal healthy subjects [68]. Liang and
colleagues first identified a possible mechanism linking PI therapy to
hyperlipidemia [69]. HIV PI treatment inhibited the proteasomal degradation of
nascent apoB [69]. ApoB secretion was also impaired with HIV PI treatment,
which associated with decreased MTP activity [69]. In the presence of oleic
acid, PI treatment increased secretion of apoB-containing lipoproteins above
controls [69]. The authors concluded that the PI-mediated hindrance to apoB
secretion can be overwhelmed by the excess supply of core lipids [69].
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Independent groups also demonstrated the ability of certain PIs to induce
hyperlipidemia in animal models [70, 71]. Treatment of ritonavir for 10 days in
WT mice on either a low fat or high fat diet produced pronounced increases in
plasma cholesterol and triglyceride levels [70]. Ritonavir treatment also resulted
in significant hepatic steatosis and hepatomegaly, which were attributable to the
accumulation of transcriptionally active SREBP1 and SREBP2 [70]. In an
independent study, the same group went on to demonstrate that ritonavir
treatment enhanced VLDL secretion without altering lipoprotein clearance [71].
Collectively, these adverse effects with HIV PI treatment associated with
increased expression of genes involved in lipid synthesis and enhanced VLDL
secretion [70, 71].
The activation of the SREBP signaling pathway with HIV PI treatment
stimulated the work by other groups. PI treatment in murine macrophages
enhanced transcriptionally active nuclear SREBP expression, which resulted in
an accumulation of free cholesterol in intracellular membranes and elevated
apoptosis [72]. The authors also observed that PI treatment induced
endoplasmic reticulum stress and activated the unfolded protein response
(UPR) in these cells [72]. Since intracellular cholesterol can activate ER stress
and the UPR [73], it is likely the adverse effects associated with PI treatment
may be linked to the initial nuclear SREBP accumulation; however, this warrants
further investigation. The same group went on to demonstrate that treatment
with various PIs resulted in a variety of responses in mouse primary
hepatocytes [74]. For example, atazanavir and ritonavir increased nuclear
SREBP levels and activated the unfolded protein response, while amprenavir
had no effect [74]. Further, atazanavir and ritonavir treatment suppressed
CYP7A1 protein levels and bile acid synthesis, while amprenavir had no
significant effect [74].
These results clearly demonstrate that individual HIV PIs may have
different effects on lipid metabolism in mice, which is what is observed in
humans [75]. There is an urgent need to identify new HAART-elicited off-target
effects that influence lipid metabolism. In Chapter 2, I provide evidence that HIV
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PIs activate PXR and induce hyperlipidemia in mice. This new signaling
pathway linking HAART to xenobiotic and lipid metabolism may partially explain
the adverse side effects associated with HAART.
1.3

Endocrine Disrupting Chemicals (EDCs) – an Overview

There is growing concern about the possible health threat posed by
endocrine-disrupting chemicals (EDCs), substances found in our food,
environment, and consumer products that ultimately disrupt normal homeostatic
processes and have the capability to cause diseases [76]. The U.S.
Environmental Protection Agency define an EDC as, “an exogenous agent that
interferes with synthesis, secretion, transport, metabolism, binding action, or
elimination of natural blood-borne hormones that are present in the body and
are responsible for homeostasis, reproduction, and developmental process”
[76]. A few examples of compounds that have been identified as EDCs are
polychlorinated biphenyls (PCBs), plasticizers (phthalates and phthalate
substitutes), and certain pesticides [76]. It was originally thought that EDCs act
primarily through nuclear hormone receptors; however, it is now widely
accepted that EDCs act through a variety of signaling mechanisms, which
include but are not limited to, nonnuclear steroid receptors, nonsteroid
receptors, orphan receptors, and enzymatic pathways ultimately responsible for
maintaining endocrine homeostasis [76]. EDCs have been linked to obesity and
CAD; however, the mechanisms governing this phenomenon remain poorly
understood.
1.3.1
Epidemiological Studies Linking EDCs to CVD
Bisphenol A (BPA) is a base compound widely used in the production of
foods and plastics, and has been recently studied in humans to correlate
exposure to disease risk. Using a cross-sectional analysis to measure urinary
BPA and health status, Lang and colleagues recently demonstrated that higher
urinary BPA concentrations were associated with cardiovascular disease,
including CAD [77]. This finding was further supported by an independent
group [78, 79]. Further, high BPA exposure in adolescents and young adults
has been associated with significantly increased carotid intima media thickness,
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a measure of atherosclerosis progression [80].
Aside from BPA, other phthalates and phthalate metabolites have been
associated with atherosclerosis. Phthalate metabolites are associated with
increased atherosclerosis in the elderly [81]. Interestingly, Sergeev and
colleagues demonstrated that people living within close proximity to sites
contaminated with organic pollutants compared to sites not containing any
identified hazardous waste had a 20% increase in acute myocardial infarction
hospital discharge rates [82]. Overall, there have been many studies
associating environmental chemicals with disease; however, whether these
compounds are causative and the mechanisms involved remain elusive.
1.3.2

Mechanisms of EDC-Elicited Hyperlipidemia and
CVD
Mechanisms linking EDC exposure to cholesterol metabolism are largely
unknown; however, a few groups have examined exposure to atherosclerosis
and obesity, which will briefly be discussed. For example, various EDCs were
screened for their ability to activate the glucocorticoid receptor (GR), and four
were identified to induce GR-promoter activity [83]. This activity was correlated
with enhanced adipogenesis in 3T3-L1 murine preadipocytes [83]. Surprisingly,
the effect of EDCs on promoting lipid accumulation during adipogenesis was not
contributed to changes in PPARγ expression [83].
Consistent with the notion that EDCs play a role in adipocyte stem cell
differentiation, an independent group demonstrated that PCBs, specifically PCB77, increased adipocyte differentiation in low doses [84]. This effect on 3T3L1
differentiation was ablated by an aryl hydrocarbon receptor (AhR) antagonist
[84]. Furthermore, administration of PCB-77 increased body weight gain in WT
mice, but not in AhR-deficient mice [84]. PCB-77 treatment also enhanced the
obesity phenotype, as well as augmenting dyslipidemia and atherosclerosis in
ApoE-deficient mice [84]. The effect on dyslipidemia with PCB-77 treatment
was pronounced with approximately a 133% increase in plasma cholesterol
levels [84]. The specific mechanism linking PCB exposure to
hypercholesterolemia was not investigated. Our group, as well as others,
discovered that BPA is proatherogenic in animal models [85, 86] (see section
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1.5.1); however, the precise mechanisms linking EDC-exposure to alterations in
lipid metabolism and atherogenesis are not well characterized and need to be
investigated further. One important area of research in our laboratory is to
understand the mechanisms linking EDC-exposure and sterol metabolism. In
Chapter 3, I identified a phthalate substitute known as tributyl citrate (TBC), as
an intestinal-specific PXR agonist. Further, acute TBC exposure stimulated
hypercholesterolemia which may be mediated through PXR transcriptional
regulation of NPC1L1.
1.4

Identification of the Pregnane X Receptor (PXR)

Pharmaceutical drugs and environmental chemicals are metabolized
through a series of enzymatic reactions to generate more polar derivatives that
are ultimately excreted by the body. Many of these compounds are first
metabolized by a member of the cytochrome (CYP) P450 monooxygenase gene
family. The CYP enzymes are comprised of four gene families (CYP1, CYP2,
CYP3, and CYP4) and are referred to as phase 1 enzymes because they
catalyze the first step in the detoxification process. The CYP enzymes are
highly expressed in the liver and intestine. Among the family of CYP enzymes,
the CYP3A family is recognized to metabolize up to 50% of clinically used drugs
as well as other xenobiotics [87, 88]. Additionally, the CYP2B enzymes
metabolize another 25-30% of these compounds [88]. The ability of organisms
to adapt to their surroundings and possess a host defense mechanism against
toxic chemicals is essential to maintain life.
The pregnane X receptor (PXR; otherwise termed the steroid and
xenobiotic sensor, or SXR) was initially discovered in 1998 by multiple groups.
PXR was designated NR1I2 (nuclear receptor subfamily 1, group I, member 2)
using standard nomenclature and was named based on the observation that
pregnanes (21-carbon steroids) activate the receptor [89]. Like other nuclear
receptors, PXR contains both an N’-terminal DNA binding domain (DBD) and a
C’-terminal ligand-binding domain (LBD), which are responsible for DNA binding
and ligand binding as well as interaction with co-regulators, respectively. PXR
is activated by numerous endogenous hormones, dietary steroids,
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pharmaceutical agents, and xenobiotic chemicals [90, 91]. It functions as a
heterodimer with the retinoid X receptor (RXR) to modulate gene transcription
[92, 93]. PXR was initially characterized based on the observation that ligands
activating the receptor induced CYP3A4 expression. Consequently, it was
further identified that PXR transcriptionally regulates CYP3A4 [89, 94-96].
Similar to the CYP enzymes, PXR is highly expressed in the liver and intestine
[89, 94-96], two sites of first line defense against toxic xenobiotics. The
discovery of PXR led to identification of many novel target genes involved in
detoxification and transport of lipophilic compounds, such as genes that encode
phase I (e.g., CYP450s) and phase II (e.g., glutathione transferase)
detoxification enzymes, as well as the ABC family transporters (e.g., multidrug
resistance 1 [MDR1]). Since its initial discovery, PXR has been shown to be a
critical regulator for other processes, such as modulating lipid levels,
atherogenesis, bone homeostasis, and inflammation.
1.4.1
PXR Gene Structure
The human PXR (hPXR) gene consists of nine exons on chromosome 3.
Despite only one PXR gene discovered in the human genome, three PXR
variants resulting from alternative splicing have been characterized [97-100].
PXR variant 1 encodes two products (isoforms hPXR.1 and hPXR.2), through
the use of alternative translational codons. PXR variant 3 (hPXR.3) has a
unique 5’ untranslated region and start codon, which encodes the longest
isoform with the addition of 39 amino acids on its N’ terminus relative to hPXR.1
[97-100]. PXR variant 4 (hPXR.4) is similar to hPXR.1 but is lacking 111 base
pairs due to an in-frame deletion in the LBD at exon 5 [97-100] (Fig. 1.2).
Particularly, hPXR.4 lacks ligand binding pocket resides 206Leu, 208Ser, and
209

Leu and has been demonstrated to lack the ability to undergo ligand-elicited

transactivation in reporter assays [100] (Fig. 1.2). Interestingly, however,
hPXR.4 has been demonstrated to act as a dominant-negative protein
interfering with hPXR.1 transactivation [100]. This is most likely due to
competing occupation for DNA binding, thus alleviating maximal ligand
activation of PXR. Further, ligands can bind to the LBD of hPXR.4, however
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with weak associations and thereby corepressors remain tightly bound and
coactivators are not recruited for PXR transactivation [100]. Likewise, UGT1A1,
1A3, and 1A4 gene expression were all induced by hPXR.1 and hPXR.3 but not
by hPXR.4 [98]. All four variants were found in human liver and intestinal tissue;
however, a great deal of interindividual variation was found [98]. This may
partially explain the great deal of interindividual variation in drug metabolism
associated with CYP expression.
The mouse PXR (mPXR) gene is located on chromosome 16. The mPXR
gene generates two variants that are quite similar with hPXR.1 and hPXR.4 [89].
Mouse PXR variant 1 (mPXR.1) is 431 amino acids in length and mouse PXR
variant 2 (mPXR.2) is a splicing variant that lacks 41 amino acids within the LBD
[89] (Fig. 1.2). Similar to the hPXR.4, mPXR.2 lacks the ability to be activated by
numerous ligands, such as the synthetic steroids dexamethasone and
pregnenolone 16α-carbonitrile (PCN) [89]. Although mPXR.2 was expressed in
a similar tissue-specific pattern as mPXR.1, it was expressed at a much lesser
extent indicating mPXR.1 is the major isoform in mice [89]. Although other
transcript variants may exist through the use of alternative promoters,
alternative splicing, and/or alternative polyadenylation, they have not been
completely characterized [91, 97, 99].
1.4.2
Species-Specific PXR Activity and Animal Models
Since the initial discovery of PXR in 1998, many orthologues have been
cloned from a wide variety of organisms, including mammals [89, 94-96, 101104], Drosophila [105], and C. elegans [101]. In Drosophila, the PXR orthologue
was termed DHR96 [105]. Furthermore, three orthologues of PXR are
represented in C. elegans as DAF12, NHR-8, and NHR-48 [101]. Despite acting
as orthologous receptors, the pharmacology of PXR differs substantially
between species. Mouse and human PXR only exhibit approximately 70-80%
homology within the LBD but share approximately 95% homology in their DNA
binding domains (DBD) [106, 107]. The observation for species differences in
CYP3A induction observed in vivo appears to be partially reliant on sequence
differences in the LBD of PXR. For example, PCN, a known CYP3A inducer in
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rodents, acts as a potent agonist of mouse and rat PXR, but does not activate
human PXR [106]. Further, rifampicin, a known inducer of CYP3A in humans
and rabbits, does not activate mouse PXR. Thus, by binding to wide array of
structurally diverse compounds, it has been suggested that PXR exhibits
directed promiscuity [106, 107].
Since the homology of PXR differs quite substantially between species,
mouse models were generated to understand human xenobiotic metabolism in
vivo. Xie et al. generated transgenic mice expressing wild-type (WT) human
PXR driven by the albumin promoter on a PXR-null background [108]. These
mice express hPXR specifically in the liver, while maintaining mouse PXRdeficiency [108]. Later in the 2000s, Ma and colleagues generated another
‘humanized’ mouse model utilizing a bacterial artificial chromosome clone
containing the complete hPXR gene and the corresponding 5’ and 3 flanking
sequences [109]. This humanized model displays the same tissue-specific
patterns as human PXR and responds to human-specific PXR agonists, such as
rifampicin, but not mouse-specific PXR agonists, such as PCN [109]. Although
these models are essential to understand the PXR-mediated effects on
metabolic homeostasis, it raises the question about the ability of human PXR to
drive expression of mouse PXR target genes. For example, the human PXR
response element within the CYP3A4 promoter is not found in mouse CYP3A11
[110]. To address this issue, CYP3A4/hPXR double transgenic mice were
generated [111]. Consequently, rifampicin is a robust inducer of CYP3A4 in the
double transgenic model [111], compared with only slight induction of CYP3A11
[112]. Since many CYP3A4 substrates are also PXR ligands, it is essential to
utilize the double transgenic model to assess the pharmacokinetics of
pharmaceuticals and other xenobiotics in vivo. Two more models were
generated to investigate constitutive activation of human PXR in the mouse liver
and intestine. The first constitutively active mouse model was generated by
utilizing the albumin promoter to drive human PXR, which was fused at the 5’
end to the herpes simplex virus activation domain (VP16) [108]. Subsequently,
another model was generated utilizing the fatty acid binding protein promoter to
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drive VP16-hPXR to overexpress PXR in both the liver and gastrointestinal tract
[113]. Collectively, all the hPXR mouse models show a normal phenotype,
except for the albumin-driven VP16hPXR mouse model, which displays growth
retardation, hepatomegaly, and histological liver toxicity [108, 114].
1.4.3
Post-Transcriptional Regulation of PXR
Micro-RNAs (miRNAs) are short noncoding regulatory RNAs that bind to
complementary regions in the 3’ UTR of mRNA target sequences and suppress
their translation and/or facilitate degradation [115, 116]. Aside from alternative
splicing, PXR has been demonstrated to undergo another level of gene
regulation from microRNAs. PXR mRNA and protein levels were measured in
25 human livers and their relative expression was compared [117]. Interestingly,
the transcript and protein levels were not associated, suggesting posttranscriptional regulation of PXR [117]. In an independent study, 19 single
nucleotide polymorphisms (SNPs) correlated with plasma cholesterol in humans
and many of these SNPs were found in the 3’ UTR [118]. Further, 16
microRNAs were predicted to bind PXR mRNA in human liver samples [117].
MiR-148a was later identified as a critical regulator of human PXR expression
[117]. Overexpression of miR-148a suppressed PXR protein levels and, in
contrast, inhibition of miR-148a elicited increases in PXR protein expression
[117]. A similar binding site was discovered in CYP3A4; however, CYP3A4 was
unresponsive to mir-148a overexpression [117]. Although the 3’UTR of PXR is
not well conserved between species, the miR-148a element has been
discovered in both mice and rat, indicating that this specific miRNA may control
PXR gene expression in other mammals [117].
In another human cohort, genetic variants in the 3’ UTR were identified in
specific genes involved in xenobiotic metabolism [116]. For example,
bioinformatics analysis revealed 1,025 unique microRNA’s that were predicted
to bind to the hPXR 3’ UTR [116]. The CYP3A4 gene was also predicted to be
regulated by 889 unique microRNAs [116]. The variant rs1054190C in hPXR
was predicted to result in the presence of a binding site for miR1250-5p [116].
In contrast, the variant rs1054191G was predicted to result in the loss of a
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binding site predicted to bind miR-371b-3p, miR-4258, and miR-4707 [116].
Although there has been evidence of other regulatory miRNAs targeting PXR
[116], the physiological consequence on PXR stability and xenobiotic and/or
lipid metabolism has not been characterized.
1.4.4
Post-Translational Regulation of PXR
It is well known that transcriptional regulation of PXR target genes is
governed by ligand-activation; however, PXR has been established to undergo
a host of post-translational modifications including phosphorylation,
SUMOylation, ubiquitination, and acetylation [119]. This section will provide a
brief overview of post-translational modifiers in altering PXR subcellular
localization, dimerization, DNA binding, coregulator activity, and transcriptional
regulation.

Phosphorylation
Recently, there has been a host of evidence demonstrating site-specific
phosphorylation of PXR, which provides a mechanism for PXR-mediated
regulation of CYP expression. It should be noted that phosphorylation of PXR is
mostly correlated with an inhibitory response in its transcriptional activity. Many
kinases have been demonstrated to phosphorylate PXR including p70 S6K
[119-122], protein kinase A (PKA) [122-124], protein kinase C (PKC) [122, 125],
cyclin-dependent kinase (Cdk2) 2 [126-128] and 5 [129], thereby regulating the
activity of PXR. Metabolic labeling studies indicated that immunopurified hPXR
is phosphorylated by numerous kinases such as glycogen synthase kinase 3
(GSK3), casein kinase II (CK2), and Cdk1 [119, 120, 123].
It was been well documented that CYP expression is greatly reduced
during hepatocyte proliferation. For example, hepatocyte exposure to human
growth factors such as hepatocyte growth factor potently induces hepatocyte
proliferation, yet significantly suppresses the CYP isoenzymes [119, 130, 131].
In recent work led by Lin and colleagues, it was initially hypothesized that hPXR
changes expression throughout various phases of the cell cycle. This study
provided compelling evidence that hPXR is phosphorylated by Cdk2, a key
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regulator of the cell cycle, and suppresses its transcriptional activity [128]. This
group went on to identify two small molecule inhibitors that were Cdk2 inhibitors,
which ultimately increased hPXR activity. This increase in hPXR activity was
thought to be ligand-independent, as these two molecules bound to hPXR with
low affinity. The serine 350 (Ser350) was discovered to be the site at which
Cdk2 phosphorylates PXR. Consistently, a phosphomimetic mutation (S350D)
of the putative Cdk2 phosphorylation site on PXR mimicked the inhibitor effect
of Cdk2. In contrast, a phosphorylation-deficient mutation (S350A) conferred
resistance to Cdk2 suppression. Furthermore, PXR transcriptional activity was
significantly reduced in the S-phase of the cell cycle, which is when Cdk2
activity increases, and this was not due to simply reduced hPXR expression.
Since neither the phosphomimetic mutation nor the phosphorylation-deficient
mutation rendered 100% resistance to the inhibitor effect of Cdk2, it is likely that
Cdk2 phosphorylates multiple sites on hPXR [128]. This work is the first to
identify a possible mechanism linking Cdk2 to CYP3A4 expression in
hepatocytes, and implicates the importance of considering cell cycle status
when investigating PXR activity and CYP expression [128].
Consistent with the notion that PXR phosphorylation suppresses
transcriptional activity, another kinase downstream of the PI3K-Akt signaling
pathway was demonstrated to phosphorylate PXR and suppress its activity. A
study by Pondugula and colleagues demonstrated that p70 S6K acts as an
upstream kinase of PXR and phosphorylates threonine 57 (Thr57), which
suppresses PXR transactivation. This Thr57 residue is a highly conserved
phosphorylation site within the DBD of human nuclear receptors, including
numerous PXR orthologous, indicative of its importance in PXR physiology
[119]. In this study, a phosphorylation-deficient (T57A) and a phosphomimetic
(T57D) were generated to assess PXR activity and subcellular localization. As
expected, the T57D but not the T57A mutation abolished its PXR transcriptional
activity. Interestingly, however, neither mutation altered hPXRs interaction with
the coactivator SRC-1. Both WT and the T57A mutant exhibited a homogenous
distribution in the nuclei of cells whereas the T57D phosphomimetic mutant
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exhibited a punctate pattern, suggesting that phosphorylation at T57 could alter
subcellular localization. However, it is still unclear how the punctate nuclear
localization pattern affects PXR signaling. Since this T57 residue is highly
conserved, it raises the possibility that this amino acid is pivotal for DNA binding
across many nuclear receptors. In conjunction with this notion, the T57D
mutation, but not the T57A mutation, impaired hPXR’s ability to bind to the
CYP3A4 promoter. The p70 S6K was later described to phosphorylate T57 on
PXR and suppress its transcriptional activation through loss of binding at the
CYP3A4 promoter [121].
A further study was conducted to investigate the mechanism by which
phosphomimetic mutations at various sites within PXR result in changes in
subcellular localization and activity. Phosphomimetic mutations at threonine290 and threonine-408 demonstrated similar subcellular localization properties,
with suppressed translocation of hPXR into the nucleus [132]. In another study,
the same group demonstrated the ability of Ca2+/calmodulin-dependent protein
kinase II (CaMKII) to phosphorylate hPXR at threonine-290, leading to its
retention in the cytoplasm [133]. They went on to further illustrate that both WT
and the T408D mutant immunoprecipitated with chaperone proteins to a similar
extent in the cytoplasm [132]. When they treated cells with autophagy
inhibitors, the T408D mutant led to higher cytoplasmic accumulation than WT
and co-localized with the autophagic cargo [132]. Collectively, these data
support the notion that PXR is phosphorylated at threonine 408 and undergoes
autophagy regulated degradation.
There has been mounting evidence in support of additional amino acid
residues on PXR that have been predicted to be phosphorylated by numerous
kinases [119, 134]. Although more work is required to functionally validate the
importance of each one of these kinases, PXR clearly has other levels of
regulation aside from ligand-dependent transcriptional activation that modulate
PXR transcriptional activity, stability and subcellular localization [119, 134].

Ubiquitination
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Ubiquitination is a multi-step process that occurs at several levels of signal
transduction. Ubiquitin attaches to the substrate by an isopeptide bond
between the C’ terminus of ubiquitin and a lysine residue on the substrate [135].
The placement of ubiquitin on the substrate is governed by three enzymes: E1
(ubiquitin activating), E2 (ubiquitin conjugating), and E3 (ubiquitin ligases) [135].
The degradation of proteins by the proteasome relies on ubiquitin tagged
substrates. The mechanisms governing degradation of PXR by ubiquitination
have not been well investigated; however, there are a few studies suggesting
PXR stability being altered by ubiquitination. In 2000, Masuyama and
colleagues demonstrated that ubiquitin may regulate PXR stability. This group
revealed that the suppressor for gal-1 (SUG1) interacted with PXR [136]. SUG1
is a known subunit of the 26S proteasome [137] and was first demonstrated to
bind to a host of other nuclear receptors [138], but PXR was not initially
described in this data. This interaction, however, only occurred in the presence
of progesterone, but not with other PXR activators, such as phthalic acid or
nonylphenol [136], which highlights the fact that various PXR activators may
alter PXR degradation differently [119]. Subsequently, the same group went on
to illustrate that PXR protein levels were increased in the presence of
proteasome inhibitors [139]. Overexpression of SUG1 elicited increases in PXR
degradation, as evident by enhanced proteolytic PXR fragments, which was
blocked by proteasomal inhibition. Interestingly, the interaction between PXR
and SUG1 depended on the presence of progesterone because proteolytic
fragments were not generated in the absence of this steroid. Overexpression of
SUG1 suppressed progesterone-mediated PXR transactivation on the CYP3A1
promoter in vitro [119, 136, 139]. It has been noted that the interaction with
SUG1 may result from conformational changes of the receptor upon distinct
ligand binding [119], such as progesterone, however more work will be required
to elucidate the precise mechanism by which this occurs.
More recently, another group identified an E3 ubiquitin ligase as an hPXRinteracting protein. The ring-B-box-coiled protein interacting with protein kinase
C-1 (RBCK1) was discovered by utilizing a yeast-two hybrid screening approach.
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Overexpression of RBCK1 in AD-293 cells decreased PXR levels, which was
inhibited by the proteasomal inhibitor MG-132. Most importantly, overexpression
and silencing of RBCK1 resulted in inhibition and induction of endogenous PXR,
respectively, in human primary hepatocytes. Silencing RBCK1 enhanced
rifampicin-elicited induction of human PXR target genes [140].
Collectively, these results provide compelling evidence that PXR stability
can be directly linked to conformational changes elicited by a specific ligand
(e.g., progesterone), in part by disrupting the association between PXR and
SUG1 [136, 139]. Furthermore, other groups have demonstrated that PXR is
directly ubiquitinated by protein kinase A and RBCK1, both of which regulate
PXR stability and ultimately, PXR transcriptional activity. However, the
interaction between PXR and the ubiquitin-signaling pathway warrants further
investigation [119].

SUMOylation
Another post-translation mechanism altering PXR protein-protein
interactions and stability, ultimately fine-tuning gene transcription is
SUMOylation. SUMOylation is characterized by the addition of a small
ubiquitin-related modifier (SUMO) to its substrate. SUMOylation shares many
common characteristics with ubiquitination [141, 142]. For instance, SUMOspecific enzymes attach SUMO proteins in an enzymatic cascade completely
reliant on ATP and some SUMO proteins can serve as direct substrates for
SUMOylation, thereby generating a protein that is polysumoylated [141, 142].
To date, four SUMO proteins (SUMO1, SUMO2/3, and SUMO4) have been
identified in mammalian cells [141, 143, 144]. The attachment of a SUMO
moiety to a target lysine residue on a specific substrate is governed by three
enzymes: E1 (SUMO activating), E2 (SUMO conjugating), and E3 (SUMO
ligases) [141]. SUMO modification to a specific substrate is reversible due to
SUMO-specific proteases that cleave the isopeptide bond between the SUMO
protein and its substrate, thereby releasing SUMO for further cycles [141].
The signaling consequences of SUMOylation are substrate-specific.
22

Interestingly, SUMOylation of a number of nuclear receptors have been linked to
inflammation [145-147]. For example, ligand-dependent SUMOylation of
PPARγ results in recruitment to inflammatory gene promoters where it inhibits
transcription by suppressing clearance of corepressor complexes in mouse
macrophages [147]. Moreover, ligand-dependent SUMOylation of LXR
represses inflammatory gene expression in brain astrocytes [146]. Consistently,
inflammatory signaling in hepatocytes increased SUMOylation of liganded hPXR
[145]. The SUMOylated form of PXR represses NF-κB target gene expression
but had little effect on CYP3A4 gene expression, indicating a promoter-specific
response upon exposure to RIF [145]. Utilizing a bioinformatics approach, Hu
and colleagues were the first to identify four potential sites of SUMOylation
within hPXR; however, the contribution of each predicted lysine in global PXR
SUMOylation was not investigated and warrants further investigation [145].
The same group recently confirmed their previous work demonstrating that
TNFα and the hPXR ligand RIF increased both global SUMOylation and
ubiquitination in primary murine hepatocytes [148]. Interestingly, however, they
discovered that PXR SUMOylation driven by two different E3 ligases actually
elicited different responses in PXR activity [148]. For example, the protein
inhibitor of activated signal transducer and activator of transcription-1 (PIAS1), a
SUMO-E3 ligase, increased SUMOylation, as well as PXR-mediated induction
of the xenobiotic response [148]. In contrast, the protein inhibitor of activated
STAT Y (PIASy), another SUMO-E3 ligase, increased SUMOylation and
alleviated interaction of PXR with the coactivator peroxisome proliferatoractivated receptor gamma coactivator-1-alpha (PGC-1α) [148]. Further, PIASymediated SUMOylation of PXR suppressed ubiquitin-mediated degradation by
the 26S proteasome [148]. Their latest work identified a possible mechanism by
which SUMOylation can alter the xenobiotic response versus the inflammatory
response in hepatocytes; however, how the cell senses the environment to
regulate these two processes by differential expression of different SUMO-E3
ligases and how this specifically alters the PXR response warrants further
investigation.
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More recently, an independent group confirmed the four predicted
SUMOylation sites and identified a Negative charge amino acid Dependent
SUMOylation Motif (NDSM) in hPXR [149]. Further, they demonstrated that
PXR SUMOylation in the presence of ligand induces target gene expression
and this was due to enhanced interaction between PXR and its coactivator,
steroid receptor coactivator-1 (SRC-1) [149]. SUMOylation did not, however,
alter PXRs ability to bind to the PXR response element within CYP3A4 [149].
They went on to demonstrate that site-directed mutagenesis of all four putative
lysine residues along with the NDSM abolished SUMO-1 mediated
transactivation [149]. Also, they identified a protein-protein interaction with an
E2 conjugating enzyme known as UbCh9, and this interaction was slightly
reduced with a NDSM mutant [149]. Collectively, these studies identified novel
putative lysine residues involved in hPXR SUMOylation and this may contribute
to ligand-elicited promoter-specific transsuppression and/or transactivation
connecting inflammation to xenobiotic metabolism, respectively (For more
information, see PXR in inflammation, section 1.5.4).

Acetylation
The last post-translational modifier that will be discussed in regards to
PXR function is acetylation. As discussed in the sections of ubiquitination and
SUMOylation, acetylation also targets the lysine side chain, which generates a
great potential for crossregulation between the post-translational modifiers [150].
Lysine acetylation was first identified in histones and is now known to occur in
more than 80 transcription factors and various cytoplasmic proteins [150, 151].
The acetylation pattern and impact vary from one protein to another, and the
effects can be multifaceted for one protein [150, 151]. Two independent groups
first described the physiological consequence of PXR acetylation and both will be
discussed below.
Biswas and colleagues first demonstrated that endogenous PXR, as well
as exogenous PXR, was acetylated in human cells [152]. Moreover, treatment
with a PXR or RXR agonist drove deacetylation (and/or suppressed acetylation)
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of PXR. Since the deacetylase sirtuin-1 (SIRT1) has been demonstrated to
deacetylate other nuclear receptors [153-155], they investigated the potential
involvement of SIRT1 on PXR acetylation [152]. Overexpressing SIRT1 had a
modest effect on PXR deacetylation but the effect was much more pronounced
with the combination of RXR/PXR ligands [152]. They did go on to determine
that SIRT1 could interact with PXR both in the presence and absence of
RXR/PXR ligands, suggesting a ligand-independent interaction [152]. Further,
resveratrol treatment (a SIRT1 activator) in WT murine primary hepatocytes
promoted lipogenesis and phenocopied the effect of PCN treatment (mousespecific PXR agonist) and this effect was alleviated with treatment of a HDAC
inhibitor (nicotinaminde), suggesting deacetylation of PXR may promote
lipogenesis independent of ligands [152]. Neither resveratrol nor nicotinamide
are PXR agonists. The effect of resveratrol treatment in lipogenesis was
alleviated in primary hepatocytes from PXR KO mice, suggestive of a PXRdependent effect. This work provides evidence that HDACs play a role in PXR
acetylation; however, SIRT1 seems to only act as a modest regulator thus more
work is required to elucidate which specific HDACs are involved in PXR
deacetylation. Moreover, it would be of interest to investigate possible
crossregulation at specific lysine residues with SUMOylation and ubiquitination
and assess the impact on PXR function. It is well known that PXR activation
promotes lipogenesis; more studies are required to investigate the possible
involvement of HDAC regulation on PXR activity in the context of lipogenesis.
An independent group examined the impact of energy sensing factors
PGC-1α and SIRT1 on PXR expression and function. Results from a mammalian
two hybrid assay indicated that SIRT1 interfered with the PXR and PGC-1α
interaction. Moreover, SIRT1 interacted directly with PXR. SIRT1 may disrupt
the PXR/PGC-1α interaction by two possible mechanisms that are not mutually
exclusive: the well-known deacetylation of PGC-1α [156] or the deacetylation of
PXR (summarized above). Collectively, both of these studies implicate
acetylation as a post-translational mechanism that modulates PXR function.
More work is required to elucidate the specific enzymes mediating
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acetylation/deacetylation and the global effect this has on PXR activity.
1.5

The Role of PXR in Sterol Metabolism

The role of PXR in xenobiotic metabolism has been thoroughly
investigated; however, its involvement in cardiometabolic diseases remains
elusive. The primary focus of this dissertation is to investigate the role of PXR
in cardiometabolic diseases, specifically hyperlipidemia. Accordingly, this
section will provide a comprehensive review of the current literature linking PXR
to lipid metabolism, atherosclerosis, diet-induced obesity, and inflammation.
1.5.1
PXR, Cholesterol Metabolism, and Atherogenesis
PXR has been implicated as a mediator of alterations in cholesterol
homeostasis in mice and humans. It has been well documented that PXR
transcriptionally regulates many genes involved in cholesterol catabolism,
specifically in the bile acid pathway (see below). However, the role of PXR in
sterol biosynthesis and secretion has been less defined. The first evidence of
PXR regulating sterol metabolism was demonstrated by Bachmann and
colleagues, who discovered that PXR agonist treatment in WT mice elicited
increases in serum HDL-C and hepatic apoA-1 levels [157]. This effect was
alleviated in PXR-deficient mice, indicating PXR is mediating this response
[157].
In contrast, an independent group demonstrated that hPXR activation with
rifampicin and lithocholic acid (LCA) treatment inhibited expression of ABCA1
and SR-B1 in human hepatic cells. This was further confirmed in rat primary
hepatocytes treated with rPXR agonists PCN and LCA [158]. Although cellular
cholesterol was unchanged with PXR agonists, cholesterol uptake or secretion
into apoA1-containing lipoproteins was not investigated. The effect of PXR
activation on ABCA1 and apoA1 gene expression and ultimately HDLcholesterol levels warrants further investigation.
The role of PXR in response to bile acids was investigated in the context
of altering lipoprotein metabolism. ApoA1 gene expression is negatively
regulated by FXR [159, 160]; however, other nuclear receptors have been
reported to positively regulate apoA1, such as HNF4α [160, 161]. Moreover,
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several PXR ligands were reported to increase HDL cholesterol and ApoA1
gene expression; thus, Masson and colleagues set out to investigate the role of
PXR in lipoprotein metabolism in response to dietary cholic acid (CA) [160].
The authors concluded that the expression of PXR antagonizes the CAmediated downregulation of plasma HDL cholesterol and apoA1 gene
expression [160]. The expression of a human PXR transgene in PXR-null mice
completely reversed the deleterious effects of CA on plasma HDL [160].
Collectively, these data support previous claims that PXR activation increases
hepatic apoA1, circulating apoA1, and HDL cholesterol in rats, mice, and
humans [96, 157, 162-167].
Recently, a more thorough investigation of intestinal PXR activation on
ABCA1 and HDL metabolism was published. Treatment with the human PXR
ligand rifampicin significantly increased CYP27A1 expression in human
intestinal Caco2 cells but not in human hepatic cells (both primary cells and the
immortal HepG2 cells); however, rifampicin treatment did stimulate expression
of CYP3A4 in both cell types, indicative of tissue-specific differences in gene
expression [168]. This was further confirmed utilizing a CYP27A1 promoter
luciferase construct overexpressed with hPXR. hPXR overexpression only
stimulated CYP27A1 promoter activity in human intestinal Caco2 cells but not
human hepatic HepG2 cells [168]. Further, 3-PXR binding sites were identified
in the CYP27A1 promoter and gel-shift analysis revealed PXR was competent
at binding to each element [168]. ChIP analysis revealed rifampicin treatment
promoted SRC-1 coactivator association at each PXR-response element. It
would have been interesting to utilize HepG2 nuclear extracts to repeat the
ChIP experiments to determine if the recruitment of SRC-1 with rifampicin
treatment is specific to human intestinal cells [168]. The authors went on to
demonstrate that the direct-repeat-5 (DR-5) element approximately 1 kB
upstream from the transcriptional start site is the most important by
transactivation assays [168]. CYP27A1 catalyzes the oxidation of cholesterol to
generate 27-hydroxycholesterol, a potent LXRα ligand [169-173]. The
consequence of PXR-mediated CYP27A1 induction was elevated intracellular
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27-hydroxycholesterol levels, which ultimately drove ABCA1 levels and
increased cholesterol efflux from intestinal cells to ApoA1 and HDL, most likely
through increased LXRα activity [168].
According to the work by Masson and colleagues, PXR antagonizes the
CA-mediated decrease in plasma HDL levels. So Hoekstra and colleagues
hypothesized that PXR activation may decrease atherosclerosis by promoting
reverse cholesterol transport via enhancing HDL-cholesterol. They utilized both
atherosclerosis mouse models (LDLR and ApoE-deficient mice) to assess the
role of PXR activation on plasma lipid levels [174]. LDLR- knockout mice fed
PCN for 3 days had a significant reduction in LDL-cholesterol levels, which was
not attributed to decreases in VLDL-secretion [174]. The authors went on to
demonstrate that lipolysis decreased with PCN treatment and this effect was
primarily due to a decrease in hepatic lipase activity [174]. Hepatic lipase and
its cofactor apolipoprotein A4 were both downregulated in the liver of PCNtreated mice [174]. Consistent with a decrease in lipolysis, VLDL triglycerides
were increased with PCN treatment. The authors concluded that the change in
the plasma lipoprotein profile was primarily due to impaired metabolism of VLDL
[174]. Lastly, they examined the role of PXR in ApoE-deficient mice fed chow
with and without PCN. In both hyperlipidemic models, hepatic steatosis was
enhanced with PCN treatment [174]. These data support the notion that PXR
activation promotes hepatic steatosis by a variety of mechanisms (Fig. 1.3);
however, the effect on plasma lipid levels needs to be further investigated.
A recent study revealed that PXR transcriptionally regulates Lipin-1, an
enzyme involved in triglyceride production [182]. Further, PXR-deficient mice
exhibit impaired VLDL secretion compared to WT mice; however, VLDL
secretion was not measured in mice treated with PXR agonists. Taken
together, the current data suggest that PXR may play some role in altering
VLDL secretion.
To further assess the role of PXR in lipid metabolism, Zhou and
colleagues fed WT and PXR-deficient mice a low-cholesterol diet with and
without PCN and examined the lipoprotein profiles [177]. After 2 weeks of
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feeding, WT but not PXR KO mice fed PCN had significantly elevated
proatherogenic VLDL and LDL cholesterol levels [177]. Moreover, PCN
treatment for 8 weeks in ApoE-deficient mice accelerated atherosclerosis
defined by neutral lipid staining in the brachiocephalic artery (+54%) and the
aortic root (+116%) [177]. Plasma lipids were similar in ApoE-deficient mice fed
control and PCN, however there was a slight reduction in HDL-cholesterol with
PCN treatment [177]. These data suggest that the atherosclerosis phenotype is
most likely independent of lipid levels in these ApoE-deficient mice.
Accordingly, PXR activation increased CD36 expression and lipid accumulation
in peritoneal macrophages [177]. This data implicates macrophage PXR as a
modulator of atherosclerosis. Furthermore, this was the first study identifying
PXR activation elicits proatherogenic hypercholesterolemia. The precise
mechanisms regulating cholesterol metabolism is still unclear.
Consistent with the notion that PXR plays a role in macrophage function in
atherosclerosis, our group demonstrated that PXR-deficiency on an ApoEdeficient background decreased atherosclerosis [178]. Our laboratory
generated PXR and ApoE double knockout mice (PXR-/-ApoE-/-) and deficiency
of PXR did not alter plasma triglycerides or cholesterol levels compared to
ApoE-/- mice [178]. However, PXR-/-ApoE-/- mice had decreased atherosclerosis
quantified by Oil-Red O staining in the aortic root (-40%) and brachiocephalic
artery (-60%) [178]. Consistent with the previous study [177], deficiency of PXR
reduced expression of CD36, lipid accumulation, and oxidized LDL uptake in
peritoneal macrophages [178]. CD36 expression was also decreased in the
atherosclerotic lesions of PXR-/-ApoE-/- mice [178]. Collectively, this data
demonstrates that basal PXR is essential for foam cell formation and
atherosclerosis.
More recently, our group demonstrated that chronic exposure to BPA
enhanced atherosclerosis in PXR-humanized ApoE-deficient mice
(huPXRApoE-/-) [86]. We previously reported that BPA and its analogs activate
PXR [179]. Interestingly, we found that BPA is a potent agonist for human PXR
but not for mouse or rat PXR [179]. Since BPA is a human PXR-specific ligand,
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we set out to generate a model to study the effects of BPA-mediated PXR
activation on atherosclerosis in mice. Thus, we utilized the previously
characterized huPXR mice [109, 180], which express the human PXR gene in
place of the mouse PXR gene, and crossed these mice with atherosclerosisprone ApoE-/- mice to generate huPXRApoE-/- and PXR-/-ApoE-/- mice [86]. The
huPXRApoE-/- and PXR-/-ApoE-/- mice have the same genetic background
(mPXR and ApoE null alleles) except for one allele of huPXRApoE-/- carrying
the human PXR transgene [86]. Chronic 12-week BPA treatment did not alter
body weight or plasma lipid levels in either huPXRApoE-/- or PXR-/-ApoE-/- mice;
however, BPA exposure significantly enhanced atherosclerotic lesion area in
both the aortic root and the brachiocephalic artery from huPXRApoE-/- mice, but
not from PXR-/-ApoE-/- mice [86]. Furthermore, BPA increased foam cell
formation and CD36 expression in macrophages and atherosclerotic lesions of
huPXRApoE-/-, but not in PXR-/-ApoE-/- mice [86]. These findings demonstrate
that BPA exposure increases atherosclerosis development in an animal model
expressing only human PXR.
Consistent with the notion that PXR agonists have been reported to alter
cholesterol levels in humans, 13 SNPs were identified in PXR that correlated
with aberrant LDL-cholesterol levels [181]. Interestingly, many of these SNPs
were located in the 3’ UTR of PXR [181], indicating possible post-transcriptional
modifications in PXR. Although the data did not demonstrate whether these
SNPs correlated with elevated or decreased LDL-cholesterol levels, it would be
worth investigating.
The main emphasis of the work in this dissertation was to identify new
PXR ligands, as well as novel PXR transcriptional targets involved in cholesterol
metabolism. We identified NPC1L1 as a direct PXR target gene in Chapter 3;
however the in vivo physiological consequence of PXR activation on intestinal
cholesterol absorption remains to be determined.
1.5.2

PXR in Cholesterol Catabolism – Emphasis on Bile
Acids
Bile acids act as signaling molecules through a variety of mechanisms,
including acting as ligands for the nuclear receptors FXR and PXR. For example,
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utilizing a mammalian two-hybrid system, Xie and colleagues revealed that LCA,
chenodeoxycholic acid, and deoxycholic acid are PXR agonists [183]. The major
mouse metabolite of LCA, 3-keto-LCA, is a more potent PXR agonist than its
parent [183, 184]. The hierarchy of potency is as follows: 3-ketoLCA>LCA>DCA=CA [88, 184, 185]. They confirmed that both these primary and
secondary bile acids could activate both mouse and human PXR and induce
downstream CYP3A4 expression [183]. LCA has been shown to cause
cholestasis and associated hepatotoxicity [183]. When WT, PXR-null, or AlbVPSXR transgenic animals were treated with control or LCA for 4 d, 58% of WT
and 100% of PXR-null exhibited clear hepatic necrosis when treated with LCA
[183]. In response to LCA treatment, compared with WT mice, PXR-null mice
exhibited more hepatic inflammatory infiltration [183]. In comparison, the AlbVPSXR transgenic mice showed no histological changes with LCA treatment
[183]. These data demonstrate that constitutive activation of hepatic PXR
protects against LCA-induced liver damage. To further investigate whether the
induction of the CYP enzymes such as CYP3A provide a protective effect against
LCA-induced hepatotoxicity, WT and PXR-null mice were pretreated with PCN
prior to LCA treatment. As anticipated, the incidence of LCA-induced histological
liver damage after PCN treatment was decreased approximately 60%; however,
PXR-null mice remained sensitive to LCA after PCN treatment [183]. This is
consistent with data demonstrating that transgenic overexpression of PXR and
the sustained induction of CYP3A enhanced protection against xenobiotic
compounds [108, 183]. Further, PXR-null mice exhibit loss of protection to a
wide range of xenobiotics, not just LCA [183]. The authors went on to
demonstrate that the CYP3A enzymes in human liver microsomes primarily
catalyze LCA hydroxylation [183].
Is PXR simply a sensor that is activated by bile acids to induce expression
of CYP enzymes to promote hydroxylation and excretion of bile-acid derivatives?
Although that is a major function of PXR in cholesterol catabolism, independent
groups have observed and identified a feedback mechanism, much like FXR,
where PXR also inhibits bile-acid synthesis by suppressing the rate-limiting
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enzyme, CYP7A1. Interestingly, rifampicin, a potent human PXR activator, has
been used to treat cholestasis [186]. It was later identified that rifampicin is
required for PXR and HNF4α binding, which blocked PGC-1α binding to HNF4α
ultimately suppressing CYP7A1 gene transcription [187]. Thus, rifampicin
inhibition of bile acid synthesis may be a protective mechanism against
xenobiotic and bile-acid induced cholestasis [187].
Aside from transcriptionally repressing CYP7A1 to inhibit subsequent bile
acid synthesis, PXR also transcriptionally activates genes involved in bile acid
uptake, as well as bile acid elimination. For instance, rat PXR was identified to
transcriptionally regulate the organic anion transporting polypeptide 2 (OATP2), a
liver transporter that mediates uptake of a variety of compounds, including
conjugated steroids, thyroid hormones, and bile salts [188]. PXR has also been
demonstrated to transcriptionally activate the multi-drug resistance associated
proteins 2 (MRP2) [189], MRP3 [190], and the bile salt export pump (BSEP) [191]
facilitating bile acid elimination [192]. Interestingly, PXR itself is a direct
transcriptional target of ligand-activated FXR [185, 193]. Taken together, PXR
acts as a bile acid sensor that can mitigate the harmful effects of toxic bile acids
by driving expression of genes involved in hepatic detoxification [185].
1.5.3
PXR and Energy Metabolism
Perturbations in lipid homeostasis are an underlying cause of many
disease states, such as obesity and diabetes. Hepatic lipid homeostasis is
tightly controlled by a variety of mechanisms including lipogenesis, β-oxidation,
lipid uptake, and secretion. Many clinical observations led to the hypothesis that
PXR may play a role in regulating lipid metabolism. Notably, patients treated
with rifampicin develop hepatic steatosis [194], which is also observed in many
animal models [114, 194-197]. This section will provide insight into the role of
PXR in modulating lipid homeostasis, with an emphasis on fatty acid and
triglyceride metabolism.
Recent work by independent groups reported that PXR activation causes
hepatic steatosis characterized by accumulation of hepatic triglycerides [114,
194-197]. Mice expressing constitutively active hPXR in the liver [108] had
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severe steatosis characterized by significant accumulation of triglycerides [114].
Further analysis revealed the lipogenic gene expression signature was vastly
altered. Interestingly, however, expression of SREBP-1c, a major regulator of
de novo hepatic lipid biosynthesis, was unaltered, as well as its major target
genes fatty acid synthase (FAS) and acetyl CoA carboxylase (ACC) [114].
These results suggest that the effect of PXR on hepatic steatosis was SREBPindependent. Further, CD36 was induced in a PXR-dependent manner [114].
Mice lacking CD36 exhibit increased plasma free fatty acids and triglyceride
levels, indicative of its role in fatty acid uptake [198]. PXR activation resulted in
a decrease in plasma free fatty acids [114]; however, it is still unclear whether
this is a CD36-dependent mechanism. The authors went on to identify a
functional PXR DR3-type response element within the CD36 promoter. These
results confirm that CD36 is indeed a PXR-target gene and may partially
contribute to the hepatic steatosis phenotype observed in mice expressing
constitutively active PXR [114].
PXR activation was also associated with upregulation of many genes
involved in lipogenesis, such as PPARγ, stearyl CoA desaturase 1 (SCD1), and
fatty acid elongase (FAE) [114, 195]. It was later confirmed that PPARγ is a
PXR target gene [199, 200]. Interestingly, PPARγ is also a positive regulator of
CD36 [201], indicating PXR activation may drive CD36 expression directly or
through crosstalk with PPARγ (Fig. 1.3). The consequence of PXR
transcriptionally regulating PPARγ in the context of hepatic steatosis remains to
be determined; however, two reports have demonstrated that overexpression of
PPARγ in mice induced hepatic steatosis [194, 202, 203]. The marked steatosis
associated with increased levels of lipogenesis-related genes, including CD36
and SCD1, as well as others [202, 203].
Aside from PPARγ, other genes involved in lipogenesis were discovered
as direct PXR targets. The thyroid hormone-responsive SPOT14 homolog
(S14) plays a critical role in inducing lipogenic enzyme gene expression, notably
FAS and ATP citrate lyase (ACLY) [194]. It was later identified that S14 is a
PXR target gene in human hepatocytes and mouse liver [204]. S14
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overexpression in human HepaRG cells provoked increases in fatty acid
accumulation and lipogenesis [204]. It was previously reported that PXR
activation did not alter mRNA levels of FAS and ACLY [114]. Thus, more work
is required to completely understand the complex mechanisms associated with
PXR and its target genes in the context of hepatic steatosis.
Several observations made by independent groups suggest that PXR
activation suppresses expression of genes involved in β-oxidation. The
constitutively active hPXR mice displayed a significant reduction in mRNA levels
of several genes involved in fatty acid β-oxidation, such as PPARα and thiolase
[114, 199]. Furthermore, an independent group revealed murine PXR activation
down-regulates the mRNA level of mitochondrial carnitine palmitoyltransferase 1
(Cpt1) and mitochondrial 3-hydroxy-3-methyl-glutarate CoA synthase 2
(Hmgcs2) [195]. Cpt1α and Hmgcs2 are the rate-limiting enzymes of βoxidation and ketogenesis, respectively. CPT1α expression is tightly controlled
by a variety of transcription factors, such as the insulin-responsive forkhead
factor A2 (FoxA2). FoxA2 has been shown to positively regulate genes
controlling β-oxidation [205]. Interestingly, it was demonstrated that PXR
physically interacts with FoxA2 through their ligand and DNA binding domains,
respectively [194, 195, 199]. This interaction prevents the binding of FoxA2 to
its DNA response elements and represses its activation of Cpt1α and Hmgcs2
gene promoters [194, 195, 199]. Consistent with the hypothesis that PXR
affects both fatty acid β-oxidation and ketogenesis, PXR-deficient mice display
elevated levels of oxygen consumption, liver mitochondrial β-oxidation, and are
completely protected against HFD-induced obesity [182]. In contrast, transgenic
expression of PXR suppressed hepatic β-oxidation and exacerbated hepatic
steatosis [182]. Moreover, PXR activation decreased ketone body (3hydroxybutylate) levels in mice [182]. Collectively, PXR regulates hepatic lipid
metabolism by driving expression of genes controlling hepatic lipid uptake and
formation, while suppressing fatty acid catabolism by turning off genes involved
in β-oxidation and ketogenesis (Fig. 1.3).
Hepatic gluconeogenesis is essential for survival during fasting or
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starving because glucose is necessary as a fuel source in central and peripheral
tissues. Pyruvate is a precursor for gluconeogenesis, which undergoes several
enzymatic steps to ultimately generate glucose. Hepatic gluconeogenesis is
positively regulated by glucocorticoids, cAMP, and glucagon, and negatively
regulated by insulin and glucose [194]. Major enzymes involved in this process
include notably phosphoenolypyruvate carboxykinase (PEPCK) and glucose-6phosphatase (G6Pase) [194]. These genes are significantly repressed in mice
expressing a constitutively active form of PXR [114]. Consistently, murine PXR
activation with PCN decreased fasting blood glucose levels in WT but not PXRdeficient mice [195]. Other groups have demonstrated that PXR can bind to
transcription factors and inhibit their ability to drive expression of target genes
involved in gluconeogenesis. For example, PXR represses glucagon-activated
transcription of both G6Pase and PEPCK by directly binding to the cAMPresponse element binding protein (CREB) and inhibiting its DNA-binding ability
[206]. Moreover, ligand-activated PXR can bind to the forkhead box protein O1
(FoxO1), another positive regulator of gluconeogenesis, subsequently
suppressing FoxO1-mediated activation of gluconeogenic gene expression
[207]. However, this mechanism does seem to be gene-specific because
FoxO1 acts as a positive regulator involved in PXR transactivation of its
xenobiotic target genes [207].
Although reports have demonstrated that PXR activation suppresses
gluconeogenesis in mice, studies in humans have suggested that PXR agonists
increase blood glucose levels [208-213]. For example, rifampicin treatment
increases blood glucose levels during oral glucose tolerance tests in
tuberculosis patients and healthy subjects [210, 213]. Statins, which are weak
PXR agonists, increase fasting blood glucose levels in patients with and without
diabetes [209, 211, 212]. Recent studies by Gotoh and Negishi have elucidated
the mechanism responsible for the species-specific differences in PXRregulated gluconeogenesis [208, 209]. They discovered that rifampicin
treatment increased G6Pase and PEPCK mRNA levels in HepG2 cells stably
expressing human PXR [208]. Further, they identified the serum- and
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glucocorticoid-regulated kinsase 2 (SGK2) as a direct PXR target gene that is
essential for PXR-induced gluconeogenic gene expression and increased
glucose production [208]. This pathway is insulin-independent, as siRNA
targeting FoxO1 did not affect rifampicin induction of G6Pase [208]. In human
primary hepatocytes, PXR induced G6Pase in the presence of high levels of
SGK2, whereas PXR repressed G6Pase in its absence [208]. These results
suggest that differential expression of SGK2 may be responsible for the
species-specific differences in PXR-mediated regulation of gluconeogenesis.
Gotoh and Negishi went on to demonstrate that PXR activation with
statins increases binding between PXR, SGK2, and the protein phosphatase 2C
(PP2C). This increase in binding stimulates PP2C dephosphorylation of SGK2
at Thr193 [209]. Nonphosphorylated SGK2 co-activates PXR transcription of
gluconeogenic genes in human liver cells, thereby enhancing gluconeogenesis
[209]. Interestingly, statin treatment increased SGK2 phosphorylation and
decreased PEPCK1 levels in mice [209]. Thus, elevated SGK2 phosphorylation
might be the underlying basis for the attenuated hepatic gluconeogenesis in
mice after statin treatment [209].
Taken together, these results clearly demonstrate that PXR has a complex
role in energy metabolism by promoting lipogenesis and suppressing fatty acid
β-oxidation and ketogenesis (Fig. 1.3). Murine and human PXR, however, have
opposing effects on gluconeogenesis possibly due to alterations in SGK2
phosphorylation and its ability to act as a PXR coactivator.
1.5.4
PXR and Inflammation
Inflammation is a biological response that recruits immune cells and tissue
repair processes to sites of infection and injury [214]. Nuclear receptor ligands
have been used extensively to treat inflammatory diseases [214]. Work
pioneered by Hench and colleagues identified the use of cortisone for the
treatment of rheumatoid arthritis [215]. It was later identified that cortisone is a
ligand for the glucocorticoid receptor (GR) [214]. Constitutive activation of
LXRα, for example, has been shown to suppress LPS-induced inflammatory
gene expression in macrophages [216]. Moreover, ligand-activated LXR also
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inhibits the induction of inflammatory genes [217-219]. The GR, as well as the
PPARs and LXRs, have been shown to suppress inflammation by a
transrepression mechanism, where the nuclear receptor tethers to the
transcription factors nuclear factor-kappa B (NF-κB) or activator protein-1,
preventing coactivator association necessary for gene activation [214]. Aside
from directly interacting with pro-inflammatory transcription factors, nuclear
receptors may also modulate inflammation by functions of their target genes.
For example, LXR activation inhibits signaling from the toll-like receptors (TLRs)
through ABCA1-dependent changes in membrane lipid composition, which
disrupt the recruitment of adaptor proteins involved in the inflammatory
response [220]. The involvement of nuclear receptors and their target genes in
inflammation is complex and warrants further investigation. Herein, I will
describe some mechanisms by which PXR undergoes reciprocal crosstalk with
NF-κB signaling.
Rifampicin, a macrocylic antibiotic and potent PXR ligand, was first used
as an antituberculus agent and now is used for a wide variety of bacterial and
fungal diseases [221, 222]. Aside from rifampicin, other PXR ligands have been
shown to exert immunosuppressive side-effects [222, 223]. For this reason,
PXR has recently been shown to be an attractive therapeutic target for the
treatment of inflammatory bowel disease (IBD) [224, 225]. IBD is a chronic
inflammatory disease of the gastrointestinal tract. IBD primarily includes
Crohn’s disease (CD) and ulcerative colitis (UC) [224, 225]. UC is an
inflammatory disease that affects the lining of the intestine, whereas CD can
affect any part of the digestive tract [224, 225]. While the etiology of IBD
remains to be determined, it is thought to involve increased intestinal
permeability and dysregulation of the mucosal immune system [226]. Both UC
and CD result in abdominal pain, diarrhea, rectal bleeding, and malnutrition
[224, 225]. Patients with either UC or CD exhibit a much higher incidence of
colon cancer compared to the general population [225].
The role of PXR in IBD has recently been investigated experimentally in
mouse models. Dextran sulfate sodium (DSS) is used experimentally to induce
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IBD in animal models. WT mice treated with the mouse PXR ligand PCN were
protected from DSS-induced IBD compared with vehicle control-treated mice
[226]. However, this phenotype was not observed in PXR-null mice [226]. PCN
treatment in WT mice did not enhance intestinal barrier function, but did
significantly decrease NF-κB target gene expression in a PXR-dependent
manner [226]. A similar phenotype was observed in human colon epithelial cells
[227], as well as in PXR-humanized mice with treatment of rifaximin [228], a
FDA-approved intestine-specific human PXR agonist used for the treatment of
traveler’s diarrhea [224]. It was then confirmed that PXR activation inhibits LPSinduced NF-κB DNA-binding activity [227]. Interestingly, treatment with PXR
ligands increases the physical association between PXR and the NF-κB subunit
p65 [227]. These results demonstrate that the suppressive effect of PXR may
be due to the physical association between PXR and p65, thereby decreasing
the overall promoter occupancy of NF-κB on its target genes [227].
Independent groups have reached a similar conclusion. It was further
confirmed that PXR agonists inhibit the expression of multiple NF-κB target
genes in human liver samples [222]. PXR inhibited NF-κB activity in the
absence of exogenous ligand and treatment with RIF further enhanced this
repression mediated by PXR [222]. Consistently, PXR activation in mice inhibits
NF-κB signaling in vivo and NF-κB target gene expression is upregulated in
PXR-deficient mice, which associated with enhanced small bowel inflammation
[222].
Targeting PXR for inflammatory diseases display some therapeutic
promise. The underlying mechanism how PXR disrupts NF-κB signaling and
ultimately inflammation needs to be dissected further. It should be noted that
activation of NF-κB has also been shown to suppress PXR target gene
expression [91], therefore implicating reciprocal regulation between PXR/NF-κB
signaling. Since others groups demonstrated that p65 and RXR physically
interact [229], the binding between p65 and RXR may interfere with the
formation of the p65-p50 complex, as well as the PXR/RXR complex upon an
inflammatory stimulus; however, this needs to be investigated further [224, 229].
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1.5.5
IKKβ and NF-κB Signaling – an Overview
Pattern recognition receptors (PRRs) are essential to sense and respond
to stimuli for early detection of invading pathogens and initiating an immune
response. PRRs are activated by a host of pathogen-associated molecular
patterns which are present in microbes or nucleic acids of viruses or bacteria.
Chronic activation of these receptors, such as the Toll-like receptors (TLRs),
has been linked to a variety of disease states, including: cancer, obesity, type-2
diabetes, and atherosclerosis. There are 10 recognized TLR genes in humans
and 12 in mice [230]. TLRs are activated by a variety of pathogen-associated
molecules and endogenous signals, such as proatherogenic forms of LDL [231],
saturated fatty acids [232, 233], and cleavage products of amyloid precursor
protein [234], which can activate TLR4 and/or TLR2 [214]. After recognition of
their ligands, TLRs recruit a set of adaptor proteins, such as MyD88, which
result in triggering downstream signaling cascades that culminates in the
activation of the transcription factor NF-κB [235].
NF-κB belongs to the Rel-homology domain-containing protein family,
which includes p65/RelA, p50/NF-κB1, p52/NF-κB2, Relb, and c-Rel [236, 237].
The prototypical NF-κB is thought to be a heterodimer consisting of the p65 and
p50 subunits [236, 237]. In unstimulated cells, the heterodimer is sequestered
in the cytoplasm by interacting with the inhibitor of NF-κB (IκB) proteins. Upon
stimulation of TLR signaling, IκBs are phosphorylated by the IKK complex
consisting of the IKKα and IKKβ protein kinases and a regulator subunit,
IKKγ/Nemo. IKKβ is the predominant catalytic subunit involved in NF-κB
activation [238, 239]. The phosphorylation targets IκBs for ubiquitination and
degradation, allowing NF-κB to translocate to the nucleus to modulate gene
transcription [237].
NF-κB signaling has been extensively studied in a variety of cell-types and
disease states. The work provided within Chapter 4 of this dissertation
investigates the role of IKKβ in adipose stem cell differentiation in HFD-induced
obesity. The next section will provide an overview of some recent advances
made in the field of inflammation and obesity, with an emphasis on IKKβ and
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NF-κB.
1.5.6

The Role of IKKβ Signaling in Diet-Induced Obesity
and Insulin Resistance
Diet-induced obesity and associated insulin resistance is becoming
increasingly prevalent, with approximately 35% of U.S. adults being obese
[240]. Thus, there is an urgent need to identify therapeutic targets to treat
obesity and its related conditions, including heart disease, stroke, type 2
diabetes, and cancer.
High doses of salicylates (4-10 g/day), which include sodium salicylate
and aspirin, have been used to treat inflammatory conditions such as
rheumatoid arthritis, but they have also been demonstrated to lower blood
glucose levels [241]. It was later demonstrated that salicylates can inhibit IKKβ
[242], as opposed to working through the cyclooxygenases [241]. Treatment of
genetically engineered obese animal models with high doses of salicylates
reversed hyperglycemia, hyperinsulinemia, and dyslipidemia by sensitizing
insulin action [241]. Further, heterozygote deletion of IKKβ protected mice
against insulin resistance associated with HFD-feeding [241]. It should be noted
that mice with homozygous deletion of IKKβ die in utero due to enhanced liver
apoptosis [243]. To further understand the tissue-specific role of IKKβ in
obesity-induced insulin resistance, Arkan and colleagues generated hepatocyte
and myeloid-specific IKKβ knockout mice and assessed the contribution of each
tissue in insulin tolerance and glucose disposal [244]. Interestingly, hepatocytespecific KO mice retained insulin sensitivity in the liver, but developed insulin
resistance in muscle and fat [244]. Myeloid-specific KO mice, however, retained
global insulin sensitivity and were protected from insulin resistance [244]. Acute
LPS injection induced acute inflammation and hyperglycemia, however both
hepatocyte and myeloid-specific KO mice were more glucose tolerant.
Conclusions from this data suggest that IKKβ activation is deleterious to insulin
signaling and inhibition in specific cell types may be beneficial against type-2
diabetes [242].
A follow-up study by an independent group tested the hypothesis that
acutely elevated FFA (as opposed to chronically elevated FFA as seen above)
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would stimulate hepatic insulin resistance, which would be completely reversed
by sodium salicylate [245]. Seven hour infusion of intralipid suppressed insulininduced stimulation of peripheral glucose utilization and endogenous glucose
production; however, salicylate co-infusion completely prevented this phenotype
[245]. The authors demonstrated that salicylate treatment reversed lipidinduced phosphorylation of insulin-receptor substrate (IRS) and protein kinase B
(Akt) [245]. Years later, salicylates were also identified to activate adenosine
monophosphate-activated protein kinase (AMPK) [246]. Aspirin also activates
AMPK, but at high doses, so the results seen in both of these studies, as well as
humans, may partially be due to AMPK activation [246].
IKKβ and NF-κB activity are enhanced in response to excess FFA in a
variety of tissues, including liver, adipose tissue, and the hypothalamus [241,
244, 247-249]. Many other inducers of insulin resistance activate IKKβ,
including sphingomyelinase and ceramide [250]. IKKβ has been demonstrated
to phosphorylate IRS-1 promoting its degradation and thereby contributing to
insulin resistance [250]. Further, mutations at these specific sites enable the
mutated IRS proteins to better propagate insulin signaling [250]. Thus, IKKβ
may contribute to insulin resistance by directly suppressing the insulin signaling
pathway.
We and others have recently published reports investigating the role of
IKKβ in adipocyte hyperplasia. Ligands that activate the IKKβ signaling
pathway, such as FFA and LPS, stimulate adipocyte hyperplasia from
surrounding progenitor cells [251-254]. Likewise, we demonstrated that deletion
of IKKβ in smooth-muscle cells impaired adipocyte differentiation [255]. These
mice had elevated energy expenditure, decreased inflammation, and were
completely protected against HFD-induced obesity [255]. The main focus of the
work within Chapter 4 of this dissertation was to identify the mechanism of HFDelicited adipocyte hyperplasia by investigating the role of IKKβ specifically in the
adipose progenitor population in vivo.
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1.6

Scope of Dissertation
1.6.1

The Role of PXR in Xenobiotic-Induced
Dyslipidemia
The general hypothesis of the research herein is that xenobiotic-elicited
PXR activation promotes cardiovascular disease by modulating plasma lipid
levels. We also hypothesized that intestinal PXR contributes to xenobioticelicited hyperlipidemia by enhancing cholesterol absorption and chylomicron
secretion. To test these hypotheses, the following specific aims were proposed:

Specific Aim 1: To test the hypothesis that specific xenobiotics, such as HIV
drugs and phthalates/phthalate substitutes, are PXR-specific agonists and that
acute exposure to these xenobiotics induces hyperlipidemia in a PXRdependent manner.

Specific Aim 2: To test the hypothesis that intestinal PXR is necessary for
xenobiotic-induced hyperlipidemia through transcriptional regulation of NPC1L1
and MTP, which facilitates cholesterol absorption and chylomicron secretion,
respectively.

1.6.2

Targeting IKKβ in Adipocyte Lineage Cells for
Treatment of Obesity and Metabolic Dysfunctions
The general hypothesis of the research herein is that IKKβ signaling in
adipose progenitor cells promotes adipocyte hyperplasia thereby contributing to
HFD-induced obesity and insulin resistance. To test this hypothesis, the
following specific aims were proposed:

Specific Aim 1: To test the hypothesis that IKKβ is essential for adipose stem
cell differentiation in vitro and targeting adipose progenitor IKKβ in vivo will
alleviate diet-induced obesity, adipose tissue inflammation, and insulin
resistance.

Specific Aim 2: To test the hypothesis that pharmacological inhibition of IKKβ
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with antisense oligonucleotides (ASOs) will protect mice from diet-induced
obesity and associated metabolic disorders.
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Figure 1.1 Schematic illustration of lipoprotein metabolism.
This figure depicting lipoprotein metabolism was reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews: Genetics [256], 2009. This
illustration coincides with Chapter 1.1 (Cholesterol Metabolism- an Overview).
Abbreviations: cholesterol (C), triglyceride (TG), fatty acid (FA), NiemannPick C1-like 1 (NPC1L1), heterodimeric ATP-binding cassette transporter
G5/G8 (ABCG5/G8), microsomal triglyceride transfer protein (MTTP),
chylomicron (CM), apolipoprotein B (APOB) isoform 48 and 100 (B48/B100),
apolipoprotein A5 (A5), apolipoprotein C2 and C3 (C2/C3), chylomicron
remnant (CMR), low-density lipoprotein (LDL), low-density lipoprotein
receptor (LDLR), LDLR-related protein-1 (LRP1), very low-density lipoprotein
(VLDL), VLDL remnant (IDL), hepatic lipase (HL), 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGCR), adaptor protein (AP), proprotein
convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein A1 (A1), ATPbinding cassette A1 and G1 (ABCA1/ABCG1), lecithin cholesterol
acyltransferase (LCAT), cholesterol ester transfer protein (CETP), endothelial
lipase (LIPG), and scavenger receptor class B type 1 (SRB1).
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Figure 1.2 Structure of human and mouse PXR.
Cartoon depiction of human and mouse PXR variants, as previously
illustrated [89, 98]. In humans, variant 1 (V1) corresponds to PXR wild type.
Variant 2 differs from V1 by the use of alternative translational start codons.
Variant 3 differs from V1 at the N-terminus, resulting in an open reading
frame 39 amino acids longer (denoted in red). Variant 4 contains an in-frame
deletion of 111 nucleotides (denoted in grey). In mice, V1 is analogous to
human V1. Mouse V2 contains an in-frame deletion of 123 nucleotides in a
similar region of the LBD and is analogous to human V4.
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Figure 1.3 Schematic representation of the role of PXR in energy
metabolism, xenobiotic metabolism, sterol metabolism, and
inflammation.
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Figure 1.3 Schematic representation of the role of PXR in energy
metabolism, xenobiotic metabolism, sterol metabolism, and
inflammation.
The information within this cartoon was compiled from previous review
articles [194, 199]. (A) PXR activation induces fatty acid uptake, lipogenesis,
and may promote VLDL secretion through induction of CD36, PPARγ, Lipin1,
Spot14, SCD-1, and possibly MTP. PXR may directly induce CD36
expression or indirectly through PPARγ. (B) PXR inhibits NF-κB-mediated
inflammation. It should be noted that mutual repression exists between these
two pathways. (C) Activation of PXR results in induction of Phase 1 and
Phase II drug-metabolizing enzymes and drug transporters. (D) PXR inhibits
fatty acid β-oxidation and ketogenesis through its suppression of PPARα
gene expression and by disrupting FoxA2-mediated activation of Cpt1α and
Hmgcs2. (E) In mice, PXR inhibits PEPCK and G6Pase gene expression by
interacting with the positive regulators of gluconeogenesis, CREB and
FoxO1, and disrupting their ability to activate these genes in mice. In
addition, mouse SGK2 remains phosphorylated at Thr193, thus it can no
longer act as a PXR coactivator on gluconeogenic promoters. In humans,
ligand-activated PXR promotes PP2C dephosphorylation of SGK2 at Thr193
leading to SGK2s ability to act as a coactivator for PXR on gluconeogenic
promoters, thus inducing gluconeogenesis. (F) PXR activation promotes
hypercholesterolemia through regulation of NPC1L1 and CYP27A1, while
suppressing CYP7A1, the rate-limiting enzyme involved in bile acid synthesis.
It has also been proposed that PXR may regulate ABCA1 gene expression,
but these studies are currently controversial. The focus of this dissertation is
to identify novel PXR target genes involved in lipid metabolism. Regulation of
NPC1L1 and MTP have been described herein, thus they have larger font
size in the current figure.

Copyright © Robert Nathaniel Helsley, 2016
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Chapter 2: HIV Protease Inhibitors Activate PXR and Induce Hyperlipidemia
in WT Mice
2.1

Introduction
The introduction of highly active anti-retroviral therapy (HAART) has led to

a marked increase in survival for people infected with human immunodeficiency
virus (HIV) [257]. However, HAART has also been associated with dyslipidemia
and an increased risk of cardiovascular disease [52, 53, 55, 58, 63, 64, 66]. For
example, findings from the Data Collection on Adverse Events of Anti-HIV Drugs
(DAD) study suggested that the incidence of cardiovascular disease increased
with longer exposure to HAART [63]. Another large-scale study including more
than 23,000 HIV patients analyzed the combination of drugs used in HAART
and concluded that protease inhibitors (PIs) are associated with an increased
risk of cardiovascular disease, which is partly explained by dyslipidemia [55]. A
Swiss HIV Cohort Study found that PIs are the cause of dyslipidemia in patients
[58], and several other studies have reached the same conclusion [64, 66].
Despite the strong evidence linking PIs with dyslipidemia and cardiovascular
disease, the underlying mechanisms responsible for the adverse effects of PIs
remain elusive.
Several PIs such as ritonavir have been implicated to activate the
pregnane X receptor (PXR, also known as steroid and xenobiotic receptor) [91,
258]. PXR is a nuclear receptor activated by numerous endogenous hormones,
dietary steroids, pharmaceutical agents, and xenobiotic chemicals [89, 91, 95].
PXR functions as a xenobiotic sensor that induces expression of genes required
for xenobiotic metabolism in the liver and intestine, including cytochrome P450s,

Reprinted with permission of the American Society for Pharmacology and
Experimental Therapeutics. All rights reserved.
Copyright © 2013 by The American Society for Pharmacology and Experimental
Therapeutics
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conjugating enzymes (e.g., glutathione transferase), and ABC family
transporters (e.g., multidrug resistance 1 [MDR1]) [90, 91]. In the past decade,
the role of PXR as a xenobiotic sensor has been well established [91].
Recent evidence indicates that PXR may also play an important role in the
regulation of lipid homeostasis [114, 177, 259, 260]. It is well known that many
clinically relevant PXR ligands can elevate plasma lipid levels in patients and
may increase their risk of cardiovascular disease [177, 261-264]. A recent
meta-analysis of seven genome-wide association studies indicated that
common genetic variants in PXR can affect plasma low-density lipoprotein
(LDL) cholesterol levels in humans [118]. Modulation of PXR activity has been
found to alter lipid homeostasis and affect plasma lipid levels in several animal
models. We recently reported that chronic activation of PXR led to increased
levels of plasma total cholesterol and atherogenic LDL and very-low-density
lipoprotein (VLDL) in wild-type (WT) mice, but not in PXR-deficient (PXR-/-) mice
[177]. Activation of PXR also increased plasma total cholesterol and VLDL
levels in apolipoprotein E (ApoE)*3-Leiden mice which exhibit a human-like
lipoprotein distribution on a cholesterol-rich diet [260]. Another report showed
that acute activation of PXR increased plasma triglyceride levels in both LDL
receptor-deficient (LDLR-/-) and ApoE- deficient (ApoE-/-) mice but decreased
LDL cholesterol levels in LDLR-/- mice [174]. Activation of PXR can regulate
many genes involved in lipid homeostasis including CD36, Stearoyl-CoA
desaturase-1, 7-dehydrocholesterol reductase, S14, and lipin-1 in the liver,
intestine, or macrophages of several animal models [91, 114, 174, 182, 204,
260, 265]. These studies indicate that PXR can mediate cholesterol and lipid
homeostasis at multiple levels.
We report that amprenavir, a widely used HIV PI, is a potent PXRselective agonist. Computational docking studies together with site-directed
mutagenesis identified several key residues within PXR’s ligand-binding pocket
that constitute points of interaction with amprenavir. Amprenavir efficiently
activated PXR and induced PXR target gene expression in vitro and in vivo.
Short-term exposure to amprenavir significantly increased plasma total
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cholesterol and atherogenic lipoprotein LDL cholesterol levels in WT mice, but
not in PXR−/− mice. Amprenavir-mediated PXR activation significantly regulated
several key intestinal genes involved in lipid homeostasis. These findings
provide critical mechanistic insight for understanding the impact of PIs on
cardiovascular disease and demonstrate a potential role of PXR in mediating
the adverse effects of PIs in humans.

2.2

Materials and Methods

2.2.1
Reagents and Plasmids
Pregnenolone 16α-carbonitrile (PCN) and rifampicin (RIF) were purchased
from Sigma- Aldrich (St. Louis, MO). Amprenavir, ritonavir, nelfinavir, saquinavir,
and indinavir sulfate were obtained from NIH AIDS Research and Reference
Reagent Program. All chemicals were dissolved in dimethyl sulfoxide (DMSO).
Human (h) and mouse (m) PXR expression vectors; GAL4 DNA-binding domain
(DBD)-linked nuclear receptor ligand-binding domain (LBD) vectors (GAL4hPXR, GAL4-mPXR, GAL4-rPXR, GAL4-RARα, GAL4-RXR, GAL4-FXR, GAL4LXR, GAL4-PPARα, GAL4-PPARγ and GAL4-VDR); and CMX-β-gal expression
vectors have been described before [179, 222, 266]. VP16-PXR, GAL4-nuclear
receptor corepressor (NCoR), GAL4-silencing mediator of retinoid and thyroid
hormone (SMRT), GAL4-steroid receptor coactivator (SRC1), GAL4-PPAR
binding protein (PBP), PXR-dependent CYP3A4 promoter reporter
(CYP3A4XREM-Luciferase); CYP3A2 promoter reporter [(CYP3A2)3-luciferase];
and GAL4 reporter (MH100-Luciferase) have also been described previously
elsewhere [179, 222, 266, 267].
2.2.2
Cell Culture and Transfections
The human hepatic cell line HepG2 and intestine epithelial cell line LS180
were obtained from the American Type Culture Collection (Manassas, VA). The
human hepatoma HepaRG cells were purchased from Life Technologies
(Carlsbad, CA). Transfection assays were performed as described previously
[179, 266]. The cells were transfected with various expression plasmids or
hPXR mutants as well as the corresponding luciferase reporter plasmids,
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together with cytomegalovirus X-β-galactosidase control plasmids using
FuGENE6 (Roche Diagnostics, Indianapolis, IN). The cells were then incubated
with the corresponding ligands as indicated in the figure legends for 24 h, and βgal and luciferase assays were performed as described elsewhere [179, 266].
Fold activation was calculated relative to solvent controls.
Each data point represents the average of triplicate experiments ± SD and
was replicated in 3-5 independent experiments. EC50 values were calculated
by curve fitting of data, using Prism software (GraphPad Software, San Diego,
CA). For the mammalian two-hybrid assays, HepG2 cells were transfected with
GAL4 reporter, VP16-hPXR, and GAL-SRC1, GAL-PBP, GAL-NCoR, and GALSMRT [179, 266]. The cells were then treated with compounds at the indicated
concentrations.
2.2.3
Computational Docking Studies
Preparation of the protein structure for subsequent ligand-receptor
docking studies was conducted as previously described [179]. Briefly, the
structural coordinates of the tethered hPXR linker PXR/SRC-1 were retrieved
from the RSCB Protein Data Bank entry 3HVL [268]. The larger PXR fragment
of chain A, Gly142-Glu458, was extracted for molecular modeling using MOE
2010 software (Chemical Computing Group, Montreal, Quebec, Canada), and
for ligand-receptor docking studies using GOLD software (version 5.0) [269].
Water molecules, salt ions, ligand [SR12813, tetraethyl 2-(3,5-di-tert-butyl-4hydroxyphenyl)ethenyl-1,1-bisphosphonate], and co-receptor fragments were
deleted. After the addition of hydrogen atoms and assigning of the AMBER99
force-field charges to the protein, the hydrogen atomic positions were allowed to
relax [268]. The resulting protein structural coordinates were saved in Tripos
mol2 format and used later for GOLD docking.
The ligands were docked to the 3HVL [268] chain A using semiflexible
docking whereby the ligand has full conformational flexibility and the hydroxyl
groups of designated protein side chains in the binding pocket can rotate to
optimize hydrogen bond contacts. Each ligand was docked 50 independent
times. The binding pocket was defined as all atoms within an 8-Å radius around
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the bound ligand, SR12813.
2.2.4
Site-Directed Mutagenesis
The hPXR full-length plasmid was used as a wild-type template to
generate a series of mutant plasmids using the QuikChange II Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the
manufacturer-supplied protocol as described before [179]. The primers used for
mutant generation are listed in Table 2.1.
2.2.5

RNA Isolation and Quantitative Real-Time
Polymerase Chain Reaction Analysis
Total RNA was isolated from mouse tissues, intestinal LS180, and
HepaRG cells using TRIzol Reagent (Life Technologies) per the manufacturersupplied protocol. Quantitative real-time polymerase chain reaction (QPCR) was
performed using gene-specific primers and the SYBR green PCR kit (Life
Technologies) as described previously [179, 266]. The primer sets used in this
study are listed in Table 2.2.
2.2.6
Animals
C57BL/6 WT mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). PXR- deficient mice (PXR-/-) on C57BL/6 background were
employed as described previously elsewhere [177]. All the animals were housed
in a specific pathogen-free environment with a light-dark cycle maintained by the
Division of Laboratory Animal Resources, University of Kentucky, and the
protocol was approved by the Institutional Animal Care and Use Committee. We
fed 8-week-old male WT or PXR-/- mice a semisynthetic low-fat AIN76 diet
containing 0.02% cholesterol (Research Diet; New Brunswick, NJ) [177, 178,
270] and treated them by oral gavage with vehicle (corn oil) or 10 mg/kg body
weight amprenavir daily for 7 days. On the day of euthanization, mice were
anesthetized by intraperitoneal injection with Ketamine (Fort Dodge Animal
Health, Fort Dodge, Iowa). The mice were exsanguinated by left ventricular
puncture, and the blood was collected into EDTA-containing syringes. Plasma
was prepared by spinning at 16,000 g for 10 min. The circulation was flushed
with phosphate-buffered saline, and the intestinal and liver tissues were
collected and stored in RNAlater solution (Life Technologies).
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2.2.7
Plasma Analysis
Plasma total cholesterol and triglyceride concentrations were determined
enzymatically by colorimetric methods as described previously (Roche
Diagnostics) [177, 271]. Plasma from multiple mice (n=4-7) was pooled, and the
plasma lipoprotein cholesterol distributions were determined by fastperformance liquid chromatography (FPLC) [178]. The lipoprotein fractions
were isolated by spinning 60 μl of plasma in a TL-100 ultracentrifuge (Beckman
Coulter, Brea, CA) at its own density (1.006 g/ml) at 70,000g for 3 hours to
harvest the supernatant, and then after adjusting the infranatant with solid KBr
to a density of 1.063 g/ml spinning it for 70,000g for 18 hours to harvest the
supernatant [272]. The cholesterol content of each supernatant and the final
infranatant were measured and taken to be very-low-density lipoprotein (VLDL)
(<1.006 g/ml), low-density lipoprotein (LDL) (1.006 ≤ d ≤ 1.063 g/ml), and highdensity lipoprotein (HDL) (d >1.063 g/ml) cholesterol, respectively. Cholesterol
concentrations in all three fractions were then determined enzymatically by a
colorimetric method (Roche Diagnostics). Plasma triglyceride levels were
determined enzymatically in the original plasma sample.
2.2.8
Statistical Analysis
All data are expressed as means ± SD unless otherwise noted. Statistical
analysis was performed using a two-sample, two-tailed Student t-test unless
otherwise noted, with P<0.05 regarded as significant. One-way analysis of
variance was used when multiple comparisons were made, followed by
Dunnett’s t-test for multiple comparisons to a control. Statistical analysis was
performed using SigmaPlot 13.0.

2.3

Results

2.3.1
Amprenavir Is a Potent PXR-Selective Agonist
We tested several widely used HIV PIs, including amprenavir, ritonavir,
nelfinavir, saquinavir, and indinavir sulfate, for PXR activation by use of
transfection assays. Because PXR exhibits considerable differences in its
pharmacology across species (namely, mouse versus human) [91, 95], the
potent PXR ligands RIF and PCN were used as the positive control for human
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(h) and mouse (m) PXR, respectively. Consistent with a previous report [258],
ritonavir activated PXR and induced PXR-mediated reporter activity (Fig. 2.1, A
and B). Interestingly, amprenavir was a more potent PXR agonist than any of
the other tested PIs (Fig. 2.1, A and B). Amprenavir can activate both human
and mouse PXR and induced reporter gene activity in a dose-dependent
manner (Fig. 2.1, A and B). Dose-response analysis indicated that amprenavir
was able to activate PXR at concentrations as low as 1 μM, reaching peak
activation at 30 μM (Fig. 2.1, C). The EC50 for amprenavir activation of PXRmediated CYP3A4 promoter activity was 8.6 μM (Fig. 2.1, C). We next tested
the ability of amprenavir to activate a panel of other nuclear receptors, including
human retinoid acid receptor, retinoid X receptor, farnesoid X receptor, liver X
receptor α, PPARα, PPARγ, vitamin D receptor, estrogen receptor α, and
estrogen receptor β (Fig. 2.1, D). Amprenavir was unable to activate any of
these other nuclear receptors. Results from this panel emphasize the
importance of studying the effects of amprenavir-mediated PXR agonism.
2.3.2

Amprenavir Promotes PXR Coactivator
Recruitment and Corepressor Disassociation
Nuclear receptor co-regulators play critical roles in nuclear receptor
signaling [90]. We used a mammalian two-hybrid assay [179, 266] to evaluate
the effects of amprenavir on PXR coregulator interaction. Similar to the potent
PXR ligand RIF, amprenavir promoted the specific interactions between PXR
and the coactivators SRC-1 and PBP (Fig. 2.2, A). Consistent with our previous
reports [179, 266], unliganded PXR interacted with corepressors, NCoR and
SMRT. Amprenavir disrupted this interaction, as did RIF (Fig. 2.2, B). Binding
of amprenavir to PXR inhibits PXR/corepressor interaction and promotes
PXR/coactivator recruitment, thereby inducing PXR transcriptional activation in
a concentration-dependent manner.
2.3.3
Computational Docking and Modeling Studies
To investigate the potential interaction pattern between amprenavir and
PXR, a structure-based approach was employed. Amprenavir was docked into
the high-resolution crystal structure of human PXR in complex with SR12813
[268]. The results from GOLD docking are shown in Figure 2.3A. The binding
54

pose of amprenavir in the PXR ligand-binding domain (LBD) is similar to
SR12813. The PXR LBD appears to possess four hydrophobic subpockets and
a connection region in the middle. Amprenavir occupies all four subpockets, and
its hydroxyl group forms a hydrogen bond with Ser247, which is located in the
connection region of PXR, to help to position the drug in the optimal orientation
inside the receptor. Another two hydrogen bonds were formed between
amprenavir and PXR (Gln285 and His407) that provide additional electrostatic
interactions.
Nonpolar contacts also play a key role in stabilizing amprenavir within the
ligand binding pocket of PXR. As displayed in Fig. 2.3B, the interaction map of
amprenavir and PXR revealed an important π-π stacking between ring A of
amprenavir and Phe288 in subpocket 1 of PXR. Tyr306 forms a 3.5-Å edge-toface contact to the same phenol ring of the drug that also engages in
hydrophobic interactions with Trp299, the other hydrophobic residue in
subpocket 1. In subpocket 2, amprenavir forms direct contacts with one residue
on αAF of the PXR activation function-2 (AF-2) surface, Phe429, which may
stabilize the active AF-2 conformation of the receptor and contribute to the
agonist activity of amprenavir on PXR. Subpockets 3 and 4 of PXR are located
on the bottom of the cavity, which corresponds to the most structurally flexible
region of the PXR LBD. This region is dominated by hydrophobic residues (e.g.,
Met323 and Leu209) that form van der Waals contacts with amprenavir.
2.3.4

Key LBD Residues of PXR Are Required for
Amprenavir’s Agonistic Activity
To validate the results of the docking analysis, we mutated the key amino
acids responsible for amprenavir’s agonist activity including Ser247, Gln285,
Phe288, and Tyr306. We also included Thr248, a key amino acid known to be
important for PXR/coactivator interaction [179, 273], and Leu411, an amino acid
predicted by the docking analysis not to interact with amprenavir, as the putative
positive and negative controls for our mutagenesis study, respectively. As
shown in Fig. 2.3C, Ser247Leu and Tyr306Leu mutations completely blocked
amprenavir’s agonist activity at all tested drug concentrations. Gln285Leu and
His407Ala exerted little or no effects on the drug at low concentration (5 μM). At
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higher concentrations (10 and 20 μM), these mutations showed inhibitory effects
on amprenavir’s activity. Phe288Ala showed some inhibitory effects on
amprenavir’s activity. As expected, the Thr248Leu mutation abolished the
activity of amprenavir; Leu411Phe did not inhibit but rather slightly promoted
amprenavir as an agonist. In summary, our site-directed mutagenesis analysis
confirmed the docking model and revealed the key residues within PXR’s
binding pocket responsible for amprenavir’s agonist effects.
2.3.5

Amprenavir Induces PXR Target Gene Expression
in Human Cells
We next used human hepatoma HepaRG cells [274] and intestinal LS180
cells [222, 266] to test the effects of amprenavir exposure on PXR activity and
target gene expression. Similar to the known human PXR ligand RIF,
amprenavir induced the expression of bona fide PXR target genes involved in
phase I (CYP3A4), phase II (UGT1A1), and phase III (MDR1) metabolism in
both HepaRG cells (Fig. 2.4, A) and LS180 cells (Fig. 2.4, B). These results
suggest that amprenavir can activate PXR and induce PXR target gene
expression in human cells.
2.3.6

Amprenavir Elevates Plasma Lipid Levels in WT
Mice, but Not in PXR-/- Mice
To further investigate the effects of amprenavir on PXR activity in vivo, WT
and PXR-/- mice were treated with vehicle (corn oil) or 10 mg/kg body weight of
amprenavir daily by oral gavage for 1 week. Amprenavir-treated WT mice had
significantly increased total cholesterol levels compared with control WT mice
(Fig. 2.5, A). By contrast, amprenavir did not affect plasma cholesterol levels in
PXR-/- mice (Fig. 2.5, B). The FPLC analysis of the cholesterol distribution
pattern revealed that amprenavir increased atherogenic LDL cholesterol
fractions in WT mice, but not in PXR-/- mice (Fig. 2.5, C and D). The lipoprotein
fractions (VLDL, LDL, and HDL) were isolated by ultracentrifugation [272], and
the cholesterol concentrations in all three fractions were then measured.
Consistent with the FPLC results (Fig. 2.5, C and D), amprenavir treatment did
not affect HDL or VLDL cholesterol levels but significantly increased LDL
cholesterol levels in WT mice (Fig. 2.6, A). By contrast, amprenavir did not
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affect any of the lipoprotein levels in PXR-/- mice (Fig. 2.6, B). These results
suggest that the adverse effects of amprenavir on plasma cholesterol levels are
mediated, at least in part, through PXR in mice.
2.3.7

Amprenavir Affects Genes Involved in Lipid
Homeostasis
To determine whether amprenavir can activate PXR in these mice, the
expression levels of known PXR target genes were measured in the intestine
and liver. Amprenavir stimulated expression of known PXR target genes,
including CYP3A11, glutathione transferase A1, and MDR1a, in the intestine
(Fig. 2.7, A) of WT mice but not in PXR-/- mice. Interestingly, amprenavir did not
affect the expression of hepatic PXR target genes (Fig. 2.7, B), which might be
due to the insufficient accumulation of amprenavir in the liver. To elucidate the
possible molecular mechanisms through which amprenavir-mediated intestinal
PXR activation might induce dyslipidemia, the expression levels of genes
involved in lipid homeostasis were measured (Fig. 2.7, C). Of the genes
surveyed, CD36 showed significant change, with its expression levels increased
more than 10-fold. CD36, a class B scavenger receptor, plays an important role
in intestinal lipid absorption [275].
Consistent with a recent report [265], the expression levels of
diacylglycerol acyltransferase 1 and 2 (DGAT1 and 2), two enzymes involved in
intestinal lipid transportation and chylomicron secretion [276], were also induced
by amprenavir-mediated PXR activation in WT mice. It was recently reported
that a Drosophila PXR ortholog DHR96 regulates expression of the intestine
lipase Magro (CG5932) which mediates cholesterol and triglyceride
homeostasis in Drosophila. Magro protein is most similar to mammalian gastric
lipase (LipF) (56% similarity) and lysosomal lipase (LipA) (50% similarity) [277].
Interestingly, amprenavir-mediated PXR activation stimulated the expression of
both LipF and LipA in the intestine of WT mice, but not in PXR-/- mice (Fig. 2.7,
C), indicating a possible role of intestinal PXR in mediating dietary lipid
breakdown and absorption in mammals. Taken together, upregulation of those
genes by PXR activation may contribute to amprenavir-elicited hyperlipidemia.
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2.4

Discussion

PIs have been associated with dyslipidemia and an increased risk of
cardiovascular disease [55, 58, 66], but the underlying mechanisms are still
unknown. Several PIs have been shown to activate PXR which functions as a
xenobiotic sensor to regulate genes required for xenobiotic metabolism in the
liver and intestine [90, 91]. We identified a widely used PI amprenavir as a
potent and selective PXR agonist. Amprenavir is usually taken by patients with
or without ritonavir. Interestingly, a case-control study suggested that the risk of
cardiovascular disease was increased by exposure to all PIs and, in particular,
to amprenavir with or without ritonavir [66]. We found that amprenavir activated
both human and mouse PXR but did not affect the activity of other nuclear
receptors. Short-term exposure to amprenavir significantly increased plasma
total cholesterol and LDL cholesterol levels in WT mice, but not in PXR-/- mice.
Amprenavir-mediated PXR activation regulated several key intestinal genes
involved in lipid homeostasis. These findings provide critical mechanistic insight
for understanding the impact of PIs on cardiovascular disease and demonstrate
a potential role of PXR in mediating adverse effects of HIV PIs in humans.
Using in silico ligand-PXR docking studies combined with site-directed
mutagenesis, we identified Tyr306, Ser247, His407, and Phe288 as
participating in the amprenavir-PXR interaction (Fig. 2.3). A critical polar
interaction with Ser247 helps to orient amprenavir in the ligand-binding cavity
that enables formation of nonpolar interactions with a highly hydrophobic region
of PXR’s ligand binding pocket lined by Phe288, Trp299 and Tyr306. These
three residues are highly conserved among different species and interact with
structurally diverse PXR agonists as shown in multiple published PXR X-ray
crystal structures. This Ser247-directed orientation of amprenavir also guided
the selection of the most plausible binding alignment among the multiple poses
generated by our docking simulations. Based on our previous modeling results
on diverse ligands with PXR, we conclude that two essential features need to be
satisfied for ligand binding to PXR, namely, (1) one key hydrogen bond with
Ser247 or His407 and (2) van der Waals contacts with subpocket 1. Besides
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the interactions formed by these two essential features, numerous hydrophobic
contacts between amprenavir and PXR further stabilize the ligand binding and
indirectly promote contact with the AF-2 region, thus forming the optimal
orientation of αAF helix to interact with coactivators. Our observations
regarding the key pharmacophoric features for PXR binding will hopefully
provide guidance useful for PXR ligand screening in the future.
The role of PXR in xenobiotic metabolism has been well established;
however, recent studies have revealed the role of PXR in dyslipidemia and
atherosclerosis. We recently demonstrated the pro-atherogenic effects of PXR
in animals [177, 178]. We previously reported that chronic activation of PXR
elicited by feeding mice the mouse PXR ligand PCN led to increased levels of
plasma total cholesterol and VLDL and LDL in WT mice, but not in PXR-/- mice
[177]. In our present study, mice were treated with 10 mg/kg per day
amprenavir to investigate its potential effects on lipid levels. Patients usually
take a daily dose of 1,400 mg or 2,800 mg of the amprenavir prodrug
fosamprenavir, which is rapidly and extensively converted to amprenavir after
oral administration [278]. Pharmacokinetic studies have demonstrated that the
mean peak plasma concentration of amprenavir is approximately 18 μM after a
1,200-mg single dose [279, 280], which is sufficient to activate PXR based on
our results (Fig. 2.1). Therefore, we believe that amprenavir can activate PXR
and regulate PXR target genes in patients taking this drug routinely.
The dose of 10 mg/kg per day amprenavir used in the present study to
treat animals is considered low or modest. Nevertheless, after 1 week of
treatment, amprenavir significantly increased plasma total cholesterol and LDL
cholesterol levels in WT mice, but not in PXR-/- mice, indicating the significant
role of PXR in mediating the adverse effects of amprenavir (Figs. 2.5 and 2.6).
Interestingly, amprenavir regulated the PXR target genes in the intestine but not
in the liver (Fig. 2.7). This could be explained by the relative low dose of
amprenavir and short-term treatment in this study. In addition, amprenavir is
metabolized by CYP3A4 enzyme in the liver [281]. Therefore, the relative low
dose of amprenavir used in the present study may be insufficient for amprenavir
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to reach the high concentrations required to activate PXR in the liver.
Intestinal lipid transportation plays a central role in lipid homeostasis. In
addition to prototypic PXR target genes (e.g., CYP3A11, MDR1a), amprenavir
significantly stimulated expression of several key genes involved in intestinal
lipid homeostasis in WT mice, including CD36, DGAT1, and DGAT2. We and
others have previously reported that activation of PXR induces CD36
expression and increases lipid accumulation in the liver [114], intestine [265],
and macrophages [177]. The role of CD36 in mediating intestinal fatty acid
uptake has been well established [275, 282, 283]; several studies have also
indicated that CD36 mediates cholesterol uptake in the intestine [282, 283]. For
example, cholesterol uptake was significantly decreased in the enterocytes
isolated from CD36-deficient (CD36-/-) mice [283]. In a lipid infusion study,
CD36-/- mice exhibited accumulation of dietary cholesterol in the intestinal lumen
and reduction of cholesterol transport into the lymph [282]. Therefore, the PXRmediated CD36 upregulation may contribute to amprenavir-stimulated elevation
of cholesterol levels.
In addition, Liang et al. [284] previously reported that PIs such as ritonavir
inhibit degradation and secretion of apolipoprotein B (ApoB), the primary
apolipoprotein of chylomicrons and LDL. Interestingly, the inhibitory effects of PI
on ApoB secretion were reversed by oleic acid, a fatty acid that stimulates
neutral-lipid biosynthesis [284]. In the presence of oleic acid, PI treatment even
increased ApoB secretion above controls [284]. Because CD36 plays an
important role in the absorption of oleic acid [283], it is plausible that PXRmediated CD36 expression increases oleic acid absorption and contributes to
PI-induced ApoB secretion and hyperlipidemia.
The precise mechanisms through which PXR modulates lipid homeostasis
and cholesterol levels in various animal models as well as in humans remain to
be determined. By contrast, the Drosophila PXR ortholog DHR96 has been
established to be a key regulator in mediating cholesterol and triglyceride
homeostasis [277, 285, 286]. Recent studies have shown that DHR96 regulates
expression of the intestine lipase Magro, which is most similar to mammalian
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LipA and LipF [277]. Both LipA and LipF were upregulated by amprenavirmediated PXR activation in the intestine of WT mice but not in PXR-/- mice (Fig.
2.7, C).
LipA is an enzyme responsible for hydrolysis of cholesterol esters and
triglycerides within lipoprotein particles internalized by receptor-mediated
endocytosis [287, 288]. Previous studies have demonstrated an important role
of LipA in maintaining cholesterol levels in mice [289], and mutations in LipA
result in cholesterol ester storage disease, which is associated with
hyperlipidemia in humans [290]. LipF also contributes to lipid catabolism by
hydrolysis of dietary triglycerides in the stomach and intestine, sequentially
producing free fatty acids and diacylglycerol [291, 292]. It would be interesting
to further investigate the detailed mechanisms by which PXR transcriptionally
regulates LipA and LipF expression and mediates intestinal lipid homeostasis.
Upregulation of those key genes by PXR activation contribute to amprenavirelicited hyperlipidemia.
In summary, we demonstrated that amprenavir as a selectively potent
PXR agonist. Amprenavir efficiently activated PXR and stimulated PXR target
gene expression in vitro and in vivo. Computational docking studies and sitedirected mutagenesis analysis identified key residues within PXR’s ligand
binding pocket that interact with amprenavir. Our study provides critical insight
for understanding the mechanism by which clinically relevant PXR ligands
interact and activate PXR. We also showed, for the first time, that amprenavirmediated activation of PXR elevated lipid levels in an animal model, which has
direct clinical consequence for patients under long-term treatment with
amprenavir and other PIs. Activation of PXR may present a key mechanism for
adverse effects of PIs in humans.
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Table 2.1 Primer sequences for site-directed mutagenesis.
Mutant

Primer sequences
5’-CTGCTGCCCCACATGGCTGACATGTTAACCTACATGTTCAAAGGC-3’

PXR-S247L
5’-GCCTTTGAACATGTAGGTTAACATGTCAGCCATGTGGGGCAGCAG-3’
5’-GGGCCGCTTTCGAGCTGTGTCTACTGAGATTCAACACAGTG-3’
PXR-Q285L
5’-CACTGTGTTGAATCTCAGTAGACACAGCTCGAAAGCGGCCC-3’
5’-CGAGCTGTGTCAACTGAGAGCCAACACAGTGTTCAACGCGG-3’
PXR-F288A
5’-CCGCGTTGAACACTGTGTTGGCTCTCAGTTGACACAGCTCG-3’
5’-GGGAGTGTGGCCGGCTGTCCCTCTGCTTGGAAGACACTGCAGG-3’
PXR-Y306L
5’-CCTGCAGTGTCTTCCAAGCAGAGGGACAGCCGGCCACACTCCC-3’
5’-CCGCAGCATCAATGCTCAGGCCACCCAGCGGCTGCTGCGCATCC-3’
PXR-H407A
5’-GGATGCGCAGCAGCCGCTGGGTGGCCTGAGCATTGATGCTGCGG-3’
5’-GCTCAGCACACCCAGCGGTTCCTGCGCATCCAGGACATAC-3’
PXR-L411F
5’-GTATGTCCTGGATGCGCAGGAACCGCTGGGTGTGCTGAGC-3’
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Table 2.2 Primer sequences for QPCR.
Genes

Primer sequences

Genes

Primer sequences

5’-CAGCTTGGTGCTCCTCTACC-3’

mDGAT2

5’-ACTCTGGAGGTTGGCACCAT-3’

mCYP3A11
5’-TCAAACAACCCCCATGTTTT-3’

5’-GGGTGTGGCTCAGGAGGAT-3’

5’-CAGCCTGGCAGCCAGAGA-3’

mGAPDH

5’-AACTTTGGCATTGTGGAAGG-3’

mGSTA1
5’-TCTGTGGCTCCATCAATGCA-3’

5’-GGATGCAGGGATGATGTTCT-3’

5’-CCCCCGAGATTGACAGCTAC-3’

hCYP3A4

5’-GGCTTCATCCAATGGACTGCATAAAT-3’

mMDR1a
5’-ACTCCACTAAATTGCACATTTCCTTC-3’

5’-TCCCAAGTATAACACTCTACACAGACAA-3’

5’-CAGTCGGAGACATGCT-3’

5’-TGCTCATTGCCTTTTCACAG-3’

mCD36

hUGT1A1
5’-CTCGGGGTCCTGAGTT-3’

5’-GGGCCTAGGGTAATCCTTCA-3’

5’-ATGGTTTGATTGCATCAGCCA-3’

5’-CCCATCATTGCAATAGCAGG-3’

mLipF

hMDR1a
5’-TTCCCCAGCCACACATCATAG-3’

5’-GAGCATACATATGTTCAAACTTC-3’

5’-TGTTCGTTTTCACCATTGGGA-3’

5’-ACAGTGGGGGTGTACGAGTC-3’
hGAPDH

mLipA
5’-CGCATGATTATCTCGGTCACA-3’

5’-AGGGGAGATTCAGTGTGGTG-3’

5’-GTGCCATCGTCTGCAAGATTC-3’
mDGAT1
5’-GCATCACCACACACCAATTCAG-3’
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Figure 2.1 Amprenavir is a potent PXR-selective agonist.
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Figure 2.1 Amprenavir is a potent PXR-selective agonist.
(A and B) HepG2 cells were transfected with (A) full-length hPXR together with a
hPXR reporter (CYP3A4-luc) or (B) full-length mPXR together with a mPXR
reporter ((CYP3A2)3-luc) and CMX-β-galactosidase control plasmid. Cells were
then treated with DMSO control, amprenavir, ritonavir, nelfinavir, saquinavir,
indinavir sulfate, RIF (a hPXR ligand) or PCN (a mPXR ligand) at the indicated
concentrations for 24 h. (C) HepG2 cells were co-transfected with hPXR together
with CYP3A4-luc reporter and CMX-β-galactosidase plasmid. Cells were then
treated with amprenavir or RIF at the indicated concentrations for 24 h. (D) HepG2
cells were co-transfected with a GAL4 reporter and a series of GAL4 constructs in
which the GAL4 DBD is linked to the indicated nuclear receptor LBD. Cells were
treated with DMSO control or 10 μM amprenavir for 24 h. Data are shown as fold
induction of normalized luciferase activity compared with DMSO treatment and
represent the mean of triplicate experiments. Results are presented as mean ±
SEM.
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Figure 2.2 Amprenavir promotes PXR co-activator recruitment and
co-repressor disassociation.
(A and B) HepG2 cells were transfected with a GAL4 reporter and VP16hPXR as well as expression vector for GAL4 DBD or GAL4 DBD linked to the
receptor interaction domains of the indicated PXR co-activators (GAL-SRC1
and GAL-PBP) (A) or co-repressor (GAL-SMRT and GAL- NCoR) (B). Cells
were then treated with DMSO control, amprenavir, or RIF at the indicated
concentrations for 24 h. Results are presented as mean ± SEM.
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Figure 2.3 Key residues of PXR LBD are required for amprenavir’s
agonistic activity.
(A) Overlay of docked amprenavir and SR12813 (green) inside the LBD of
PXR. Atoms in amprenavir were colored by atom type (oxygen in red,
phosphor in yellow, nitrogen in blue and carbon in grey), while all the atoms
in SR12813 were colored in green for clear comparison. Four subpockets
were presented by black circles. (B) Interaction map between amprenavir
and PXR. Amprenavir was computationally docked in the ligand binding
pocket of the hPXR X-ray crystal structure (3hvl.pdb). The amprenavir-PXR
complex was stabilized by three hydrogen bonds with residues Ser247,
Gln285 and His407, respectively. The noncovalent contacts with the
aromatic side chains Phe288, Trp299, and Tyr306 lining in the subpocket 1
contributed significantly to amprenavir binding. Phe288 was well positioned
to engage in π-stacking interactions with the phenyl ring of amprenavir. The
interaction diagram reveals that amprenavir occupied the major portion of the
large, flexible PXR ligand binding pocket. (C) HepG2 cells were cotransfected with a full-length PXR WT plasmid or mutant PXR plasmids as
indicated, together with CYP3A4-luciferase reporter and CMX-β-galactosides
plasmid. After transfection, cells were treated with control medium or
medium containing amprenavir at indicated concentrations for 24 h. Results
are presented as mean ± SEM.
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Figure 2.4 Amprenavir induces PXR target gene expression in
human cells.
(A and B) Human HepaRG hepatoma cells (A) and LS180 intestinal cells (B)
were treated with control medium or medium containing 10 μM amprenavir
for 24 h. Total RNA was isolated and gene expression levels were analyzed
by QPCR with primers for human CYP3A4, UGT1A1 or MDR1 (n=3,
**P<0.01, ***P<0.001; assessed by one-way ANOVA). Results are presented
as mean ± SEM.
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Figure 2.5 Amprenavir elicits hyperlipidemia in WT, but not in
PXR-/- mice.
(A and B) 8-week-old WT (A) and PXR-/-(B) mice were treated with vehicle
(corn oil) or 10 mg/kg of amprenavir by oral gavage for 1 week. Plasma
total cholesterol levels were measured by a standard method (n= 4-7;
*P<0.05; assessed by student’s t-test). (C and D) Plasma cholesterol
distribution of WT (C) and PXR-/- mice (D) was analyzed by FPLC. Results
are presented as mean ± SEM.
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Figure 2.6 Amprenavir elevates atherogenic LDL cholesterol levels
in WT mice.
(A and B) Eight-week-old WT (A) and PXR-/-(B) mice were treated with
vehicle or 10 mg/kg of amprenavir by oral gavage for 1 week. Lipoprotein
fractions (VLDL, LDL, and HDL) were isolated and the cholesterol levels of
each fraction were measured by a standard method (n=4-7; *P<0.05;
assessed by student’s t-test). Results are presented as mean ± SEM.
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Figure 2.7 Activation of PXR by amprenavir stimulates the
expression of intestinal genes involved in lipid homeostasis.
Eight-week-old WT and PXR-/- mice were treated with vehicle (corn oil) or 10
mg/kg of amprenavir by oral gavage for 1 week. Total RNA was isolated from
the small intestine (duodenum) and liver. (A and B) The mRNA levels of
known PXR target genes, CYP3A11, GSTA1, and MDR1a, in the intestine
(A) and liver (B) were measured by QPCR. (C) Expression levels of intestinal
genes involved in lipid homeostasis were measured by QPCR. (n=4-5;
*P<0.05, **P<0.01; assessed by student’s t-test). Results are presented as
mean ± SEM.
Copyright © Robert Nathaniel Helsley, 2016
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Chapter 3: Intestinal PXR Links Xenobiotic Exposure and
Hypercholesterolemia
3.1

Introduction

Influences of the chemical environment on human health have recently
become the subject of intense interest. Mounting evidence shows that
endocrine disrupting chemicals (EDCs) can interfere with complex endocrine
signaling mechanisms and result in adverse consequences in humans and
wildlife [76, 293]. Recent findings have implicated exposure to EDCs in the
etiology of cardiovascular disease (CVD) and metabolic disorders [76-78, 293295]. For instance, higher bisphenol A (BPA) exposure has been consistently
associated with CVD in multiple large-scale human population studies [77-79].
Exposure to certain polychlorinated biphenyls (PCBs) induces
hypercholesterolemia and promotes atherosclerosis in animals [84, 296].
Circulating PCB levels have been associated with atherosclerotic plaques in
elderly individuals [297]. High circulating levels of phthalates are also
associated with carotid atherosclerosis [81]. However, the underlying
mechanisms responsible for these associations remain largely unknown, which
continues to hamper rational assessment of the health risks of EDC exposure.
Many EDCs such as phthalates, PCBs, and BPA and its analogs have
been implicated in the activation of the pregnane X receptor (PXR) (also known
as steroid and xenobiotic receptor, or SXR) [91, 136, 179, 298]. PXR is a
nuclear receptor activated by numerous endogenous hormones, dietary
steroids, pharmaceutical agents, and xenobiotic chemicals [89, 91, 95]. PXR
functions as a xenobiotic sensor that induces expression of genes required for
xenobiotic metabolism in the liver and intestine, including cytochromes P450s
(CYP), conjugating enzymes (e.g., glutathione transferase), and ABC family
transporters (e.g., multidrug resistance 1 [MDR1]) [90, 91]. In the past decade,
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the role of PXR as a xenobiotic sensor has been well established [91].
However, the role of PXR in mediating the pathophysiological effects of EDCs in
humans and animals remains elusive.
The identification of PXR as a xenobiotic sensor provided an important
tool for the study of new mechanisms through which xenobiotic exposure
impacts diseases. Recent evidence indicates that PXR may also play an
important role in the regulation of lipid homeostasis [114, 177, 260, 265, 299,
300]. For instance, it is well-known that many clinically relevant PXR ligands
(e.g. rifampicin, ritonavir) can elevate plasma lipid levels in patients and
increase their CVD risk [52, 261, 263, 264]. A meta-analysis of 7 genome-wide
association studies indicated that common genetic variants in PXR can affect
plasma lipid levels in humans and 19 PXR SNPs were identified to significantly
affect plasma low-density lipoprotein (LDL) cholesterol levels [118]. We recently
demonstrated the pro-atherogenic effects of PXR in animals. Chronic activation
of PXR elicited by feeding mice the mouse PXR ligand pregnane 16αcarbonitrile (PCN) led to increased levels of plasma total cholesterol and
atherogenic lipoproteins LDL and very-low-density lipoprotein (VLDL) in wildtype (WT) mice, but not in PXR-deficient (PXR-/-) mice [177]. Activation of PXR
also increased plasma total cholesterol and VLDL levels in apolipoprotein E*3Leiden mice, which exhibit a human like lipoprotein distribution on a cholesterolrich diet [260]. In Chapter 2, we identified amprenavir, a widely used antiretroviral drug, as a potent PXR-selective agonist [299]. Exposure to
amprenavir significantly increased plasma total cholesterol and LDL cholesterol
levels in WT mice, but not in PXR-/- mice [299].
Despite emerging evidence consistent with the hypothesis that modulation
of PXR activity alters lipid homeostasis, the mechanisms underlying PXR ligandelicited hyperlipidemia remain largely unknown. PXR is expressed at high
levels in the liver and intestine, two organs that play a central role in whole-body
lipid homeostasis. PXR has been reported to regulate several key hepatic
lipogenic genes that promotes dyslipidemia and hepatic steatosis, including
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CD36, SCD-1, lipin-1, Insig-1, and S14 [114, 182, 204, 301]; however, the role
of intestinal PXR in the regulation of lipid homeostasis remains elusive. Here
we report that intestinal PXR plays an important role in linking EDC exposure
and hypercholesterolemia. We identified several widely used phthalate
substitute plasticizers widely used in food packaging materials, medical devices,
cosmetics, and pharmaceutical drugs as agonists of PXR. Tributyl citrate
(TBC), one of a large group of Food and Drug Administration (FDA)-approved
pharmaceutical plasticizers, is a potent and selective PXR agonist but does not
activate other nuclear receptors. Interestingly, TBC is an intestine-specific PXR
ligand but does not affect hepatic PXR activity. Short-term TBC exposure
increased plasma total cholesterol and atherogenic LDL cholesterol levels in WT
mice, but not in PXR-/- mice. We found that TBC-mediated PXR activation
stimulated the expression of the intestinal cholesterol transporter Niemann-Pick
C1-Like 1 (NPC1L1) and significantly increased lipid uptake by human and
murine intestinal cells. We also identified a PXR-binding site in the NPC1L1
promoter, indicating NPC1L1 is a bona fide PXR target gene. These findings
provide critical mechanistic insight for understanding the impact of EDCmediated PXR activation on lipid homeostasis and demonstrate a potential role
of PX R in mediating adverse effects of EDCs on CVD risk in humans.

3.2

Materials and Methods

3.2.1
Reagents and Plasmids
TBC, acetyl tributyl citrate (ATBC), di (2-ethylhexyl) phthalate (DEHP),
acetyltriethyl citrate (ATEC), diisononyl phthalate (DiNP), triethyl citrate (TEC),
di-n-butyl phthalate (DnBP), di-isobutyl phthalate (DiBP), diethyl phthalate
(DEP), pregnenolone 16α-carbonitrile (PCN) and rifampicin (RIF) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). All the chemicals were
dissolved in dimethyl sulfoxide (DMSO). Human (h) and mouse (m) PXR
expression vectors; GAL4 DNA-binding domain (DBD)-linked nuclear receptor
ligand-binding domain (LBD) vectors (GAL4-hPXR, GAL4-mPXR, GAL4-rat
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PXR, GAL4-retinoid acid receptor [RARα], GAL4-retinoid X receptor [RXR],
GAL4-farnesoid X receptor [FXR], GAL4-liver X receptor [LXR], GAL4peroxisome proliferator-activated receptor [PPAR]α, GAL4-PPARγ and GAL4vitamin D receptor [VDR]); and CMX-β-gal expression vectors were been
described before [179, 222, 266]. VP16-PXR, GAL4-nuclear receptor
corepressor (NCoR), GAL4-silencing mediator of retinoid and thyroid hormone
(SMRT), GAL4-steroid receptor coactivator (SRC1), GAL4-PPAR binding
protein (PBP), PXR-dependent CYP3A4 promoter reporter (CYP3A4XREMLuciferase), CYP3A2 promoter reporter [(CYP3A2)3-luciferase], and GAL4
reporter (MH100-Luciferase) were described previously[179, 266, 267]. For the
human NPC1L1/DR-4 reporter, 4 copies of the DR-4 element were synthesized
and inserted into a pGL3 promoter vector (Promega) by annealing
complementary oligonucleotides 5’-GCAGATCACTTGAGGTCAGG-3’
containing cohesive ends of the restriction enzyme sites, KpnI and MluI.
3.2.2
Cell Culture and Transfections
The human intestine epithelial cell line LS180 and hepatic cell line HepG2
were obtained from the American Type Culture Collection. The human
hepatoma HepaRG cells were purchased from Life Technologies. Transfection
assays were performed as described previously [179, 299]. The cells were
transfected with various expression plasmids as well as the corresponding
luciferase reporter plasmids, together with CMX-β-galactosidase control
plasmids using FuGENE 6 (Roche Diagnostics). The cells were then incubated
with the corresponding ligands as indicated in the figure legends for 24 hours,
and β-galactosidase and luciferase assays were performed as described [179,
301]. Fold activation was calculated relative to solvent controls. Each data
point represents the average of triplicate experiments ± SEM and was replicated
in 3-5 independent experiments. For the mammalian 2-hybrid assays, LS180
cells were transfected with GAL4 reporter, VP16-hPXR, and GAL-SRC1, GALPBP, GAL-NCoR, and GAL-SMRT [179, 301]. The cells were then treated with
compounds at the indicated concentrations.
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3.2.3
Animals
C57BL/6 WT mice were purchased from The Jackson Laboratory. PXRdeficient mice (PXR-/-) on C57BL/6 background were employed as described
previously [177]. All the animals were housed in the Division of Laboratory
Animal Resources, University of Kentucky, as approved by the Institutional
Animal Care and Use Committee in the specific pathogen-free environment with
a light-dark cycle. Eight-week-old male WT or PXR-/- mice were fed a
semisynthetic low-fat AIN76 diet containing 0.02% cholesterol (Research Diets)
[177, 178, 270, 299] and treated by oral gavage with vehicle (corn oil) or 10
mg/kg body weight (BW) TBC daily for 7 days. In addition, WT mice were also
treated with vehicle control or 10 mg/kg/BW TBC daily by ip injection. On the
day of euthanization, mice were fasted for 6 hours after the dark phase (feeding
cycle) [177, 178]. Mice were then anesthetized by intraperitoneal injection with
Ketamine (Fort Dodge Animal Health). Mice were exsanguinated by left
ventricular puncture, and blood was collected into EDTA-containing syringes.
Plasma was prepared by spinning at 16,000 g for 10 min. The circulation was
flushed with PBS; intestinal and liver tissues were collected and stored in
RNAlater solution (Life Technologies). Mouse primary hepatocytes and
enterocytes were isolated as previously described [302, 303]. Primary cells
were cultured in multiwell plates and treated with the indicated compounds
before being harvested for quantitative real-time PCR (qPCR) and Western blot
analysis or cholesterol uptake assays.
3.2.4
Plasma Analysis
Plasma total cholesterol and triglyceride concentrations were determined
enzymatically by colorimetric methods as described previously (Roche) [299,
304]. Lipoproteins fractions were isolated by spinning 60 μl of plasma in a TL100 ultracentrifuge (Beckman Coulter) at its own density (1.006 g/ml) at 70,000
RPM for 3 hours to harvest the supernatant, and then after adjustment of the
infranatant with solid KBr to a density of 1.063 g/ml spinning it for 70,000 RPM
for 18 hours to harvest the supernatant [304]. The cholesterol content of each
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supernatant and the final infranatant were measured and taken to be very-lowdensity lipoprotein (VLDL) (<1.006 g/ml), low-density lipoprotein (LDL) (1.006 ≤
d ≤ 1.063 g/ml), and high-density lipoprotein (HDL) (d >1.063 g/ml) cholesterol,
respectively. Cholesterol concentrations in all three fractions were then
determined enzymatically by a colorimetric method (Roche). Total plasma
cholesterol levels were determined enzymatically in the original plasma sample.
3.2.5
Cholesterol Uptake Assay
Cholesterol uptake assay was performed as previously described [305]. In
brief, micelles were prepared by mixing 9.7 mM of Taurocholate (SigmaAldrich), 6.47 mM of egg yolk L-α-Phosphatidylcholine (Sigma-Aldrich), and 1.5
mM of Cholesterol (Sigma-Aldrich), together with 1 µCi of [1,2-3H(N)]Cholesterol (PerkinElmer)/µmol of Cholesterol and evaporated under a mild
stream of argon. The lipid film was hydrated in serum-free MEM containing
0.5% fatty acid-free BSA (Sigma-Aldrich) and incubated at 37 ºC in a rotating
incubator. Solutions were filtered through a 0.45 μm surfactant-free cellulose
acetate filter (Corning) and used to incubate the LS180 cells or primary
enterocytes. After extensive PBS washing, cellular [3H]-cholesterol was
counted by a β-counter.
3.2.6
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as described previously [255, 303]. In brief,
NPC1L1/DR-4 and CYP3A4/ER-6 probes were created by annealing the
oligonucleotides 5’-GGGCAGATCACTTGAGGTCAGGAG-3’ (NPC1L1/DR-4),
5’-GGGCAGAACACTTGAGAACAGGAG-3’ (NPC1L1/DR-4m1), 5’GGGCAGATCTCTTGAGATCTGAG-3’(NPC1L1/DR-4m2), or 5’ATATGAACTCAAAGGAGGTCAGTG-3’ (CYP3A4/ER6) to the complementary
strand. Double-stranded oligonucleotides were end labeled using T4
polynucleotide kinase (New England Biosciences) and γ-[32P]-ATP
(PerkinElmer). Then 5 μl of in vitro-translated PXR or RXR protein was
incubated with 2 µg poly d(I-C) (Promega), 2 µl bandshift buffer (50 mM MgCl2
and 340 mM KCl), and 6 µl delta buffer (0.1 mM EDTA, 40 mM KCl, 25 mM
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HEPES (pH 7.6), 8% Ficoll 400, and 1 mM dithiothreitol) on ice for 10 minutes.
32

P-labeled double-stranded oligonucleotide probe (100,000 cpm) was then

added, and the reaction was incubated for another 30 minutes on ice. For the
supershift assays, proteins were incubated with 2 μg of goat anti-PXR (sc-7739;
Santa Cruz Biotechnology) or rabbit anti-PXR (sc-25381; Santa Cruz
Biotechnology) antibodies for 1 hour before the addition of 32P-labeled probe.
The binding complexes were subjected to electrophoresis in a 6%
nondenaturing polyacrylamide gel containing 0.5× Tris-borateEDTA (TBE). The gels were dried and visualized by exposure to X-ray film.
3.2.7
Chromatin Immunoprecipitation
ChIP analysis was performed by using an antibody against PXR (sc25381; Santa Cruz Biotechnology) and SimpleChIP Enzymatic Chromatin IP Kit
(Cell Signaling). The precipitated genomic DNA relative to inputs was analyzed
by semi-quantitative PCR using specific primers and DNA polymerase (Takara).
The sequences of primer sets used for PCR are listed in Table 3.1.
3.2.8
RNA Isolation and QPCR Analysis
Total RNA was isolated from mouse tissues and intestinal LS180,
HepaRG, and primary cells using TRIzol Reagent (Life Technologies) per the
manufacturer-supplied protocol. QPCR was performed using gene-specific
primers and the SYBR green PCR kit (Life Technologies) as described
previously [179, 299]. The primer sets used in this study are listed in Table 3.1.
3.2.9
Western Blot Analysis
Western blot analysis was performed as previously described [255].
Proteins were isolated from cells or mouse tissues by homogenization in
radioimmunoprecipitation assay buffer with complete mini protease inhibitor
cocktail (Roche). Protein concentrations were determined by the Pierce BCA
protein assay kit (Thermo scientific). Anti-PXR antibodies were purchased from
Santa Cruz Biotechnology (sc-7739); anti-NPC1L1 antibodies were purchased
from Novus Biologicals (NB400-128); and anti-β-actin antibodies were
purchased from Sigma-Aldrich (A2066).
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3.2.10
Statistical Analysis
Data are expressed as means ± SEM unless otherwise noted. Statistical
analysis was performed using a two-sample, two-tailed Student t-test unless
otherwise noted, with P < 0.05 regarded as significant. One-way analysis of
variance was used when multiple comparisons were made, followed by
Dunnett’s t test for multiple comparisons to a control. Two-way analysis of
variance was used when multiple comparisons were made, followed by a
Bonferroni’s post-hoc test. Analysis was performed using SigmaPlot 13.0.

3.3

Results
3.3.1

FDA-Approved Phthalate Substitute Plasticizers
can Activate PXR
Based on previous findings that several plastic-associated chemicals
including BPA and phthalates can activate PXR [179, 306], we examined
several widely used phthalates and phthalate substitute plasticizers for PXR
activation in transient transfection assays. Consistent with previous reports
[307, 308], DEHP, DiNP, and ATBC can activate PXR and induce PXRmediated CYP3A4-luciferase reporter activities (Fig. 3.1, A). TBC, an FDAapproved phthalate substitute plasticizer used in food contact substances and
as a pharmaceutical excipient, was a more potent PXR agonist than any of the
other tested plasticizers and induced reporter gene activity in a dose-dependent
manner (Fig. 3.1, A). We tested the ability of TBC to activate a panel of other
nuclear receptors, including mouse PXR, human RARα, RXR, FXR, LXRα,
PPARα, PPARγ, VDR, constitutive adrostane receptor, and estrogen receptor α
(Fig. 3.1, B). TBC can activate both human and mouse PXR but was unable to
activate any of other nuclear receptors. Thus, TBC is a PXR-selective agonist.
Nuclear receptor co-regulators play critical roles in nuclear receptor
signaling. We then used a mammalian 2-hybrid assay to evaluate the effects of
TBC on PXR co-regulator interaction. TBC promoted the specific interactions
between PXR and the coactivators SRC-1 and PBP (Fig. 3.1, C). Consistent
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with our previous report [179, 266], unliganded PXR interacted with corepressors, NCoR and SMRT (Fig. 3.1, D), and TBC disrupted this interaction
as did the potent human PXR ligand RIF (Fig. 3.1, D). Thus, binding of TBC to
PXR inhibits PXR-corepressor interaction and promotes PXR-coactivator
recruitment, thereby inducing PXR transcriptional activation in a concentrationdependent manner.
3.3.2
TBC is an Intestine-Specific Ligand
We next used human hepatoma HepaRG cells [274] and intestinal LS180
cells [266, 299] to test the effects of TBC exposure on PXR activity and target
gene expression. The known human PXR ligand RIF induced the expression of
bona fide PXR target genes involved in phase I (CYP3A4), phase II (UGT1A1),
and phase III (MDR1) metabolism in both cell lines. Interestingly, TBC
stimulated PXR target gene expression in intestinal LS180 cells but not in
HepaRG cells (Fig. 3.2, A). We then isolated mouse primary hepatocytes and
enterocytes to confirm these findings. As expected, the mouse PXR ligand PCN
induced PXR target gene expression in both hepatocytes and enterocytes (Fig.
3.2, B). However, TBC was only able to induce PXR target gene expression in
enterocytes but not in hepatocytes (Fig. 3.2, B). We also performed transfection
assays in LS180 and HepG2 cell lines. Consistently, TBC did not activate PXR
in HepG2 cells but was able to induce PXR reporter activity in LS180 cells after
being treated for as few as 3 hours (Fig. 3.3, A and B).
To further investigate the effects of TBC on PXR activity in vivo, WT mice
were treated with vehicle (corn oil), 10 mg/kg BW TBC, or PCN daily by oral
gavage for 1 week. Consistent with our previous report [303], PCN activated
PXR and induced target gene expression in both liver and intestine (Fig. 3.2, C).
However, TBC only stimulated expression of known PXR target genes in
intestine but not in liver (Fig. 3.2, C). To examine whether lower TBC doses can
activate intestinal PXR in vivo, we also treated mice with 2.5 or 5 mg/kg/d TBC
by oral gavage for 1 week. Neither 2.5 nor 5 mg/kg/d TBC activated PXR or
induced PXR target gene expression in the intestine (Fig. 3.4). Next, to
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determine whether the tissue-specific effect of TBC on intestinal PXR is related
to poor absorption into the circulation, WT mice were also treated with 10
mg/kg/d TBC by ip deliver. Interestingly, TBC was still unable to induce PXR
target gene expression in liver even by ip delivery (Fig. 3.5). Therefore, it is
unlikely that the inability of TBC to activate hepatic PXR is due to poor
absorption by the intestine. Taken together, these results suggest that
exposure to TBC at a relevant dose via oral delivery activates intestinal PXR but
does not affect hepatic PXR signaling.
3.3.3

TBC Exposure Elevates Plasma Lipid Levels in WT
Mice, but not in PXR-/- Mice
We previously reported that activation of PXR by feeding PCN at a high
dose (200 mg/kg in diet) for 2 weeks significantly increased plasma total
cholesterol levels and atherogenic LDL and VLDL levels in WT mice [177].
Consistent with our previous report, WT mice treated with a relatively low dose
of PCN (10 mg/kg/BW/d via oral deliver) for 1 week also had significantly
increased plasma total, LDL, and VLDL cholesterol levels (Fig. 3.6, A).
Although TBC only activates intestinal PXR, TBC treatment significantly
increased total cholesterol levels compared with those in control WT mice (Fig.
3.6, A). TBC treatment did not affect HDL or VLDL cholesterol levels but
significantly increased LDL cholesterol levels in WT mice (Fig. 3.6, A). The
relatively stronger effects of PCN on plasma lipid levels could be due to its
effects on hepatic PXR signaling. In contrast, TBC did not affect any of the
lipoprotein levels in PXR-/- mice (Fig. 3.6, B), indicating that TBC-elicited
hypercholesterolemia effects are mediated by PXR signaling. Taken together,
these results suggest that activation of intestinal PXR by TBC is sufficient to
increase plasma cholesterol levels.
3.3.4

TBC Stimulates the Expression of Intestinal
Cholesterol Transporter NPC1L1 and Drives
Cholesterol Uptake by Intestinal Cells
Small intestine lipid absorption is the key step for lipid accumulation in the
body. Interestingly, we found that TBC stimulated expression of the
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transporters responsible for intestinal lipid absorption including CD36 and
NPC1L1 in the intestines of WT mice, but not in intestines of PXR-/- mice (Fig.
3.7, A). The known PXR target gene, CD36 [114], encodes a fatty acid
transporter that plays an important role in intestinal fatty acid absorption and
chylomicron production [282, 309]. NPC1L1 is an essential transporter
mediating intestinal cholesterol absorption [6, 20, 27]. Western blot analysis
also confirmed that TBC induced intestinal NPC1L1 protein levels in WT mice
but not in PXR-/- mice (Fig. 3.7, B). Consistent with a previous report [310], PXR
activation did not affect expression levels of the cholesterol efflux transporters
ABCG5 and ABCG8. In addition, the known PXR ligand PCN was also able to
induce NPC1L1 expression in intestine (Fig. 3.8), indicating that NPC1L1 is a
downstream target of PXR.
To further investigate the effects of TBC on PXR activity and NPC1L1
expression, we isolated primary enterocytes from WT and PXR-/- mice.
Consistent with in vivo results, TBC treatment increased NPC1L1 mRNA and
protein levels in WT enterocytes (Fig. 3.7, C and D). TBC-mediated NPC1L1
induction was abolished in PXR-deficient enterocytes. Because NPC1L1 plays
a key role in cholesterol uptake by intestinal cells, we then performed
cholesterol uptake assays using primary enterocytes. As expected, TBC
treatment increased [H3]-cholesterol uptake by primary enterocytes of WT mice
but did not affect cholesterol uptake by PXR-deficient enterocytes (Fig. 3.7, E).
Taken together, these results indicate a previously unrecognized role of PXR in
the regulation of intestinal cell cholesterol uptake.
3.3.5

Activation of PXR by TBC Transcriptionally
Regulates NPC1L1 Expression and Increases
Cholesterol Uptake by Human Intestinal Cells
To determine the impact of TBC-mediated PXR activation on NPC1L1
regulation and cholesterol uptake in human intestinal cells, we used small
interfering RNA (siRNA) to successfully reduce PXR expression in human
LS180 cells (Fig. 3.9, A). As expected, TBC treatment induced NPC1L1 mRNA
levels in control LS180 cells and siRNA-mediated PXR knockdown decreased
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TBC-induced NPC1L1 induction (Fig. 3.9, B). In addition, TBC was also able to
significantly increase [H3]-cholesterol uptake by LS180 cells (Fig. 3.9, C).
LS180 cells transfected with siRNA against PXR can still take up [H3]cholesterol, which may be due to incomplete inhibition of endogenous PXR
expression by siRNA. However, TBC-mediated cholesterol uptake was
significantly reduced by siRNA-mediated PXR knockdown. These results
confirm that TBC-mediated PXR activation can increase NPC1L1 expression
and cholesterol uptake in human intestinal cells.
We next analyzed the promoter of the human NPC1L1 gene and identified
a DR-4-type (direct repeat spaced by 4 nucleotides) of nuclear receptor
response element (AGATCACTTGAGGTCA), similar to DR-4 element found in
other PXR target genes [95]. EMSA confirmed that PXR and RXR heterodimer
was able to bind to this DR-4 element as well as the positive control, the ER-6
(everted repeat spaced by 6 nucleotides) element in the CYP3A4 promoter (Fig.
3.10, A). The binding of NPC1L1/DR-4 or CYP3A4/ER-6 by PXR-RXR is
specific as excess cold probe decreased PXR-RXR binding to those elements
(Fig. 3.10, A). In addition, 2 different anti-PXR antibodies disrupted the proteinDNA complex (Fig. 3.10, B), suggesting that PXR is a component of the protein
complex that binds to the NPC1L1/DR4 element. Further, mutations of the DR4 elements were also able to abolish the binding of PXR-RXR dimers to both
mutant DR-4 sites (Fig. 3.10, C).
Next, ChIP analysis demonstrated that TBC can promote the recruitment
of PXR onto the NPC1L1 promoter region containing the DR-4 element (Fig.
3.10, D). ChIP on the CYP3A4 promoter region containing the ER-6 element
was included as a positive control. Last, 4 copies of the NPC1L1/DR-4 or
mutated DR-4 elements were synthesized and inserted into a luciferase reporter
vector. Transfection assays were performed to determine whether the DR-4
motif is necessary and sufficient for mediating PXR transactivation. Indeed,
both TBC and RIF can activate PXR and increase the NPC1L1/DR-4 reporter
gene activity in a dose-dependent manner (Fig. 3.10, E). In contrast, TBC and
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RIF had no effect on activity of 2 mutated DR-4 reporters (Fig. 3.10, F and G).
Collectively, activation of PXR by TBC transcriptionally regulates NPC1L1
expression and increases cholesterol uptake by human intestinal cells.

3.4

Discussion

Because of their variety and low costs, plastics are fundamental in modern
life and plastic production exceeded 300 million tons in 2010 [293]. Plasticassociated chemicals are produced in high volume for use in the production of
plastics, including the base chemical BPA and numerous plasticizers. The
adverse effects of BPA and several phthalate plasticizers (e.g., DEHP) on
human health have attracted considerable attention and engendered
controversy in the past few decades, partly due to their endocrine-disrupting
properties. We and others have identified BPA, BPA analogs (e.g., bisphenol B
and bisphenol AF), and the widely used phthalate plasticizer DEHP as potent
PXR agonists [179, 298, 306]. In addition to these well-known EDCs, there are
many phthalate substitute plasticizers that have not been tested for endocrine
disruption. For example, citrate esters, including TBC, ATBC, and TEC,
represent a large group of plasticizers that have been approved by the FDA to
be used in food packaging materials, vinyl toys, medical devices, cosmetics,
and pharmaceutical drugs [311-314]. ATBC has recently been shown to
activate PXR and induce PXR target gene expression [308]. However, it is
unclear whether ATBC or other phthalate substitute plasticizers have any
adverse effects on the development of complex diseases. In the current study,
we demonstrate that TBC is a more potent PXR agonist than ATBC in our
assays. Similar to ATBC, TBC activated intestinal PXR and induced PXR target
gene expression but did not affect hepatic PXR activity. Nevertheless, TBCmediated intestinal PXR activation was sufficient to increase plasma cholesterol
levels, especially atherogenic LDL levels in WT mice. We then identified a key
intestinal cholesterol transporter, NPC1L1, as a direct transcriptional target of
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PXR. Activation of PXR stimulated NPC1L1 expression and promoted
cholesterol uptake by intestinal cells, which may contribute to TBC-induced
hyperlipidemia. These findings demonstrate a previously unrecognized role of
intestinal PXR in the regulation of lipid homeostasis.
Whereas the role of PXR in xenobiotic metabolism has been well
established, recent studies have revealed a role of PXR in dyslipidemia and
atherosclerosis. We previously reported that chronic activation of PXR elicited
by feeding mice the potent mouse PXR agonist PCN led to increased levels of
plasma total cholesterol and VLDL and LDL in WT mice but not in PXR-/- mice
[177]. PCN-mediated PXR activation affected several genes involved in hepatic
lipid homeostasis. Because TBC does not activate PXR in the liver, it is unlikely
that hepatic PXR signaling contributes to TBC-elicited hypercholesterolemia.
Cholesterol uptake from the intestinal lumen by the enterocytes is the ratelimiting step in cholesterol absorption [309]. NPC1L1, a multitransmembrane
protein containing a conserved N-terminal NPC1 domain and a putative sterolsensing domain, has been established as an essential transporter in mediating
intestinal cholesterol uptake [20, 27, 309]. NPC1L1 expression is enriched in
the small intestine and is in the brush border membrane of enterocytes [20].
NPC1L1 takes up free cholesterol into cells through vesicular endocytosis and is
required for intestinal cholesterol absorption [20, 27, 309]. Indeed, NPC1L1deficient mice had substantially reduced intestinal cholesterol absorption and
plasma cholesterol (particularly LDL) levels and were completely resistant to
diet-induced hypercholesterolemia [20, 27]. NPC1L1 is also the molecular
target of the clinically used drug ezetimibe, a potent cholesterol absorption
inhibitor widely used to treat hypercholesterolemia [20]. Very recently,
inactivating mutations in NPC1L1 has been associated with reduced plasma
LDL cholesterol levels and as reduced risk of CVD in a large-scale human study
[315]. Despite the established function of NPC1L1 in intestinal cholesterol
absorption, the transcriptional regulation of NPC1L1 has not been fully
understood. Our results suggest that PXR is an important regulator of NPC1L1
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transcription. PXR can directly bind to a DR-4 motif in human NPC1L1
promoter and stimulate NPC1L1 expression upon ligand activation. Thus, PXRmediated NPC1L1 up-regulation may contribute to the TBC and other ligandinduced hypercholesterolemia.
Whereas NPC1L1 plays an essential role in intestinal cholesterol
absorption, another PXR-regulated transporter, CD36, mediates enterocyte
uptake of fatty acids, which are then converted to triglycerides for transport into
chylomicrons [282, 309]. We and others previously reported that activation of
PXR induces CD36 expression and increases lipid accumulation in the liver
[114], intestine [265], and macrophage [177]. In addition, activation of intestinal
PXR can also induce the expression levels of several enzymes involved in
intestinal lipid transportation and chylomicron secretion including diacylglycerol
acyltransferase 1 and 2 [265]. Therefore, the functions of PXR in intestinal lipid
homeostasis are complex, and further studies are needed to define the precise
mechanisms through which intestinal PXR modulates lipid homeostasis in
animal models as well as in humans.
It is intriguing that TBC can only activate intestinal PXR but not hepatic
PXR. Several tissue-specific PXR ligands have been identified [265, 267, 316].
For example, rifaximin, a nonsynsynthetic antibiotic, has been shown to be a
potent intestine-specific PXR ligand [316]. The tissue-specific effect of rifaximin
on intestinal PXR was probably related to its poor absorption as rifaximin
accumulated in the intestine after oral treatment. However, the reason that TBC
cannot activate hepatic PXR is unlikely due to poor absorption by the intestine
as TBC was unable to activate hepatic PXR even after ip delivery. Further, TBC
treatment did not affect PXR activity in HepaRG and HepG2 cells in vitro. It is
possible that hepatic cells can rapidly catalyze TBC. Further studies, including
development of appropriate HPLC-tandem mass spectrometry assays and
examination of TBC metabolites in vivo and in vitro, will be required to elucidate
the detailed mechanisms underlying the tissue-specific effects of TBC and
similar chemicals. In addition, we previously demonstrated that tocotrienols,
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members of the vitamin E family, show tissue-specific induction of PXR target
genes, particularly CYP3A4 [267]. Tocotrienols can up-regulate expression of
CYP3A4 in human primary hepatocytes but not in LS180 cells. Nuclear
receptor co-regulators play critical roles in nuclear receptor activation and are
also involved in the mechanisms underlying the divergent activities of selective
estrogen receptor modulators [317, 318]. We found that NCoR is expressed at
different levels in intestinal LS180 cells and primary hepatocytes and that
tocotrienols can only partially disrupt the interaction of unliganded PXR and
NCoR in LS180 cells [267]. Therefore, it is plausible the coregulator difference
between liver and intestine may contribute to the tissue-specific effects of TBC.
A fundamental question about all EDC studies is whether low-dose
exposure to EDCs can influence human endocrine functions and cause adverse
effects. Currently, there is little information about human exposure to TBC. The
dose of 10 mg/kg/d TBC used in the present study to treat animals was based
on human exposure to other plasticizers such as DEHP, DnBP, and ATBC. A
retrospective human biomonitoring study of German adults aged 20 to 29 years
showed median daily intakes for DnBP and DEHP of 7 and 4 mg/kg BW/day,
respectively. Fourteen percent of subjects showed DnBP intakes above the
tolerable daily intake value of 10 mg/kg BW/d set by the European Food Safety
Authority [319, 320]. Patients taking drugs containing another citrate ester
plasticizer, ATBC, may be exposed to as much as 20 mg ATBC daily [308]. The
10 mg/kg BW/d TBC dose used in our study was also significantly lower than
concentrations experimentally used for DEHP (1000 mg/kg BW/d) and DnBP
(2000 mg/kg BW/d) to treat mice in some studies [293, 321]. We have also
examined whether lower TBC concentrations can activate PXR in vivo by testing
2 lower doses, 2.5 and 5 mg/kg/d, but neither dose activated PXR. Therefore,
the 10 mg/kg/d dose used in this study is close to the lower limit of the TBC
concentration that activates PXR in vivo. Considering the wide use TBC in
consumer products (e.g., plastic wrap, toys, and drugs), we believe that the
dose, which was sufficient to activate PXR activity and cause adverse effects in
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vivo, was reasonable. It would be interesting to measure the internal TBC
concentrations in human samples and correlate internal TBC concentrations to
plasma lipid levels in the future. Such information would provide important
insights about the relationship of EDC exposure and disease outcomes in
humans.
In addition to TBC, we and others have identified many other
environmentally significant chemicals (e.g. BPA, bisphenol B, and DEHP) as
PXR agonists. Further, we recently demonstrated that certain EDCs can
synergistically activate human PXR [179]. The synergism between different
EDCs supports the need to include mixtures for future in vitro and in vivo
studies, which may have important implications for environmental chemical risk
assessment. In addition to CVD, activation of PXR has been shown to induce
tumor aggressiveness in humans and mice [322]. Further studies are needed to
investigate whether TBC-mediated intestinal PXR activation can induce
tumorigenesis in animal models.
In summary, we have demonstrated that the phthalate substitute
plasticizer TBC is potent agonist of PXR. Of particular interest is the finding that
TBC activated intestinal PXR but did not affect hepatic PXR activity.
Nevertheless, activation of intestinal PXR by TBC was sufficient to increase
plasmas cholesterol levels in mice. We then identified the intestinal cholesterol
transporter NPC1L1 as a direct transcriptional target of PXR and found that
activation of PXR increased cholesterol uptake by intestinal cells. These
findings demonstrate a previous unrecognized role of PXR in the regulation of
intestine lipid homeostasis. Findings from this study will hopefully stimulate
further investigations of phthalate substitute plasticizers, in particular, the
mechanisms by which TBC and other chemicals activate PXR, the tissuespecific TBC activation of PXR, and PXR regulation of intestinal lipid
homeostasis. Activation of PXR should be taken into consideration for future
risk assessment of phthalate substitute plasticizers and related environmental
chemicals.
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Table 3.1 Primer sequences for QPCR and ChIP
Genes
mCYP3A11

Primer sequences

Genes

5’-CAGCTTGGTGCTCCTCTACC-3’

hCYP3A4

5’-TCAAACAACCCCCATGTTTT-3’

Primer sequences
5’-GGCTTCATCCAATGGACTGCATAAAT-3’
5’-TCCCAAGTATAACACTCTACACAGACAA-3’

5’-CAGCCTGGCAGCCAGAGA-3’

5’-TGCTCATTGCCTTTTCACAG-3’

mGSTA1

hUGT1A1
5’-TCTGTGGCTCCATCAATGCA-3’

5’-GGGCCTAGGGTAATCCTTCA-3’

5’-CCCCCGAGATTGACAGCTAC-3’

5’-CCCATCATTGCAATAGCAGG-3’

mMDR1a

hMDR1a
5’-ACTCCACTAAATTGCACATTTCCTTC-3’

5’-GAGCATACATATGTTCAAACTTC-3’

5’-CAGTCGGAGACATGCT-3’

5’-CTGGTATCACTGGAAGCGAGT-3’

mCD36

hNPC1L1
5’-CTCGGGGTCCTGAGTT-3’

5’-CACGCGGGTCACATTGATGA-3’

5’-TTGCCTTGACCTCTGGCTTAG-3’

5’-GGCCTCCAAGGAGTAAGACC-3’
hGAPDH

mNPC1L1
5’-AGGGCGGATGAATCTGTGC-3’

5’-AGGGGAGATTCAGTGTGGTG-3’

5’-TGCCCATTCCTTTAAAAATCC-3’

hCYP3A4
(ChIP)

mABCG5
5’-GATGAACTGGACCCCTTGG-3’

5’-TTGGACTCCCCAGTAACATTG-3’
5’-TGCATGGAGCTTTCCTGC-3’

5’-GTAGCTGATGCCGATGACAA-3’

hNPC1L1

5’-TTGTGGTCAGGTGCAATGGCTCATG-3’

5’-GGGGCTGATGCAGATTCA-3’

(ChIP)

5’-GTGCCACAATCTTGGCTCACTGCA-3’

mABCG8

5’-AACTTTGGCATTGTGGAAGG-3’
mGAPDH
5’-GGATGCAGGGATGATGTTCT-3’
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Figure 3.1 Activation of PXR by phthalates and phthalate substitute
plasticizers.
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Figure 3.1 Activation of PXR by phthalates and phthalate substitute
plasticizers.
(A) LS180 cells were cotransfected with full-length human PXR and a
CYP3A4-luciferase reporter. Cells were treated with DMSO vehicle,
TBC, DEHP, ATBC, ATEC, DiNP, TEC, DnBP, DiBP, and DEP at the
indicated concentrations for 24 hours. (B) LS180 cells were
cotransfected with a GAL4 reporter and a series of GAL4 DBD-nuclear
receptor ligand- binding domain constructs. Cells were treated with
DMSO vehicle or 10 µM TBC for 24 hours. CAR, constitutive androstane
receptor; ERα, estrogen receptor α. (C and D) LS180 cells were
cotransfected with a GAL4 reporter, VP16-hPXR, and expression vector
for GAL4 DBD or GAL4 DBD linked to the receptor interaction domains
of PXR coactivators (GAL-SRC1 or GAL-PBP) (C) or PXR corepressors
(GAL-SMRT or GAL-NCoR) (D). Cells were treated with DMSO vehicle,
TBC, or RIF at the indicated concentrations for 24 hours. Data are
shown as fold induction of normalized luciferase activity compared with
that for DMSO treatment and represent the means from triplicate
experiments. Results are presented as mean ± SEM.
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Figure 3.2 TBC activates intestinal PXR but does not affect hepatic
PXR activity.
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Figure 3.2 TBC activates intestinal PXR but does not affect hepatic
PXR activity.
(A) Human HepaRG hepatoma cells and LS180 intestinal cells were
treated with control medium or medium containing 10 μM TBC or RIF.
Total RNA was isolated, and gene expression levels of human PXR
target genes were analyzed by qPCR (n=3; **P<0.01, ***P<0.001;
assessed by one-way ANOVA). (B) Primary hepatocytes and
enterocytes were isolated from WT mice and were incubated with
control medium or medium containing 10 µM TBC or PCN. Total RNA
was isolated, and gene expression levels of mouse PXR target genes
were analyzed by qPCR (n=3; *P<0.05, **P<0.01, ***P <0.001;
assessed by one-way ANOVA). (C) Eight-week-old WT mice were
treated with vehicle or 10 mg/kg BW TBC or PCN daily by oral gavage
for 1 week. Total RNA was isolated from liver and small intestine.
Expression levels of PXR target genes, CYP3A11, GSTA1, and
MDR1a, were measured by qPCR (n = 4-5; *P<0.05, **P<0.01, and
***P<0.001 assessed by one-way ANOVA). Results are presented as
mean ± SEM.
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Figure 3.3 TBC increases PXR reporter activity in human intestinal
cells but not in hepatic cells.
(A and B) Human hepatic HepG2 cells (A) or intestinal LS180 cells (B) were
cotransfected with full-length hPXR and a CYP3A4-luc reporter. Cells were
treated with TBC or RIF at the indicated concentrations for 1, 3, or 6 h. Data
are shown as fold induction of normalized luciferase activity compared with
DMSO treatment and represent the mean of triplicate experiments. Results
are presented as mean ± SEM.
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Figure 3.4 TBC does not activate intestinal PXR at 2.5 or 5 mg/kg/day
doses.
Eight-week-old WT mice were treated with vehicle control, 2.5, or 5 mg/kg BW
of TBC daily by oral gavage for 1 week. Expression levels of PXR target
genes, CYP3A11 (A), GSTA1 (B), and MDR1a (C) in the proximal intestine
was measured by QPCR (n=5). Results are presented as mean ± SEM.
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Figure 3.5 Intraperitoneally delivered TBC does not alter hepatic PXR
signaling.
Eight-week-old WT mice were treated with vehicle control or 10 mg/kg BW of
TBC daily via intraperitoneal (IP) deliver for 1 week. Expression levels of PXR
target genes, CYP3A11, GSTA1, and MDR1a in liver were measured by
QPCR (n=5). Results are presented as mean ± SEM.
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Figure 3.6 Exposure to TBC induces hyperlipidemia in WT but not in
PXR-/- mice.
(A) Eight-week-old male WT mice were treated with vehicle or 10
mg/kg BW TBC or PCN daily by oral gavage for 1 week. Plasma total
cholesterol levels and lipoprotein levels (LDL, VLDL, and HDL) were
measured (n = 6-10; *P<0.05 and ***P<0.001; assessed by one-way
ANOVA). (B) Eight-week-old male PXR-/- mice were treated with
vehicle or 10 mg/kg BW TBC daily by oral gavage for 1 week. Plasma
total cholesterol levels and lipoprotein levels (LDL, VLDL, and HDL)
were measured (n=4-5). Results are presented as mean ± SEM.
97

Figure 3.7 Activation of PXR by TBC stimulates the expression of the
intestinal cholesterol transporter NPC1L1 in mice and increases
cholesterol uptake by murine intestinal cells.
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Figure 3.7 Activation of PXR by TBC stimulates the expression of the
intestinal cholesterol transporter NPC1L1 in mice and increases
cholesterol uptake by murine intestinal cells.
(A) WT and PXR-/- mice were treated with vehicle or 10 mg/kg BW TBC
daily for 1 week. Total RNA was isolated from small intestine, and the
expression levels of indicated genes were measured by qPCR (n=5-6;
*P<0.05; assessed by student’s t-test). (B) Western blot analysis of
intestinal NPC1L1 protein levels in control or TBC-treated WT and
PXR-/- mice. The top band indicates glycosylated NPC1L1. (C and D)
Primary enterocytes isolated from WT and PXR-/- mice were treated
with vehicle control or 10 µM TBC for 3 hours. NPC1L1 mRNA levels
were measured by qPCR (n=3; ***P<0.001; assessed by student’s ttest), and protein levels were analyzed by Western blot (D). (E) Primary
enterocytes isolated from WT and PXR-/- mice were treated with vehicle
control or 10 µM TBC for 2 hours, followed by incubation with [3H]cholesterol and TBC for 1 hour. The cellular cholesterol uptake was
then measured (n=3; *P<0.05, **P<0.01; assessed by two-way
ANOVA). Results are presented as mean ± SEM.
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Figure 3.8 Both TBC and PCN can stimulate intestinal NPC1L1
expression in vivo.
Eight-week-old WT mice were treated with vehicle control, 10 mg/kg BW of
TBC, or PCN daily by oral gavage for 1 week. Expression levels of intestinal
PXR were measured by QPCR (n=5, *P<0.05, ***P<0.001; assessed by oneway ANOVA). Results are presented as mean ± SEM.
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Figure 3.9 TBC promotes cholesterol uptake by human intestinal
cells.
(A) Western blot analysis of PXR levels in human intestinal LS180
cells transfected with control siRNA or siRNA against PXR (siPXR).
(B) Control or siPXR LS180 cells were treated with 10 µM TBC for 3
hours, and NPC1L1 expression was analyzed by qPCR (n=3;
***P<0.001; assessed by student’s t-test). (C) Control or siPXR
LS180 cells were treated with 10 µM TBC for 2 hours followed by
incubation with [3H]-cholesterol and TBC for an additional 1 hour. The
cellular cholesterol uptake was then measured (n=3; *P<0.05,
**P<0.01; assessed by two-way ANOVA). Results are presented as
mean ± SEM.
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Figure 3.10 NPC1L1 is a direct transcriptional target of PXR
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Figure 3.10 NPC1L1 is a direct transcriptional target of PXR.
(A) In vitro translated human PXR and RXR, as indicated, were incubated
with 32P-labeled NPC1L1/DR-4 or CYP3A4/ER-6 probes and analyzed by
EMSA. Ten- or 25-fold excess of unlabeled NPC1L1/DR-4 or
CYP3A4/ER-6 probes were used for the competition experiments. (B)
PXR/RXR proteins were incubated with 2 different anti-PXR antibodies,
goat anti-PXR (1) or rabbit anti-PXR antibodies (2) for 1 hour before the
addition of the 32P-labeled NPC1L1/DR-4 probe. (C) PXR/RXR proteins
were incubated with 32P-labeled WT NPC1L1/DR-4 or mutated DR-4 (DR4m1 and DR-4m2) probes and were analyzed by EMSA. (D) LS180 cells
were treated with 10 µM TBC for 3 hours, and ChIP analysis was
performed to determine the recruitment of PXR onto the NPC1L1 or
CYP3A4 promoter. (E–G) LS180 cells were cotransfected with full-length
hPXR and RXR expression plasmids along with a synthetic reporter
containing 4 copies of NPC1L1/DR-4 element (E) or mutated DR-4
elements, DR-4m1 (F) and DR-4m2 (G). Cells were then treated with
DMSO vehicle (control), TBC, or RIF at the indicated concentrations for 24
hours. Data are shown as fold induction of normalized luciferase activity
compared with that for DMSO treatment and represent the means for
triplicate experiments. Results are presented as mean ± SEM.
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Chapter 4: Targeting IKKβ in Adipocyte Lineage Cells for Treatment of
Obesity and Metabolic Dysfunctions
4.1

Introduction

Obesity is a rapidly growing epidemic representing a serious threat to the
health of populations in an increasing number of countries and the number of
overweight and obese individuals are expected to increase to over half of the
world’s population by 2030 [323]. There is an urgent need to understand the
mechanisms underlying obesity and obesity-related metabolic diseases.
Obesity is associated with both increased adipocyte size (hypertrophy) and
adipocyte number (hyperplasia). Adipocyte number is a major determinant of
fat mass in adults [252, 324] and approximately 10% of the body’s adipocytes
are re-generated annually at all adult ages [324]. Obese individuals also have a
significantly greater number of adipocytes added per year than lean individuals
[252, 324]; suggesting that regulation of new adipocyte production is a potential
therapeutic target to treat obesity. However, the mechanisms underlying
nutritionally induced hyperplasia remain largely unknown.
It is generally accepted that obesity is associated with a state of chronic
low-grade inflammation that is a major contributor to type 2 diabetes and
atherosclerosis [325, 326]. Many inflammatory pathways that contribute to the
pathogenesis of insulin resistance and atherosclerosis are regulated by the
transcriptional factor NF-κB, a master regulator of the innate and adaptive
immune responses [238]. IκB kinase (IKK) β is the predominant catalytic
subunit of the IKK complex and is required for activation of NF-κB by
inflammatory mediators in the canonical or classical activation pathway [238,
239, 255, 271, 327]. It has been well established that overnutrition can lead to
IKKβ activation in vitro and in vivo [327-329], and recent studies have implicated
IKKβ as a key molecular link between obesity, inflammation and metabolic
disorders [325, 330, 331]. For example, diet-induced insulin resistance has
been associated with the activation of IKKβ/NF-κB in multiple tissues including
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liver, adipose tissue, and brain [241, 244, 247-249, 327, 332]. Deletion of IKKβ
in the liver improved diet-induced insulin resistance, and deficiency of IKKβ in
myeloid cells rendered global insulin sensitivity upon high-fat (HF) feeding [244].
By contrast, constitutive activation of IKKβ in the liver caused systemic insulin
resistance [247]. Activation of IKKβ in the hypothalamus has also been linked
to obesity and metabolic disease [249, 333].
We have recently demonstrated that IKKβ functions in smooth muscle
cells (SMCs) to regulate vascular inflammatory responses and atherosclerosis
development [255]. Of particular interest is that many adipocyte precursor cells
express SMC markers and ablation of IKKβ blocked adipocyte differentiation in
vitro and in vivo, suggesting that IKKβ functions in adipocyte precursor cells to
regulate adipose tissue development [255]. In the present study, we explored a
novel and more efficient pharmacological approach to inhibit IKKβ in vivo by
using antisense oligonucleotides (ASOs) and found that ASO-mediated IKKβ
knockdown ameliorated diet-induced obesity and metabolic disorders in mice.
Interestingly, IKKβ ASO also inhibited high-fat diet (HFD)-elicited adipocyte
differentiation and reduced adipose tissue growth. As the functions of IKKβ in
regulating adipogenesis and adipose tissue development has not been fully
understood, we then selectively deleted IKKβ in the white adipose lineage in
mice to further elucidate the role of adipose progenitor cell IKKβ signaling in
obesity and metabolic function. Deficiency of IKKβ decreased adipogenesis
and systemic inflammation elicited by HF feeding, leading to resistance to dietinduced obesity and insulin resistance. Lastly, inhibition of IKKβ in human
adipose stem cells also blocked adipogenesis in these cells. Our results
establish IKKβ as an important regulator of adipogenesis and adipose tissue
development. Overnutrition-mediated IKKβ activation may serve as an initial
signal that triggers adipose progenitor cell differentiation in response to
consumption of a HFD. Inhibition of IKKβ with antisense therapy may present
as a novel therapeutic approach to combat obesity and metabolic dysfunctions.
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4.2

Materials and Methods

4.2.1
Animals and Diet
For the IKKβ ASO studies, 8-week-old male C57BL/6 mice (Jackson
Laboratory) were fed a normal chow diet (ND) or a Western-type HFD (21.2%
fat, 0.2% cholesterol; Harlan Teklad) and received biweekly intraperitoneal
injections of either a nontargeting control ASO (5’CCTTCCCTGAAGGTTCCTCC-3’) or an IKKβ targeted ASO (5’GCAGACTCTCATCCTCCGTC-3’) for 8 weeks at a dose of 25 mg/kg body
weight/week. The 20-mer phosphorothioate ASOs were designed to contain 2’O-methoxyethyl groups at positions 1 to 5 and 15 to 20, and were generated
and purified by Ionis Pharmaceuticals (Carlsbad, CA). For cell lineage analysis,
PDGFRβ-Cre mice [334] were crossed with Rosa26lacZ reporter mice [335] to
generate PDGFRβ-Cre/Rosa26lacZ mice. To delete IKKβ in adipocyte lineage
cells, mice containing loxP-flanked IKKβ alleles (IKKβF/F) [255, 336] was
crossed with PDGFRβ-Cre transgenic mice [334] to generate PDGFRβCre/IKKβF/F mice (termed as IKKβΔPDGFRβ). For obesity studies, 4-week-old
male IKKβF/F and IKKβΔPDGFRβ littermates were fed a normal chow diet (ND) or a
HFD for 16 weeks until euthanization at 20 weeks of age. For the BrdU studies,
4-week-old male IKKβF/F and IKKβΔPDGFRβ littermates were intraperitoneal
injected with 50 mg/kg body weight/day BrdU (TCI America) and mice were
placed on a HFD for 7 days prior to euthanization. All animals were housed in a
specific pathogen-free environment with a light-dark cycle, under a protocol
approved by the University of Kentucky Institutional Animal Care and Use
Committee.
4.2.2
Metabolic Analysis
Body weight was measured weekly and body composition was measured
by NMR spectroscopy (Echo MRI). Intraperitoneal glucose tolerance test (GTT)
and insulin tolerance test (ITT) were performed, as previously described [255].
Plasma insulin was measured using a Rat/Mouse Insulin ELISA kit (Millipore).
Plasma TNFα levels were measured by a mouse TNFα ELISA kit (BioLegend).
Plasma cytokine levels were measured by a mouse cytokine multiplex assay kit
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and a BioPlex 200 system (Bio-Rad Laboratories). For insulin stimulation
studies, 20-week-old male IKKβF/F and IKKβΔPDGFRβ littermates or ASO-treated
C57BL/6 mice were injected with insulin (0.35 U/kg body weight) into the inferior
vena cava [337]. After 5 minutes, mice were euthanized and tissues were
collected for protein isolation and Western blot analysis.
4.2.3
Glucose Uptake in Adipose Tissue Explants
Glucose uptake in adipose tissue explants was achieved following a
previously described protocol [337]. Briefly, HFD-fed IKKβF/F and IKKβΔPDGFRβ
littermates were fasted at the beginning of the light cycle for 7 h and epiWAT
was collected. The tissue explants were minced into small pieces and incubated
for 2 h in 1% BSA-Krebs-Ringer Bicarbonate (KRB) buffer. The tissues were
washed and then incubated with saline or 17 nm insulin for 40 min at 37̊C. After
the insulin incubation, 1 μCi [3H]-2-deoxyglucose (Perkin Elmer) was added to
the buffer and incubated for another 20 min at 37̊C and then the tissues were
washed with cold 1% BSA-KRB and the weight of the tissues were measured
and recorded. The explants were then added to 1 ml 1N NaOH and incubated
for 1 h at 65̊C. Half of the cell lysate was then used to measure the amount of
radioactivity in a scintillation counter and a portion was used to measure the
protein concentration.
4.2.4
MRI Analysis and Data Segmentation
HFD-fed IKKβF/F and IKKβ∆PDGFRβ littermates were imaged on a 7T
CliniScan MRI (Bruker, Ettlingen, Germany) using a 2 point Dixon technique and
a 72 mm diameter circularly polarized transmit receive coil at the Magnetic
Resonance Imaging and Spectroscopy Center at the University of Kentucky.
Anesthesia was induced and maintained using 1-2 % isoflurane in oxygen at a
rate of 1.0 L/min. Respiration and temperature were monitored. Temperature
was maintained between 36-37 °C using a water bath and tubing. Image data
sets including a fat only and water only image were obtained using a dual echo
Flash sequence with TR 12ms, TE 2ms and 3.5ms; flip 15°, FOV 80mm x
57.5mm x 31.7, and resolution 0.18mm x 0.18 mm x 0.18 mm. The fat and
water images were generated from the in and out of phase images using
Siemens Syngo software. FSL software was used for image analysis [338]. The
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fat image was resampled to 1.8mm x 0.18mm x 0.18mm using FSL. The
visceral cavity was segmented out manually. The total fat volume was
calculated by taking a histogram from the fat only image of the visceral cavity
and including voxels that were greater than 80% of the fat peak. 80% was
chosen to include adipose tissue and exclude voxels from the liver [339].
4.2.5
Histological Analysis
For hematoxylin and eosin staining of liver, tissues were fixed in 4%
neutral buffered formalin and embedded in paraffin. 5 μm tissue sections were
stained with hematoxylin and eosin following standard protocols. Oil-Red O
staining of hepatic neutral lipids was performed as previously described [255]. In
brief, livers were embedded in OCT and sectioned at 10 μm. Liver sections
were then dried, fixed in 4% PFA, incubated for 5 min in 60% isopropanol then
incubation in 0.3% Oil-Red O (Sigma) for 20 min. The livers were
counterstained with hematoxylin and mounted with glycerol-gelatin (Sigma).
4.2.6
Immunohistochemistry
Immunohistochemistry was performed on 5 μm adipose tissue sections
embedded in paraffin. For F4/80 staining, rehydrated sections were subjected to
antigen retrieval by heating in antigen unmasking solution (Vector Laboratories).
Slides were cooled and treated with 5% BSA, 3% hydrogen peroxide, and
avidin/biotin blocking kit (Vector Laboratories). Sections were incubated with
anti-F4/80 (Serotec) or rat IgG (negative control; Jackson Immunoresearch)
antibodies at 4̊C overnight. Sections were then incubated with biotinylated antirat IgG (Vector) for 1 h, VECTASTAIN ABC reagent (Vector Laboratories) for 30
min at room temperature and visualized by the avidin-biotin-complex method
using the ImmPACT DAB Peroxidase Substrate Kit (Vector Laboratories).
Sections were then mounted with glycerol-gelatin. For BrdU staining, sections
were incubated with anti-BrdU (Life Sciences; B35130) antibodies for 30 min
using a M.O.M. Immunodetection kit (Vector Laboratories) per manufacturer’s
instructions. Sections were then counterstained with DAPI. Percent BrdUpositive cells were calculated by dividing BrdU-positive cells by DAPI-positive
cells. Two view fields were randomly selected from each mouse for calculation
of BrdU-positive cells.
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4.2.7
3T3L1 Cell Differentiation and Transfection Assays
3T3-L1 cells were obtained from American Type Culture Collection. For
adipocyte differentiation assays, confluent 3T3-L1 cells were exposed to
differentiation media (high-glucose DMEM supplemented with 10% FBS and
differentiation cocktail including 1 ug/ml insulin, 1 μM dexamethasone, and 0.5
mM isobutylmethylxanthine[255]. Forty eight hours post-induction, the cells were
maintained in high-glucose DMEM containing insulin (1ug/ml) and 10% FBS
until they were ready for analysis [255]. The Clustered regularly interspaced
short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9)
method was used to delete IKKβ in 3T3-L1 cells [340]. Briefly, annealed oligos
(5-CACCGGCAGCCGTTGGGGCCATACT-3’) were cloned using BsmBI
digestion into the lentiCRISPRv2 plasmid (generously provided by Dr. Feng
Zhang, Addgene plasmid #52961). The lentivirus was prepared in 293T cells
and the viral supernatant was then used to infect 3T3-L1 cells. Cells were
selected with puromycin and single clones were expanded and screened by
western blot. Further, the Transgenomic Surveyor Mutation Detection Kit
(Fisher Scientific) was used to verify genomic mutations within the IKKβ locus.
For transfection assays, 3T3-L1 cells were transfected with the TOP-flash
reporter [341] and β-gal control plasmid [342] by electroporation using Amaxa
Cell Line Nucleofector kit V (Lonza). Two days post-transfection, cells were
lysed and luciferase and β-gal values were measured as previously described
[299, 342]. We would like to thank Dr. Brett Spear (University of Kentucky) for
the TOP-flash reporter.
4.2.8
Adipose SV Cell Isolation and Differentiation
Adipose SV cells and mature adipocytes were isolated as previously
described [255]. The SV cells were used for RNA and protein isolation or
cultured in 12-well plates for differentiation. For differentiation assays, SV cells
were induced by high-glucose DMEM containing dexamethasone (1 μM),
isobutylmethylxanthine (0.5 mM), insulin (10 μg/ml), rosiglitazone (1 μM), and
10% FBS until they were ready for analysis [255].
4.2.9
RNA Isolation and QPCR Analysis
Total RNA was isolated from mouse tissues or cells using TRIzol Reagent
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(Life Technologies) and QPCR was performed using gene-specific primers and
the SYBR Green PCR kit (Life Technologies) as previously described [179,
299]. The sequences of primer sets used in this study are listed in Table 4.1.
4.2.10
Western Blot Analysis
Western blot was performed as previously described [255, 271]. Briefly,
protein was isolated from cells or tissues with homogenization in RIPA buffer
containing complete mini protease inhibitor cocktail (Roche). Protein
concentrations were determined by the Pierce BCA protein assay kit (Thermo
Fisher Scientific). Anti-IKKβ, anti-IKKα, anti-Smurf2, and anti-TFIIB were
purchased from Cell Signaling Technology; anti-β-catenin and anti-β-actin were
purchased from Sigma-Aldrich. For immunoprecipitation experiments [255],
control or IKKβ knockdown cells, or adipose SV cells, were incubated with 100
nM of PS-341 for 4 h. The whole-cell lysates were isolated, incubated with antiβ-catenin antibody overnight at 4̊ C, and then incubated with Protein A Agarose
beads (Roche) for another 5 h. The samples were washed and analyzed by
Western blot using anti-ubiquitin monoclonal antibodies [255].
4.2.11
Human Subjects and ADHASC Isolation
Human adipocytes were derived from the differentiation of adult derived
human adipocyte stem cells (ADHASC) as described previously [343, 344]. The
adipose tissue was from a collagenase digestion of the lipoaspirate of patients
undergoing liposuction of subcutaneous fat. These patients were generally
young, healthy women undergoing cosmetic procedures, and this method of
collection was approved by the University of Kentucky Institutional Review
Board. Differentiation was induced using differentiation media as previously
described [343, 344]. At least 80 to 90% of the cells developed lipid droplets in
7-10 days.
4.2.12
Quantification of Mitochondrial DNA
Genomic DNA was extracted from subcutaneous WAT by the DNAeasy Blood
and Tissue kit (Qiagen). QPCR was performed on COX1 mitochondrial DNA
and normalized to a nuclear 28S sequence [345, 346]. The sequences of
primer sets used in this study are listed in Supporting Information Table 4.1.
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4.2.13
Statistical Analysis
All data are presented as the mean ± SEM. Individual pairwise
comparisons were analyzed by two-sample, two-tailed Student’s t-test unless
otherwise noted, with P<0.05 was regarded as significant. Two-way analysis of
variance (ANOVA) was used when multiple comparisons were made followed
by a Bonferroni multiple comparisons test. N numbers and the statistical tests
are listed in figure legends. All statistics were done using SigmaPlot 13.0.

4.3

Results
4.3.1

ASO-Mediated IKKβ Knockdown Protects Mice
from Diet-Induced Obesity
We recently demonstrated that IKKβ inhibitors can inhibit adipocyte
differentiation in vitro and ameliorate diet-induced adiposity in mice [255]. To
explore novel and more efficient pharmacological approaches for IKKβ
inhibition, we utilized second-generation ASO targeting technology [347] and
investigated the impact of IKKβ ASO treatment on diet-induced obesity and
metabolic disorders. Subcutaneous delivery of ASO has been shown to reach a
variety of tissues including liver and adipose tissue [348, 349]. Indeed, we
found that IKKβ ASO can efficiently decrease IKKβ gene expression in multiple
tissues including liver, skeletal muscle, and white adipose tissue (WAT) at a
relatively low dose, 25 mg/kg BW/week (Fig. 4.1, A). Interestingly, IKKβ mRNA
levels were not significantly altered in brown adipose tissue (BAT) by IKKβ ASO
treatment at this dose. Western blot analysis also confirmed the specific and
efficient IKKβ knockdown in tissues including liver and WAT as IKKα protein
levels were not affected by IKKβ ASO treatment (Fig. 4.1, B).
We next determined whether IKKβ ASO treatment can ameliorate dietinduced obesity. Groups of 8-week-old wild-type male mice were fed a ND or a
HFD and were treated with control ASO or IKKβ ASO for 8 weeks (Fig. 4.1, C).
HF-feeding increased body weight in mice treated with both control and IKKβ
ASOs. However, IKKβ ASO treatment significantly decreased HFD-induced
body weight gain and adiposity. While lean mass was slightly but significantly
increased in IKKβ ASO-treated mice, fat mass was decreased by 45% in HFD111

fed mice treated with IKKβ ASOs (Fig. 4.1, D). IKKβ ASO was able to decrease
both subcutaneous (sub) WAT and visceral WAT including epididymal (epi) and
retroperitoneal (retro) fat pads in HFD-fed mice as compared with littermate
controls (Fig. 4.1, E).
4.3.2

IKKβ ASOs Improves Insulin Sensitivity and
Reverses Hepatic Steatosis in Obese Mice
Obesity is frequently associated with metabolic disorders such as insulin
resistance and hepatic steatosis. We next investigated whether IKKβ ASO
treatment can protect HFD-fed mice from these disorders. IKKβ ASO-treated
mice had decreased fasting plasma glucose and insulin concentrations as
compared with control mice (Fig. 4.1, F), suggesting improved diabetic
phenotype. Upon glucose and insulin tolerance test, IKKβ ASO-treated mice
had improved glucose tolerance and showed an increased hypoglycemic
response to the injected insulin (Fig. 4.1, G). To further assess the impact of
IKKβ ASO treatment on insulin signaling, HFD-fed mice were injected with
insulin prior to euthanization and phosphorylation of Akt was analyzed in
multiple tissues. IKKβ ASO was able to enhance phosphorylation of Akt in
response to insulin in liver, skeletal muscle and WAT (Fig. 4.1, H). While
hepatic IKKβ signaling has been demonstrated to contribute to obesityassociated insulin resistance [244, 247], the role of adipose IKKβ signaling in
the regulation of insulin sensitivity has not been well-defined. We then
performed adipose glucose uptake assays. Interestingly, adipose tissue
explants from IKKβ ASO-treated mice had elevated glucose uptake in the
absence of insulin and insulin stimulation further enhanced glucose update by
adipose tissues (Fig. 4.1, I). Therefore, the enhanced Akt phosphorylation and
increased glucose uptake in adipose tissue likely contribute to the improved
insulin sensitivity in IKKβ ASO-treated mice. Further, HF feeding also caused
lipid accumulation and hepatic steatosis in control mice. However, IKKβ ASOtreated mice were protected from these detrimental effects (Fig. 4.1, J and K).
Consistently, hepatic triglyceride and cholesterol contents were significantly
reduced in IKKβ ASO-treated mice (Fig. 4.1, L). Collectively, these results
suggest that pharmacological inhibition of IKKβ by ASO ameliorates obesity112

associated metabolic disorders in mice.
4.3.3
IKKβ Regulates Murine Adipocyte Differentiation
We next investigated whether IKKβ ASO treatment can also affect IKKβ
expression in adipocyte precursor cells and affect adipocyte differentiation.
Indeed, we found that IKKβ expression was decreased in both adipose SV cells
and mature adipocytes in IKKβ ASO-treated mice (Fig. 4.2, A). Consistent with
our previous study [255], ASO-mediated IKKβ knockdown diminished the ability
of adipose SV cells to differentiate into adipocytes (Fig. 4.2, B). As expected,
the expression levels of adipogenic genes including PPARγ, Zfp423, and
C/EBPs were significantly decreased in epiWAT from IKKβ ASO-treated mice
(Fig. 4.2, C). Further, IKKβ ASO treatment also decreased the expression of a
known NF-κB target, Smad ubiquitination regulatory factor 2 (Smurf 2) (Fig. 4.2,
D). Smurf2 is an ubiquitin E3 ligase that regulates proteasome-mediated
degradation of several proteins including β-catenin [255, 350, 351].
Consistently, ASO-mediated IKKβ knockdown increased nuclear β-catenin
protein levels in epiWAT (Fig. 4.2, E). Since Wnt/β-catenin signaling has been
well defined to inhibit adipogenesis in vitro and in vivo [352, 353], the increased
Wnt signaling likely contributes to the decreased adipogenesis in IKKβ ASOtreated mice.
To further define the role of IKKβ in adipogenesis, we used the CRISPRCas9 system to delete the IKKβ gene in murine 3T3-L1 preadipocytes (Fig. 4.2,
F). We found that deletion of IKKβ almost completely blocked 3T3-L1 cell
differentiation (Fig. 4.2, G). Gene expression analysis showed that mRNA
levels of adipogenic genes and adipocyte markers including PPARγ and
adiponectin were significantly decreased by IKKβ-deficiency (Fig. 4.2, H).
Consistently, deletion of IKKβ decreased the expression of Smurf2 (Fig. 4.2, I)
and increased nuclear β-catenin accumulation (Fig. 4.2, J), leading to increased
β-catenin activity in these cells (Fig. 4.2, K). We further confirmed that βcatenin ubiquitination was inhibited by IKKβ deficiency in 3T3-L1 cells (Fig. 4.2,
L), suggesting the impact of reduced Smurf2 expression. Taken together, these
results confirm the important role of IKKβ in adipogenesis and indicate that
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pharmacological inhibition of IKKβ by ASO can decrease adipogenesis and dietinduced adiposity.
4.3.4

Targeted Deletion of IKKβ in the White Adipose
Lineage
Since ASO treatment affects many tissues and cell types, it is not clear
how significantly the ASO-mediated IKKβ knockdown in adipose progenitor
contributes to the beneficial effects on obesity and metabolic disorders in mice.
Compared with other tissues or cell types, the role of IKKβ signaling in adipose
progenitor cells has not been well-defined. To investigate the function of IKKβ
signaling in adipose progenitors, we sought to generate a mouse model that
selectively lacks IKKβ in white adipose lineage. Recent studies have identified
a subset of perivascular cells as adipose progenitors which express multiple
mural stem cell markers, including platelet-derived growth factor receptor
(PDGFR) β, α smooth muscle actin (SMA), and NG2 [354]. For example,
PDGFRβ, a human mesenchymal stem cell (MSC) marker [355], and another
isoform of PDGFR, PDGFRα have been confirmed to be adipose progenitor
markers by independent groups [356-359]. Consistently, we also found high
expression levels of PDGFRβ in adipose SV cells as compared with mature
adipocytes (Fig. 4.3, A). We then crossed PDGFRβ promoter-drive Cre mice
[334] with Rosa26lacZ reporter mice that express β-galactosidase (lacZ) in target
tissues upon Cre-mediated excision of a “Stop” sequence to generate PDGFRβCre/Rosa26lacZ mice (Fig. 4.3, B). While none of the adipose SV cells from
control Rosa26lacZ mice were lacZ+ cells, many of the adipose SV cells from
PDGFRβ-Cre/ Rosa26lacZ mice were lacZ+ cells (Fig. 4.3, C). Staining of the
white adipose depots and tissue sections also indicated that PDGFRβ-Cre is
activated in adipose progenitors that give rise to white adipocytes as PDGFRβ
generated strong lacZ expressed in adipocytes, in addition to the vasculature
(Fig. 4.3, D and E). Taken together, our results are consistent with previous
reports [354, 357] and confirm that PDGFRβ is a marker for adipose lineage
cells.
We then deleted IKKβ in adipocyte lineage cells by intercrossing PDGFRβCre mice with mice containing loxP-flanked IKKβ alleles (IKKβF/F) [255, 336].
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The resulting PDGFRβ-Cre/IKKβF/F (termed IKKβΔPDGFRβ) mice were viable and
appeared indistinguishable from their control IKKβF/F littermates. Western blot
analysis confirmed the deletion of IKKβ in WAT including epiWAT and subWAT
but not in BAT, liver, and skeletal muscle (Fig. 4.4, A). As expected, PDGFRβCre-mediated IKKβ deletion also caused reduced IKKβ expression in adipose
SV cells of IKKβΔPDGFRβ mice (Fig. 4.4, B). Further, IKKβ deficiency reduced NFκB-mediated proinflammatory gene expression in response to LPS in adipose
SV cells of IKKβΔPDGFRβ mice (Fig. 4.4, C-G), suggesting impaired NF-κB
activation in these cells.
4.3.5

Deficiency of IKKβ in Adipocyte Lineage Cells
Renders Mice Resistant to Diet-Induced Obesity
To determine the role of adipose progenitor IKKβ signaling in obesity,
IKKβF/F and IKKβΔPDGFRβ littermates were fed a normal chow diet (ND) or a HFD
for 16 weeks. There were no significant differences in body weight for ND-fed
mice. Body weight was significantly increased following HFD-feeding for both
IKKβF/F and IKKβΔPDGFRβ mice; however, IKKβ deficiency significantly decreased
diet-induced bodyweight gain in HFD-fed mice (Fig. 4.5, A). While lean mass
was not affected by IKKβ deficiency, HFD-fed IKKβΔPDGFRβ mice had
significantly decreased fat mass as compared with control littermates (Fig. 4.5,
B).
HFD-fed IKKβΔPDGFRβ mice also had decreased visceral adipose pads
including epididymal and retroperitoneal fat pads. However, deficiency of IKKβ
did not affect the size or weight of subWAT and BAT (Fig. 4.5-4.6). As subWAT
often undergoes “browning” process which enhances oxidative metabolism and
protects mice from metabolic dysfunctions [254, 345, 360, 361], we then
examined whether deficiency of IKKβ affects “browning” of subWAT in these
mice. Interestingly, the expression levels of beige or brown adipocyte markers
as well as mitochondrial function-related genes such as UCP-1 and PGC-1α
[345, 360, 361] were not affected in subWAT of IKKβΔPDGFRβ mice (Fig. 4.7, A).
Consistently, IKKβΔPDGFRβ mice also had comparable mitochondrial content in
subWAT as that of control littermates (Fig. 4.7, B). MRI analyses confirmed that
IKKβΔPDGFRβ mice had a significantly decreased volume of visceral adipose
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tissue but a similar subcutaneous adipose tissue volume as compared with
IKKβF/F mice under HF feeding conditions (Fig. 4.5-4.6). We next analyzed the
expression levels of IKKβ and adipose progenitor markers in SV cells isolated
from subWAT and epiWAT of control mice. Interestingly, IKKβ expression levels
were significantly higher in visceral SV cells than subcutaneous SV cells.
Further, the expression levels of adipose progenitor markers such as PDGFRβ
were much higher in visceral SV cells as compared with subcutaneous SV cells,
indicating more abundant adipose progenitor cell population in visceral WAT
(Fig. 4.8). Collectively, these results demonstrate that PDGFRβ-Cre-driven
IKKβ deficiency in the white adipose lineage decreases diet-induced obesity
and visceral adiposity.
4.3.6

IKKβ-Deficient Mice are Protected From ObesityAssociated Metabolic Disorders
We next investigated whether deficiency of IKKβ also protected mice from
obesity-associated insulin resistance. IKKβΔPDGFRβ mice had comparable
glucose and insulin levels and similar glucose tolerance and insulin tolerance as
that of IKKβF/F when fed a ND (Fig. 4.9-4.10). As expected, HF feeding
increased plasma glucose and insulin levels in both IKKβF/F and IKKβΔPDGFRβ
mice (Fig. 4.9, A). Although glucose concentrations were not affected by IKKβ
deficiency, HFD-fed IKKβΔPDGFRβ mice had significantly decreased insulin
concentrations as compared with HFD-fed control littermates (Fig. 4.9, A).
Consistently, IKKβΔPDGFRβ mice also had improved glucose tolerance and insulin
tolerance as compared with IKKβF/F mice under HF feeding conditions (Fig. 4.9,
B). PDGFRβ-Cre-mediated IKKβ deletion also enhanced phosphorylation of Akt
in response to insulin in WAT but not in liver and skeletal muscle (Fig. 4.9, C).
Further, adipose tissue explants from IKKβΔPDGFRβ mice had significantly
increased insulin-stimulated glucose uptake compared with that of IKKβF/F mice
(Fig. 4.9, D).
Obesity-associated macrophage infiltration contributes to the development
of systemic insulin resistance [362]. Although IKKβ expression levels were not
affected in macrophages of IKKβΔPDGFRβ mice (Fig. 4.9, E), macrophage
infiltration was substantially decreased in WAT of IKKβΔPDGFRβ mice fed a HFD
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(Fig. 4.9-4.10), suggesting that deficiency of IKKβ in adipose lineage blocks the
increased inflammatory infiltrates in WAT under obese conditions. Consistently,
the mRNA levels of macrophage markers and several key pro-inflammatory
cytokines including TNFα, MCP-1, and IL-1β were significantly decreased in
WAT of IKKβΔPDGFRβ mice (Fig. 4.9, G). Next, we measured plasma cytokine
levels to determine whether IKKβ-deficient mice also had decreased systemic
inflammation. Indeed, deficiency of IKKβ significantly decreased HFD-induced
plasma pro-inflammatory cytokines including TNFα, MCP-1 and IL-6 in
IKKβΔPDGFRβ mice (Fig. 4.9, H). Taken together, deficiency of IKKβ improved
insulin signaling in adipose tissue and protected mice from obesity-associated
metabolic disorders.
4.3.7
Deficiency of IKKβ Inhibits Adipogenesis in Mice
We next investigated whether deficiency of IKKβ can decrease HF
feeding-elicited adipogenesis in vivo. For this experiment, IKKβF/F and
IKKβΔPDGFRβ mice were treated with BrdU during the first week of HF feeding.
We then used BrdU as a marker to track newly differentiated adipocytes in
these mice after 7d of HFD. Immunostaining of adipose tissue sections with
BrdU antibodies revealed that IKKβΔPDGFRβ mice had significantly decreased
BrdU positive adipocytes in WAT (Fig. 4.11, A and B), indicating decreased
adipogenesis. We also assessed the adipogenic potential of adipose SV cells
isolated from visceral adipose tissue of IKKβF/F and IKKβΔPDGFRβ mice and
confirmed that IKKβ deficiency impaired the adipogenic potential of SV cells
from IKKβΔPDGFRβ mice (Fig. 4.11, C). Further, the expression levels of
adipocyte markers and key adipogenic genes including PPARγ, C/EBPα, and
Zfp423, were significantly reduced by IKKβ deficiency (Fig. 4.11, D). Consistent
with results from IKKβ ASO treatment and 3T3-L1 experiments (Fig. 2),
IKKβΔPDGFRβ mice had decreased Smurf2 levels and increased nuclear β-catenin
levels in epiWAT (Fig. 4.11, E and F) as well as in primary adipose SV cells
(Fig. 4.11, G and H). Further, deficiency of IKKβ substantially decreased βcatenin ubiquitination in adipose SV cells (Fig. 4.11, I), which likely contributes
to the accumulation of nuclear β-catenin in IKKβΔPDGFRβ mice.
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4.3.8

Inhibition of IKKβ Decreases Adipogenesis in
Human Adipose Stem Cells
In addition to murine 3T3-L1 preadipocytes and primary SV cells, we also
determined whether IKKβ regulates the differentiation of human adipose stem
cells. Human adipose stem cells, also known as adult-derived human adipose
stem cells (ADHASCs) [343, 344, 363], were isolated from healthy subjects.
Consistent with previous reports [343, 344, 363], human adipose stem cells
were able to efficiently differentiate into mature adipocytes in vitro and at least
80 to 90% of the cells developed lipid droplets in 7-10 days (Fig. 4.12, A).
Pharmacological inhibition of IKKβ by BMS-345541 strongly inhibited human
adipose stem cell differentiation and repressed human adipogenic gene
expression (Fig. 4.12, B). BMS-345541 treatment also led to reduced Smurf2
expression and decreased β-catenin ubiquitination, leading to increased nuclear
β-catenin levels (Fig. 4.12, C-E), which likely contribute to the decreased
adipogenesis in human adipose stem cells. Collectively, these results
demonstrated IKKβ as an important regulator of both human and murine
adipocyte differentiation.

4.4

Discussion

As a central coordinator of inflammatory responses, IKKβ signaling in
multiple tissues including liver, pancreas, and brain have been associated with
obesity and obesity-related metabolic dysfunctions [241, 244, 247, 249, 333,
364]. High doses of IKKβ inhibitors such as salicylates have been used to treat
inflammatory conditions including diabetes in humans for more than a century
[365, 366]. Moreover, inhibition of IKKβ activity by salicylates also protected
mice against insulin resistance triggered by HFD or obesity [241, 248].
Interestingly, long-term anti-inflammatory therapy has also been associated with
weight loss in human studies [367]. We recently demonstrated that salicylates
and the potent IKKβ inhibitor, BMS-345541, can also inhibit adipocyte
differentiation in a dose-dependent manner [255]. In the current study, we
demonstrated that IKKβ ASO can efficiently decrease IKKβ expression in
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various tissues including liver and WAT, and ameliorate diet-induced obesity
and metabolic disorders in mice. To our knowledge, our study is the first to use
ASOs targeting IKKβ in vivo and investigate its metabolic impact. Consistent
with previous reports demonstrating that hepatic IKKβ signaling contribute to
insulin resistance [244, 247], IKKβ ASO-treated mice had improved insulin
signaling in the liver. Nevertheless, knockdown of IKKβ in WAT also resulted in
enhanced Akt phosphorylation and increased glucose uptake. Therefore, the
improved diabetic phenotype in IKKβ ASO-treated mice was likely due to the
repressed IKKβ signaling in multiple tissues including liver and WAT. In
addition to improved insulin signaling, IKKβ ASO treatment also repressed IKKβ
expression in SV cells, leading to decreased adipogenesis in WAT. Collectively,
our studies demonstrate IKKβ as a potential target for future anti-obesity drugs
and provide evidence for the use of appropriate IKKβ ASOs as a potential
therapeutic strategy to treat obesity and metabolic disease (Fig.4.12, A-C).
Despite substantial progress in defining transcription factors such as
PPARγ and C/EBPs in the regulation of committed preadipocyte differentiation,
the initial signals that trigger adipose progenitor cell commitment to adipocyte
lineage in response to overnutrition remained unknown. In addition to its wellestablished role as a central mediator of inflammation and immune responses,
IKKβ/NF-κB signaling plays key roles in the regulation of hematopoietic cell
development and stem cell differentiation [350, 368-370]. It has also been
reported that NF-κB activity increases during adipocyte differentiation [371] and
IKKβ/NF-κB activation is associated with increased adipogenesis and insulin
resistance in maternal obesity [372]. Further, pro-inflammatory signals have
been demonstrated to be important for adipogenesis in vivo and many IKKβ/NFκB activators including LPS, IL-1β, and MCP-1 can stimulate adipogenesis and
promote adipocyte differentiation [373-375]. While the role of IKKβ signaling in
regulating HFD-elicited tissue inflammation and insulin resistance is well
recognized [327, 330, 331], it remained elusive if activation of IKKβ also
mediates adipogenesis and adipose tissue growth in response to overnutrition.
Since ASOs affects many cell types, we then selectively deleted IKKβ in white
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adipose lineage in mice and confirmed that deficiency of IKKβ in adipocyte
lineage cells decreased adipogenesis and systemic inflammation elicited by HF
feeding, leading to resistance to diet-induced obesity and insulin resistance.
Intriguingly, IKKβΔPDGFRβ mice displayed no significant phenotype under
standard laboratory conditions but were resistant to obesity when challenged
with a HFD, indicating that HFD-induced IKKβ activation in adipose progenitors
is essential for HFD-induced adipose tissue growth. Consistent with our
previous report [255], deficiency of IKKβ significantly decreased Smurf2
expression and substantially inhibited β-catenin ubiquitination in adipose SV
cells, leading to accumulation of nuclear β-catenin and increased β-catenin
activity. Wnt/β-catenin signaling plays an important role in the regulation of
MSC lineage and has been well defined to inhibit adipogenesis in vitro and in
vivo [352, 353, 376]. Consistently, Cre-mediated IKKβ deletion or ASOmediated IKKβ knockdown impaired the adipogenic potential of adipose SV
cells in mice. We also demonstrated, for the first time, that inhibition of IKKβ
activity can also block human adipose stem cells differentiation, suggesting that
IKKβ plays an important role in regulation of both murine and human adipocyte
differentiation.
It is worth noting that IKKβΔPDGFRβ mice had decreased visceral adipose
tissue but comparable subcutaneous adipose tissue as control mice when fed a
HFD. There is a major ontogenetic difference between visceral and
subcutaneous fat as they have different developmental origins [377]. Wang et
al. [254] demonstrated that different fat depots have extensive differences in
adipogenic potential. Visceral adipose tissue has a high capacity for
adipogenesis in vivo but subcutaneous adipogenesis is limited [254]. A recent
study also confirmed that HF feeding rapidly and specifically activates
adipogenesis in visceral but not subcutaneous depots in mice [378]. Further,
subcutaneous fat depot can also undergo extensive “browning” process after
cold exposure and the appearance brown-like cells or beige cells are mainly
found in subcutaneous fat but not in visceral fat [254]. It has been recently
demonstrated that the PDGFRβ-positive adipocyte lineage cells contribute to
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beige adipogenesis after prolonged cold exposure [253]. While deficiency of
IKKβ did not affect the beige or brown adipocyte marker expression or
mitochondrial content in subWAT of IKKβΔPDGFRβ mice under HF-feed conditions,
it would be of interest to investigate whether IKKβΔPDGFRβ mice have affected
beige adipocyte formation or mitochondrial function after chronic cold exposure
in the future. Consistent with previous studies demonstrating that human
visceral adipose tissue expresses high levels of IKKβ as compared with
subcutaneous adipose tissue [379], we also found that IKKβ expression levels
were significantly higher in murine visceral SV cells than in murine
subcutaneous SV cells. Moreover, the expression levels of adipose progenitor
markers including PDGFRβ were much higher in visceral SV cells than in
subcutaneous SV cells. It is plausible that visceral adipose tissue has more
abundant adipose progenitor population and activation of IKKβ signaling is
required for these cells differentiating into adipocytes in response to HF feeding.
Deletion of IKKβ in adipocyte lineage cells therefore has more impact on
visceral adipose tissue growth than that of subcutaneous adipose tissue when
challenged with a HFD. Further studies will be required to determine the
detailed mechanisms that account for the different effects of IKKβ deficiency on
visceral vs. subcutaneous fat. While both subcutaneous and visceral fat are
increased in obese mice and human, accumulation of visceral but not
subcutaneous adipose tissue contributes to the increased risk of obesityassociated metabolic dysfunctions [380]. Our data suggest that targeting IKKβ
in adipocyte lineage cells may represent a novel therapeutic approach to reduce
visceral adipose tissue mass in obesity.
In summary, we have revealed a pivotal role of IKKβ in the regulation of
adipocyte differentiation and adipose tissue growth in obesity. ASO-mediated
IKKβ knockdown protected mice from diet-induced obesity and metabolic
dysfunctions. Deficiency of IKKβ in adipocyte lineage cells also inhibited HF
feeding-elicited adipocyte differentiation and adipose tissue growth, leading to
resistance to obesity and insulin resistance. Our findings suggest that
overnutrition-induced IKKβ activation in adipose progenitors is an important
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trigger for adipocyte differentiation and inhibition of IKKβ with antisense therapy
may represent as a novel therapeutic approach to combat obesity and related
metabolic dysfunctions.
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Table 4.1 Primer sequences for QPCR.
Gene

Primer sequence

Genes

5’-GAGCTCAGCCCAAAGAACAG-3’

Primer sequence
5’-AGCAGGCAGGGCTTCAACGG-3’

PDGFRα

IKKβ
5’-AGGTTCTGCATCCCCTCTGG-3’

5’-ACACAGTCTGGCGTGCGTCC-3’

5’-TTAAAAACCTGGATCGGAACCAA-3’

5’-CGTGCAGAACTCCTGTGATAAC-3’

MCP-1

CD137
5’-GCATTAGCTTCAGATTTACGGGT-3’

5’-GTCCACCTATGCTGGAGAAGG-3’

5’-GCACCTTACACCTACCAGAGT-3’

5’-GCAGCAAGCACAAAGAGGAGAAG-3’
HOXC9

IL-1α
5’-TGCAGGTCATTTAACCAAGTGG-3’

5’-GCGTCTGGTACTTGGTGTAGGG-3’

5’-GCAACTGTTCCTGAACTCAACT-3’

5’-TGGAACAACTCAACGAGCTGGAGA-3’
SHOX2

IL-1β
5’-ATCTTTTGGGGTCCGTCAACT-3’

5’-TTCAAACTGGCTAGCGGCTCCTAT-3’

5’-TAGTCCTTCCTACCCCAATTTCC-3’

5’-GGCAGGCAGACGAATGTTC-3’
TBX1

IL-6
5’-TTGGTCCTTAGCCACTCCTTC-3’

5’-TTGTCATCTACGGGCACAAAG-3’

5’-GCTCTTACTGACTGGCATGAG-3’

5’-ACTGCCACACCTCCAGTCATT-3’

IL-10

UCP1
5’-CGCAGCTCTAGGAGCATGTG-3’

5’-CTTTGCCTCACTCAGGATTGG-3’

5’-CCCATATACCTGGGAGGAGTCTTC-3’

5’-AACCACACCCACAGGATCAGA-3’
PGC1α

TNFα
5’-CATTCCCTTCACAGAGCAATGAC-3’

5’-TCTTCGCTTTATTGCTCCATGA-3’

5’-CTTTGGCTATGGGCTTCCAGTC-3’

5’-CTTTGACCCGCTTCCACTT-3’

F4/80

MEOX2
5’-GCAAGGAGGACAGAGTTTATCGTG-3’

5’-AATCTAGACCTCACTGAAAGACAGG-3’

5’-CTTCCCACAGGCAGCACAG-3’

5’-CCACTTCTCCTGAGTTTACAGC-3’

CD68

EVA1
5’-AATGATGAGAGGCAGCAAGAGG-3’

5’-GCATTTTAACCGAACATCTGTCC-3’
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Table 4.1 (continued)
Gene

Primer sequence

Genes

5’-AGACACTGGGGAATACTTTTGTG-3’

Primer sequence
5’-GAGCTCGGACCAGCTTCA-3’

PDGFRβ

LHX8
5’-CGGCCCTAGTGAGTTGTTGT-3’

5’-TTGTTGTCCTGAGCGAACTG-3’

5’-GTGCCAGTTTCGATCCGTAGA-3’

5’-CTACAGGCCTTGCTCAGCTC-3’
MYOGENIN

PPARγ
5’-GGCCAGCATCGTGTAGATGA-3’

5’-TGGGAGTTGCATTCACTGG-3’

5’-GACATCAGCGCCTACATCGA-3’

Human
PPARγ

C/EBPα
5’-TCGGCTGTGCTGGAAGAG-3’
5’-ATTTCTATGAGAAAAGAGGCGTATGT-3’

Human
Zfp423

C/EBPβ
5’-AAATGTCTTCACTTTAATGCTCGAA-3’
5’-TGGCCTGGGATTCCTCTGT-3’

Human
C/EBPα

Zfp423
5’-CTCTTGACTTGTCACGCTGTT-3’
5’-CCACAAACGACCAAGCCTTCT-3’

5’-CCAGGAAGGCCTTGACCTTT-3’
5’-CTGATCATCCAGCAGGTGTT-3’
5’-GGCATCAACCACGAGTGTAAGC-3’
5’-CTTCTGCGGAGAGGTGTCCTGT-3’
5’-CGGTGGACAAGAACAGCAAC-3’
5’-CGGAATCTCCTAGTCCTGGC-3’
5’-ACCAGGAAAGTGGCTGGCAT-3’

SM22

Human aP2
5’-CGGCTCATGCCGTAGGAT-3’

5’-CAGGTCAACGTCCCTTGGCT-3’

5’-AGGCGTCTACCGATGTGATGT-3’

Human
Adiponectin

NG2
5’-TGGCTGCCCTGTAGTGAAAC-3’
5’-AAGGTGAAGAGCATCATAACCCT-3’

Human
GAPDH

aP2
5’-TCACGCCTTTCATAACACATTCC-3’
5’-GCACTGGCAAGTTCTACTGCAA-3’

mtDNA
(COX1)

Adiponectin
5’-GTAGGTGAAGAGAACGGCCTTGT-3’
5’-CCAGGAAGGCCTTGACCTTT-3’

5’-AGCCTCCTTCTCCTGGGTCC-3’
5’-GTTGCCTCTAGCCTGGTGGG-3’
5’-GGCCTCCAAGGAGTAAGACC-3’
5’-AGGGGAGATTCAGTGTGGTG-3’
5’-CCGCAAGGGAAAGATGAAAGAC-3’
5’-TCGTTTGGTTTCGGGGTTTC-3’
5’-GCCAGCCTCTCCTGATTTTAGTGT-3’

36B4

nDNA (28S)
5’-CTGATCATCCAGCAGGTGTT-3’

5’-GGGAACACAAAAGACCTCTTCTGG-3’
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Figure 4.1 Pharmacological inhibition of IKKβ with ASOs protects
mice from diet-induced obesity, improves insulin sensitivity, and
reverses hepatic steatosis in obese mice.
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Figure 4.1 Pharmacological inhibition of IKKβ with ASOs protects
mice from diet-induced obesity, improves insulin sensitivity, and
reverses hepatic steatosis in obese mice.
(A) IKKβ mRNA expression in liver, kidney, spleen, skeletal muscle (Sk.M.),
brown adipose tissue (BAT), subcutaneous white adipose tissue (subWAT),
retroperitoneal WAT (retroWAT), and epididymal WAT (epiWAT) from mice
treated with control ASO or IKKβ ASO for 8 weeks (n=6-10; *P<0.05,
***P<0.001, assessed by Student’s t-test). (B) Western blot analysis of IKKβ
and IKKα expression in liver and epiWAT from mice treated with control or
IKKβ ASO for 4 weeks. (C and D) Growth curves (C), and fat mass and lean
mass (D) of ND and HFD-fed mice treated with control ASO or IKKβ ASO
(n=10 for ND and 30 for HFD; *P<0.05, **P<0.01, and ***P<0.001, assessed
by two-way ANOVA). (E) Representative images of adipose depots (top) and
weight of adipose depots (bottom) from mice treated with control or IKKβ ASO
for 8 weeks (n=20; ***P<0.001, assessed by Student’s t-test). (F) Fasting
plasma glucose and insulin levels of HFD-fed mice treated with control or IKKβ
ASO (n=29-30; ***P<0.001, assessed by Student’s t-test). (G) Intraperitoneal
glucose tolerance test (IPGTT), intraperitoneal insulin tolerance tests (IPITT),
and area of curve (AUC) of IPGTT and IPITT of HFD-fed mice treated with
control or IKKβ ASO (n=8-10; **P<0.01, ***P<0.001, assessed by Student’s ttest). (H) Western blot analysis of phosphorylated Akt and total Akt levels in
liver, epiWAT, and skeletal muscle of control or IKKβ ASO-treated mice
injected with saline or 0.35U/kg body weight. (I) Glucose uptake was
measured in primary adipose tissues from mice treated with control or IKKβ
ASO (n=9; **P<0.01, ***P<0.001, assessed by two-way ANOVA). (J and K):
Representative appearance (J) and hematoxylin and eosin (top) and Oil-red-O
(bottom) stained sections (K) of livers from mice treated with control or IKKβ
ASO (scale bar=100μm). (L) Hepatic cholesterol and triglyceride levels of
mice treated with control or IKKβ ASO (n=10; ***P<0.001, assessed by
Student’s t-test). Results are presented as mean ± SEM.
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Figure 4.2 IKKβ regulates murine adipocyte differentiation.
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Figure 4.2 IKKβ regulates murine adipocyte differentiation.
(A) IKKβ mRNA expression in adipose SVF and mature adipocytes isolated
from epiWAT of mice treated with control or IKKβ ASO (n=6; **P<0.01,
assessed by Student’s t-test). (B) Oil-red-O staining of adipose SV cells
isolated from epiWAT of mice treated with control and IKKβ ASO induced by
differentiation media (scale bar=100 μm, bottom panels). (C) Expression of
adipogenic genes in epiWAT of control and IKKβ ASO treated mice was
measure by QPCR (n=6; **P<0.01, ***P<0.001, assessed by Student’s t-test).
(D) Western blot analysis of Smurf2 protein levels in epiWAT. (E) Western
blot analysis of nuclear β-catenin levels in epiWAT. (F) Western blot analysis
of IKKβ and IKKα protein levels in control 3T3-L1 cells or CRISPR-mediated
IKKβ-deficient 3T3-L1 cells. (G) Oil-red-O staining of control and IKKβdeficient 3T3-L1 cells induced by differentiation media (scale bar=100μm,
bottom panels). (H) Expression of adipogenic genes and adipocyte markers in
control or IKKβ-deficient 3T3-L1 cells (n=6; **P<0.01, ***P<0.001, assessed by
Student’s t-test). (I) Western blot analysis of Smurf2 protein levels in control or
IKKβ-deficient 3T3-L1 cells. (J) Western blot analysis of nuclear β-catenin
protein levels in control or IKKβ-deficient 3T3-L1 cells. (K) β-catenin reporter
(TOP-flash reporter) activity in control or IKKβ-deficient 3T3-L1 cells (n=6;
***P<0.001, assessed by Student’s t-test). (L) Control or IKKβ-deficient 3T3L1 cells were treated with vehicle control or 100 nM PS-341, as indicated, for 4
h. β-catenin was immunoprecipitated with anti-β-catenin antibodies and then
probed with anti-ubiquitin monoclonal antibodies. The whole cell lysates were
probed with anti-β-catenin antibodies as an internal control. Results are
presented as mean ± SEM.
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Figure 4.3 PDGFRβ labels adipose progenitor cells in vivo.
(A) The expression levels of endogenous PDGFRβ in adipose SV cells and
adipocytes isolated from epiWAT of mice were measured by QPCR (n=4;
***P<0.001, assessed by Student’s t-test). (B) Schematic of the
PDGFRβCre+lacZF/F mouse model. (C) Primary adipose SV cells isolated from
lacZF/F and PDGFRβCre+lacZF/F mice were stained with X-Gal (blue) and
nuclear fast red (red) (scale bar=100μm). (D) EpiWAT of lacZF/F and
PDGFRβCre+lacZF/F mice were stained for β-galactosidase expression (blue)
(top). White arrows indicate the vasculature in stained epiWAT of
PDGFRβCre+lacZF/F mice (bottom). (E) Cross-sections of epiWAT from lacZF/F
and PDGFRβCre+lacZF/F mice were stained for β-galactosidase expression
(scale bar=100μm). Results are presented as mean ± SEM.
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Figure 4.4 Generation of mice lacking IKKβ in the white adipose
lineage.
(A) Western blot analysis of IKKβ and IKKα protein levels in epiWAT, subWAT,
liver, BAT, and skeletal muscle (Sk.M.) of IKKβF/F and IKKβΔPDGFRβ mice. (B)
Western blot analysis of IKKβ and IKKα protein levels in adipose SV cells
isolated from IKKβF/F and IKKβΔPDGFRβ mice. (C-G) Adipose SV cells isolated
from IKKβF/F and IKKβΔPDGFRβ mice were treated with LPS for 3 h. The
expression levels for proinflammatory cytokines including TNFα (C), MCP-1
(D), IL-1α (E), IL-1β (F), and IL-6 (G) were examined by QPCR (n=5;
**P<0.01, ***P<0.001, assessed by two-way ANOVA). Results are presented
as mean ± SEM.
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Figure 4.5 Deficiency of IKKβ in adipocyte lineage cells renders mice
resistant to diet-induced obesity.
(A) Growth curves of ND or HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (n=9-18,
***P <0.001 when comparing HFD-fed IKKβF/F mice to HFD-fed IKKβΔPDGFRβ
mice, assessed by Student’s t-test). (B) Body weight, fat mass, percentage of
fat, and lean mass of 10-week-old IKKβF/F and IKKβΔPDGFRβ mice fed a ND or
HFD for 16 weeks (n=7-19; **P<0.01, ***P<0.001, assessed by two-way
ANOVA). (C) Representative photographs of epiWAT, retroWAT, subWAT,
and BAT from ND or HFD-fed IKKβF/F and IKKβΔPDGFRβ mice. (D and E)
Representative coronal section MRI images (D) and visceral and
subcutaneous adipose tissue volume (E) of HFD-fed IKKβF/F and IKKβΔPDGFRβ
(n=3; ***P<0.001, assessed by Student’s t-test). Results are presented as
mean ± SEM.
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Figure 4.6 Loss of adipocyte progenitor IKKβ decreases visceral
adiposity in mice fed a HFD.
(A) Representative images of IKKβF/F and IKKβΔPDGFRβ mice fed a ND and
HFD. (B) Tissue weight of liver, epiWAT, subWAT, retroWAT and BAT of ND
or HDF-fed IKKβF/F and IKKβΔPDGFRβ mice (top panels), and percentage of
body weight of indicated tissues (bottom panels) (n=6-12, **P<0.01,
***P<0.001, assessed by Student’s t-test). Results are presented as mean ±
SEM.
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Figure 4.7 Deficiency of IKKβ in adipocyte lineage cells does not
affect beige and brown adipocyte markers or mitochondrial DNA
content in subWAT.
(A) The expression levels of beige or brown adipocyte markers and
mitochondrial function-related genes in subWAT of HFD-fed IKKβF/F and
IKKβΔPDGFRβ mice were analyzed by QPCR (n=6). (B) Quantification of
mitochondrial DNA in subWAT of HFD-fed IKKβF/F and IKKβΔPDGFRβ mice
(n=5). Results are presented as mean ± SEM.
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Figure 4.8 Adipose progenitor cell markers are highly enriched in
visceral fat.
The expression levels of IKKβ and adipose progenitor cell markers in adipose
SV cells isolated from subWAT or epiWAT of WT mice were analyzed by
QPCR (n=4; **P<0.01, ***P<0.001, assessed by Student’s t-test). Results are
presented as mean ± SEM.
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Figure 4.9 IKKβ-deficient mice are protected from obesity-associated
metabolic disorders.
(A) Fasting plasma glucose and insulin levels in ND or HFD-fed IKKβF/F and
IKKβΔPDGFRβ mice (n=5-11; **P<0.01, ***P<0.001, assessed by two-way
ANOVA). (B) IPGTT, IPITT, and area under the curve (AUC) of IPGTT and
IPITT of HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (n=6-11; *P<0.05, **P<0.01,
***P<0.001, assessed by Student’s t-test). (C) Western blot analysis of
phosphorylated Akt and total Akt levels in epiWAT, liver, and skeletal muscle
of IKKβF/F and IKKβΔPDGFRβ mice injected with saline or 0.35U/kg body weight.
(D) Glucose uptake was measured in primary adipose tissues from HFD-fed
IKKβF/F and IKKβΔPDGFRβ mice (n=9; ***P<0.001, assessed by two-way
ANOVA). (E) Western blot analysis of IKKβ protein levels in peritoneal
macrophages of IKKβF/F and IKKβΔPDGFRβ mice. (F) Representative
immunohistochemistry for the macrophage marker, F4/80, in epiWAT from
HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (scale bar=100μm). (G) The
expression levels of pro-inflammatory genes and macrophage markers in
epiWAT of HFD-fed IKKβF/F and IKKβΔPDGFRβ mice were measured by QPCR
(n=5; *P<0.05, **P<0.01, ***P<0.001, assessed by Student’s t-test). (H)
Plasma cytokine levels of ND or HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (n=57; **P<0.01, ***P<0.001, assessed by two-way ANOVA). Results are
presented as mean ± SEM.
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Figure 4.10 Deficiency of IKKβ in adipocyte lineage cells has no
impact of adipose tissue inflammation or glucose and insulin
tolerance in mice fed a normal chow.
(A) Representative immunohistochemistry for the macrophage marker, F4/80
in epiWAT from ND-fed IKKβF/F and IKKβΔPDGFRβ mice (scale bar=100μm). (B)
IPGTT, IPITT and area under the curve (AUC) of IPGTT and IPITT of ND-fed
IKKβF/F and IKKβΔPDGFRβ mice (n=5-11). Results are presented as mean ±
SEM.
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Figure 4.11 Deficiency of IKKβ inhibits adipogenesis in mice.
(A and B) Representative images (A) and quantification (B) of immunostaining
for BrdU in epiWAT from BrdU-treated IKKβF/F and IKKβΔPDGFRβ mice fed a
HFD for 7 days (n=4-5; **P<0.01, significance assessed by Student’s t-test).
The nuclei were stained with DAPI (blue) and the BrdU-positive cells are
indicated by arrows. (C) Oil-red-O staining of adipose SV cells isolated from
epiWAT of IKKβF/F and IKKβΔPDGFRβ mice induced by differentiation media.
(Scale bar=100μm, bottom panels). (D) The expression levels of adipogenic
genes and adipocyte markers in adipose SV cells of IKKβF/F and IKKβΔPDGFRβ
mice were measured by QPCR (n=5-8; *P<0.05, **P<0.01, ***P<0.001,
assessed by Student’s t-test). (E and F) Western blot analysis of Smurf2
protein levels (E) and nuclear β-catenin protein levels (F) in epiWAT of IKKβF/F
and IKKβΔPDGFRβ mice. (G and H) Western blot analysis of Smurf2 protein
levels (G) and nuclear β-catenin protein levels (H) of adipose SV cells isolated
from IKKβF/F and IKKβΔPDGFRβ mice. (I) Adipose SV cells isolated from IKKβF/F
and IKKβΔPDGFRβ mice were treated with vehicle control or 100 nM PS-341, as
indicated, for 4 h. β-catenin was immunoprecipitated with anti-β-catenin
antibodies and then probed with anti-ubiquitin monoclonal antibodies. The
whole cell lysates were probed with anti-β-catenin antibodies as an internal
control. Results are presented as mean ± SEM.
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Figure 4.12 Inhibition of IKKβ decreases adipogenesis in human
adipose stem cells.
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Figure 4.12 Inhibition of IKKβ decreases adipogenesis in human
adipose stem cells.
(A) Oil-red-O staining of adult-derived human adipose stem cells induced by
differentiation media or media containing 5 μM IKKβ inhibitor BMS-345541
(scale bar=100μm, bottom panels). (B) The expression levels of adipogenic
genes and adipocyte markers of human adipose stem cells treated with
vehicle control or 5μM BMS-345541 were measured by QPCR (n=4; *P<0.05,
**P<0.01, ***P<0.001, assessed by Student’s t-test). (C and D) Western blot
analysis of Smurf2 protein levels (C) and nuclear β-catenin protein levels (D) in
control or BMS-345541-treated human adipose stem cells. (E) Control or
BMS-345541-treated human adipose stem cells were treated with vehicle
control or 100 nM PS-341, as indicated, for 4 h. β-catenin was
immunoprecipitated with anti-β-catenin antibodies and then probed with antiubiquitin monoclonal antibodies. The whole cell lysates were probed with antiβ-catenin antibodies as an internal control. **p<0.01, ***p<0.001. Results are
presented as mean ± SEM.
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Figure 4.13 Working model of the role of IKKβ signaling in adipocyte
lineage cells in obesity.
(A) Under normal feeding conditions, the IKKβ/NF-κB signaling is maintained
at basal activity. (B) Under HFD feeding conditions, overnutrition (e.g. excess
FFA) activates IKKβ, leading to increased adipogenesis and inflammation. (C)
In our current study, pharmacological inhibition or genetic deletion of IKKβ in
adipocyte lineage cells impairs adipogenesis and protects mice from HFDinduced obesity and metabolic dysfunctions.

Copyright © Robert Nathaniel Helsley, 2016
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Chapter 5: Future Directions
5.1

Investigate the Consequences Associated with the SNPs Located
Within the 3’ UTR of PXR

The SNPs found within PXR that correlate with alterations in cholesterol
metabolism are intriguing. Interestingly, many of these SNPs are located within
the 3’ UTR of PXR, indicative of extensive post-transcriptional regulation.
Whether or not these SNPs are the causal variant in altering cholesterol balance
remains to be determined; however, the idea that SNPs elicit changes in host
gene expression by altering binding sites of transcription factors and/or
microRNAs is well accepted. For instance, Musunuru and colleagues recently
demonstrated that a SNP linked to myocardial infarction and high LDLcholesterol levels disrupts a binding site for the transcription factor
CCAAT/enhancer binding protein (C/EBP) in the sortilin 1 (Sort1) gene [381,
382]. Subsequently, the risk allele generates reduced expression of Sort1,
ultimately increasing VLDL and LDL cholesterol levels in the blood and
increased risk for CAD [381, 382]. It is possible that the SNPs within PXR
generate gain-of-function and/or loss-of-function miRNA binding sites that
subsequently elicit changes in RNA stability. For example, miR-148a has been
recently implicated as a significant modulator of plasma cholesterol by
regulating many genes involved in cholesterol homeostasis, including LDLR and
ABCA1 [383]. Micro-RNA 148a has also been demonstrated to regulate PXR
[117], but whether these SNPs are altering miR148a-binding, or other microRNA
binding, remains to be ascertained.

5.2

Determine the Involvement of PXR in Currently Recommended
ARV Drug-Associated Dyslipidemia

We recently reported that amprenavir and ritonavir, HIV PIs, are potent
PXR agonists and that acute amprenavir exposure induced pro-atherogenic
LDL cholesterol levels in WT but not in PXR-deficient mice [299]. Both PIs have
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been associated with dyslipidemia and increased risk for CVD in HIV infected
individuals [65, 67]. Currently, amprenavir is not widely prescribed, partially due
to its deleterious effects on lipid levels, and ritonavir is most commonly used as
a booster drug at relatively low doses (e.g. 100 mg/day). In addition to these
well-studied PIs, several currently recommended first-line antiretroviral (ARV)
drugs including efavirenz, darunavir, and lopinavir also have dyslipidemic effects
in HIV patients [61, 67]. Recently, we tested currently recommended first-line
HIV drugs from three commonly used drug classes (NNRTIs, NRTIs, and PIs)
and found that several widely-prescribed ARV drugs including efavirenz and
rilpivirine (NNRTIs), etravirine and darunavir (PIs) can also activate human PXR
(Fig A.1). Many of these drugs have been associated with dyslipidemia in HIV
patients [67]. For example, efavirenz has profound effects on elevating total
and LDL-cholesterol levels in patients [61, 67]. By contrast, the widely used
NRTIs, emtricitabine (FTC) and tenofovir, which do not activate PXR, have low
risk of dyslipidemia [384-386]. These results suggest the involvement of PXR in
ARV drug-associated dyslipidemia.
To further investigate the role of these widely used ARV drugs on PXR
activity, we utilized a mammalian two-hybrid system to determine if these drugs
can permit association of two well-known coactivators, SRC-1 and PBP.
Binding of these ARV drugs to human PXR allowed co-activator/PXR interaction
in a dose-dependent manner (Fig. A.2). Similarly, these drugs dosedependently promoted co-repressor/PXR disassociation (Fig. A.2). To
determine whether these ARV drugs act specifically through PXR, we tested
their ability to activate a panel of other nuclear receptors, including RXR, FXR,
LXRα, PPARα/γ, VDR, and ERα/β. Efavirenz, darunavir, and rilpivirine were
unable to activate any of these other nuclear receptors (Fig. A.3), indicating the
importance of investigating the effects of these ARV drugs on PXR activity in
vivo. These results indicate that these ARV drugs specifically activate PXR and
promote coactivator association leading to transcriptional activation.
We are currently investigating the role of these ARV drugs on PXR activity
and plasma lipid levels in vivo. We plan to choose ARV drugs from three
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commonly used classes: emtricitabine (NRTI), efavirenz (NNRTI), and darunavir
(PI). Based on previous pharmacokinetic studies, steady state plasma levels of
these compounds reach approximately 10-20 μM, which is sufficient to activate
PXR in cell culture systems [387]. Since emtricitabine does not affect PXR
activity, we do not anticipate that it will alter plasma lipid levels in vivo. Based
on the observation that both efavirenz and darunavir are agonists for both
mouse and human PXR, we do not feel it is necessary to include another cohort
of mice expressing the huPXR transgene on a mouse PXR-deficient
background. Since we previously demonstrated that PXR transcriptionally
regulates NPC1L1 [342], we also may consider incorporating ezetimibe into the
diet to determine if cholesterol absorption is a major determinant in PXR-elicited
hypercholesterolemia. It will be interesting to see if these widely-used drugs
can promote hypercholesterolemia in vivo in a PXR-dependent manner. All
drugs should be assessed for their ability to activate PXR considering the
adverse side effects of PXR activation in sterol and energy metabolism.

5.3

Investigate the PXR/HNF4α Axis in Regulating MTP

Mechanisms governing transcriptional regulation of MTP have been
investigated by a few groups; however, identification of novel regulators is
warranted. A comparative alignment of promoter sequences from different
species revealed an evolutionarily conserved 204 bp element upstream from the
MTP transcriptional start site that contains several cis elements [7, 44, 388,
389]. For example, three HNF-1 family members synergistically enhance the
HNF-4α mediated transactivation of the proximal MTP promoter [388].
Moreover, MTP was identified as a possible PXR-target gene in Chromatin
Immunoprecipitation-sequencing (ChIP-seq) assays [390]. Furthermore, PXR
has been demonstrated to bind to HNF4α and ligand treatment enhanced this
interaction [187]. HNF4α also mediates PXR transactivation of CYP3A4 [391].
ChIP-seq of HNF4α and several nuclear receptors revealed PXR binds within
close proximity to all HNF4α binding sites within the genome [392]; whether
PXR is directly binding to cis elements in MTP or binding is mediated through
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HNF4α remains to be determined.
To gain insight into whether PXR directly regulates MTP expression, we
first isolated primary enterocytes, treated with a wide array of PXR agonists and
measured expression of genes involved in lipid metabolism. As expected, PXR
activation stimulated NPC1L1 mRNA expression with all ligands tested (Fig.
A.4). Furthermore, PXR activation also stimulated MTP expression with all
ligands tested in a PXR-dependent manner (Fig A.4). These results suggest
that PXR is absolutely essential for the xenobiotic-elicited MTP response. In the
immediate future, we plan to use ChIP and gel-shift assays to determine if PXR
is directly binding to the MTP promoter or if activation is mediated through
HNF4α or other factors. These experiments are pivotal in understanding why
PXR activation promotes hyperlipidemia.
If PXR does indeed transcriptionally regulate MTP, we plan to examine the
role of PXR activation on chylomicron secretion. Since MTP is a major regulator
of secretion of apoB-containing lipoproteins, we hypothesize that PXR activation
may elicit increases in chylomicron secretion. Once the intestinal-specific PXRknockout mice are available, we will gavage mice with [H3]-triolein and inject a
LPL inhibitor to examine the amount of tritium in the plasma over time, as
previously described [276, 393]. Moreover, with our colleagues at the University
of Cincinnati, we plan to measure the intestinal uptake, absorption and
lymphatic transport of dietary lipid in the conscious mouse [394]. Taken
together, the overall contribution of intestinal PXR on whole body metabolism
will be investigated in the near future.

5.4

Determine the Role of IKKβ in Hepatic Gluconeogenesis

The regulation of hepatic glucose production (HGP) is a critical step in
maintaining blood glucose levels, and pathological changes in gluconeogenesis
in the liver are a central characteristic in type-2 diabetes. Arkan and colleagues
first demonstrated that mice with hepatocyte-specific deletion of IKKβ had
improved glucose tolerance in aged and HFD-fed mice [244]. Utilizing a
euglycemic-hyperinsulinemic clamp, the same group demonstrated that these
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hepatocyte IKKβ deficient mice had approximately 50% suppression of HGP
during insulin clamp, compared to only a 15% reduction in floxed mice fed a
HFD [244]. Furthermore, an independent group demonstrated that mice with
hepatocyte IKKβ-overexpression were resistant to the suppression of HGP
during the insulin clamp [247]. These data demonstrate that the effect of IKKβ
in HGP may result from enhanced insulin sensitivity in mice fed a HFD.
In Chapter 4 of this dissertation, we observed a significant decrease in
fasting glucose levels and improved glucose tolerance in mice fed a HFD with
IKKβ ASO treatment (Fig. 4.1, F and G). Further, mice treated with the IKKβ
ASOs had significantly enhanced Akt signaling in the liver, adipose tissue, and
skeletal muscle with and without exogenous insulin (Fig. 4.1, H). To examine
whether the benefit of reducing IKKβ expression with ASOs on adiposity was
HFD-elicited, we treated another cohort of mice fed chow for 8 weeks. Chowfed mice had no changes in body weight or fat mass, but still had small, albeit
significant, increases in lean mass (Fig. 4.1, C and D). Interestingly, however,
fasting glucose was decreased and these mice were considerably more glucose
tolerant (Fig. A.5, A and B). It would be of interest to examine plasma insulin
levels in these mice. Since IKKβ is a negative regulator of insulin signaling by
direct phosphorylation of IRS-1 [250], these mice most likely have enhanced
hepatic insulin signaling and more suppressed HGP, which would explain the
decrease in plasma glucose levels. The IKKβΔPDGFRβ mice did not exhibit
changes in plasma blood glucose levels, but that is most likely due to intact
IKKβ signaling in the liver in these mice (Fig. 4.4, A). Further, the improvement
of glucose tolerance in both models may also be due to enhanced glucose
uptake in other tissues, such as skeletal muscle. IKKβΔPDGFRβ mice fed a HFD
had increased expression of genes involved in skeletal muscle mitochondrial
biogenesis and oxidative metabolism (data not shown). Moreover, IKKβΔPDGFRβ
mice exhibited increases in mitochondrial content in skeletal muscle (data not
shown). Taken together, these results demonstrate that the improved metabolic
parameters associated with IKKβ deletion in adipose progenitor cells is likely
attributed to enhanced oxidative metabolism in skeletal muscle.
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5.5

Does IKKβ Act as a “Switch” Modulating Stem Cell Commitment?

The IKKβ/NFκB signaling pathway has been demonstrated to play a role in
stem cell commitment. Mesenchymal stem cells (MSCs) are multipotent stem
cells that differentiate into mesoderm-type cells, including osteoblasts and
adipocytes. There has been a lot of work trying to identify the modulators that
link MSC commitment between bone and adipose tissue, such as β-catenin.
For example, disruption of a negative regulator of Wnt, axin-2, in mice leads to
enhanced osteoblast differentiation and matrix mineralization [395]. Mutations
in the Wnt antagonist SFRP1 results in high bone mass in mice, suggesting the
involvement of canonical Wnt signaling on osteoblast differentiation and bone
formation [396]. It was later identified that β-catenin transcriptionally regulates
Runx2, a transcription factor that is absolutely essential for osteoblast
differentiation [397]. Aside from bone formation, Wnt signaling is a potent
suppressor of adipogenesis and fat formation [353]. Thus, signaling pathways
converging on Wnt signaling may alter bone and fat formation.
Interestingly, the IKKβ/NFκB signaling pathway exerts opposite effects on
mesenchymal stem cell differentiation into bone and adipose tissue. Ligands for
IKKβ/NF-κB have been shown to promote adipocyte differentiation and
suppress osteoblast formation [253, 254, 350, 374, 378]. Moreover, NFκB
inhibits MSC differentiation into bone by promoting β-catenin degradation via the
E3 ligases Smurf1 and Smurf2 [350]. The major questions is, are all these
effects mediated primarily through NF-κB or does IKKβ mediate NF-κBindependent changes that play a role in the commitment of MSCs?
Interestingly, IKKβ has been demonstrated to directly phosphorylate β-catenin
[398]. It was initially thought that phosphorylation of β-catenin by IKKβ may
stimulate its degradation by the proteasome by enhancing the ubiquitination by
β-TrCP; however, no evidence was presented to support this mechanism.
Thus, further work identifying the specific amino acids that are phosphorylated
by IKKβ and the physiological consequence of the initial phosphorylation is
warranted. Taken together, these data demonstrate that IKKβ may sense its
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environment (e.g. FFA) and propagate a signaling cascade that initiates stem
cell commitment into bone or fat.

5.6

Investigate the Role of PXR and IKKβ in Inflammation

It is evident that reciprocal crosstalk exists between the PXR and NF-κB
signaling pathways. What remains to be determined is the precise mechanism.
As mentioned above, PXR can suppress NF-κB signaling by a variety of
mechanisms, including the physical interaction between PXR and the NF-κB
subunit, p65. Furthermore, activation of NF-κB signaling may also suppress
PXR signaling by binding to RXR, which may interfere with RXR binding to PXR
and ultimately suppress PXR transactivation. Recent work by Ito and
colleagues revealed a mechanism linking LXRs to inflammation through its
target gene ABCA1 [220]. ABCA1 was demonstrated to alter the lipid
membrane composition and disrupt binding of adaptor proteins to the TLRs
[220]. Since PXR has also been implicated to regulate ABCA1 [168, 399], it is
worth investigating if activation of PXR works in a similar manner by disrupting
TLR signaling.
Since IKKβ clearly has NF-κB independent substrates that play a role in
many different processes, it is plausible that upon stimulation, IKKβ directly
phosphorylates many different nuclear receptors leading to their
degradation/suppression in activity. Moreover, IKKβ has the potential to also
phosphorylate and regulate the activity of several cofactors needed for proper
nuclear receptor signaling. It would be interesting to do phosphoproteomics in
cells with and without IKKβ stimulation. This would provide an unbiased
approach to identify several signaling pathways that crosstalk and explore novel
areas of research. Taken together, there is a lot of room for discovery in this
area of research that could lead to druggable targets for the cure of certain
inflammatory conditions.
Copyright © Robert Nathaniel Helsley, 2016
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Appendices
Figure 5.1 Currently recommended HIV drugs activate PXR.
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Figure A.1 Currently recommended HIV drugs activate PXR.
(A-D) LS180 cells were transfected with full-length hPXR or full-length
mPXR together with a hPXR reporter (CYP3A4-luc) or a mPXR reporter
((CYP3A2)3-luc) and a CMX-β-galactosidase control plasmid. Cells were
then treated with HIV protease inhibitors (A, C), non-nucleoside and
nucleoside reverse transcriptase inhibitors (B, D), RIF (a hPXR ligand; A,
B), or PCN (a mPXR ligand; C, D) at the indicated concentrations for 24
h. Data are shown as fold induction of normalized luciferase activity
compared with that for DMSO treatment and represent the means from
triplicate experiments. Results are presented as mean ± SEM.
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Figure A.2 Currently used HIV drugs promote PXR coactivator
association and corepressor disassociation.
(A and B) LS180 cells were cotransfected with a GAL4 reporter, VP16-hPXR,
and expression vector for GAL4 DBD or GAL4 DBD linked to the receptor
interaction domains of PXR coactivators (GAL-SRC1 or GAL-PBP) (A) or PXR
corepressors (GAL-SMRT or GAL-NCoR) (B). Cells were treated with DMSO
control, efavirenz, darunavir, rilpivirine, or RIF at the indicated concentrations
for 24 hours. Data are shown as fold induction of normalized luciferase activity
compared with that for DMSO treatment and represent the means from
triplicate experiments. Results are presented as mean ± SEM.
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Figure A.3 Widely used HIV drugs are PXR-selective agonists.
LS180 cells were co-transfected with a GAL4 reporter and a series of GAL4
constructs in which the GAL4 DBD is linked to the indicated nuclear receptor
LBD. Cells were treated with DMSO control, 10μM efavirenz, 10μM darunavir,
or 10μM rilpivirine for 24 h. Data are shown as fold induction of normalized
luciferase activity compared with DMSO treatment and represent the mean of
triplicate experiments. Results are presented as mean ± SEM.
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Figure A.4 PXR activation increases mRNA expression of NPC1L1
and MTP in primary enterocytes isolated from WT but not PXRdeficient mice.
Primary enterocytes were isolated from WT and PXR-deficient mice and
were incubated with control medium or medium containing 10 µM
amprenavir, TBC, or PCN. Total RNA was isolated and expression of
genes involved in lipid metabolism were analyzed by qPCR (n=3; **P<0.01
and ***P <0.001; assessed by one-way ANOVA). Results are presented as
mean ± SEM.
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Figure A.5 Glucose metabolism is improved in IKKβ ASO mice fed
chow.
(A and B) Fasting plasma glucose levels (A) and intraperitoneal glucose
tolerance test (B) in chow-fed mice treated with control ASO or IKKβ ASO
(n=10; *P<0.05, **P<0.01, ***P<0.001, assessed by Student’s t-test
compared to control). Results are presented as mean ± SEM.
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